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Abstract 
Part I. HIV Protease Targeted Synthesis of Conformationally
_
Rigid Hydroxyethylene  
           Dipeptide Isosteres: A Combinatorial approach 
With the success of Highly Active Anti-Retro Viral therapy (HAART), the life 
expectancy of HIV patients has dramatically increased. However, emergence of drug resistance, 
toxicity, pharmacokinetic issues, and side effects etc. are some of the concerns still associated 
with the currently available drugs. To address these issues, there is a continuous need for the 
development of novel and improved anti-HIV agents.  
Drugs acting via potent inhibition of the critical enzyme HIV protease constitute a major 
class of drugs in AIDS therapy. Currently available HIV protease inhibitors utilize peptide 
hydrolysis transition-state isosteres as the key element for their anti-HIV activity. 
Hydroxyethylene, dihydroxyethylene, hydroxyethyl amine, and methyleneamine moieties are 
some of the strategic nonhydrolyzable transition state isosteres that have been employed in the 
construction of various HIV protease inhibitors.  
As part of our research towards medicinal chemical studies of bioactive compounds, the 
present research investigates the design and synthesis of conformationally rigid hydroxyethylene 
dipeptide mimics. Among the various structural motifs useful in imparting conformational 
rigidity, cyclopropane rings remain a popular choice in drug discovery endeavors. Accordingly, 
in an as yet unreported investigation, synthesis of cyclopropane ring-constrained dipeptide 
isosteres containing a hydroxyethylene ‘warhead’ has been initiated.   Utilizing a multifunctional 
enantiopure aminobutenolide (developed in our research group) as a ‘second-generation’ chiral 
building block, the synthesis involved an initial diastereoselective cyclopropanation to construct 
a strategic [3,5]-bicyclic lactone. Utilizing two diversification sites in the target analogs, and 
employing select sets of amines and amino acids as the diversity elements, a combinatorial 
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parallel synthetic approach has been followed towards rapid construction of a demonstration 
library of cyclopropane ring containing hydroxyethylene dipeptide isosteres. The synthetic route 
designed also offers additional flexibility in terms of further diversification in future studies.  
Part II. Total Synthesis and Structure
_
Activity Relationship Studies of the Cytotoxic  
             Anhydrophytosphingosine Jaspine B 
Jaspine B, also known as Pachastrissamine, is a cytotoxic marine natural product isolated 
from the sponges Pachastrissa sp. and Jaspis sp. In biological assays, Jaspine B exhibited sub-
micromolar cytotoxicity (IC50 ≤ 0.5 M) against several different cancer cell lines (murine B16, 
human Sk-Mel28 melanoma etc.). 
 
Exposure of these cells to Jaspine B triggered cell death by 
typical apoptosis, as indicated by phosphatidylserine externalization, the release of cytochrome 
C, and caspase processing. Recent studies have indicated that interference with ceramide 
metabolism via inhibition of sphingomyelin synthase is most probably responsible for the 
apoptotic effects of this natural product. Despite its impressive biological activity, detailed 
structure-activity relationship (SAR) investigations of Jaspine B are relatively limited.  
The present research describes an efficient and practical total synthetic route to Jaspine B, 
and application of the method thereof in the structure-activity relationship (SAR) studies of this 
bioactive natural product. Starting from the previously mentioned chiral aminobutenolide as an 
advanced building block, a key reaction in our synthetic route involved a stereocontrolled 
synthesis of the cis-fused [5,5]-bicyclic lactone. Subsequent functional group transformations of 
this lactone led to a short-step total synthesis of enantiopure Jaspine B. Easy amenability of 
various advanced chiral intermediates from the total synthesis route has also allowed us to 
perform strategic structural modifications to access a number of unique Jaspine B analogs for 
biological investigations. Subsequent in vitro cytotoxicity assays of the analogs thus obtained 
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have provided important SAR information, which is expected to provide useful direction in the 
potential development of new anti-cancer agents, based on the Jaspine B structural lead.  
Simultaneously to the above studies, a previously reported synthetic route to Jaspine B from 
our group has also been reinvestigated in order to help clarify some unanswered questions. 
Gratifyingly, the results from the above study have also confirmed the utility of the previous 
route in stereoselective synthesis of enantiopure Jaspine B.  
Part III. A Rapid Approach Towards Diastereoselective Synthesis of Azacarbohydrate  
               Scaffolds of Biological Significance 
A wide range of monocyclic and bicyclic polyhydroxylated alkaloids 
(azacarbohydrates/iminosugars) have been isolated from various plants, insects and 
microorganisms. Many of these compounds have been found to be potent inhibitors of 
glycosidase and glycosyl transferase enzymes of clinical importance. Advancements involving 
stereoselective synthesis, structural modification, and biological evaluation of these compounds 
resulted in therapeutic agents Glyset
®
 and Zavesca
®
 for use in patients with type II diabetes and 
type I Gaucher’s disease respectively.  
In further application of the L-serine-derived chiral aminobutenolide as an advanced 
building block, a rapid stereoselective synthesis of azacarbohydrate structural scaffolds have 
been investigated in the present study. The key reaction steps involved, utilization of an enone in 
the starting material towards stereoselective installation of key functional groups, and an 
intramolecular cyclization of an appropriately located amine into the lactone carbonyl resulting 
in the formation of the desired azacarbohydrate structural scaffolds. Subsequent reduction and 
deprotection provided an efficient and short-step route to variously functionalized 
azacarbohydrates.  
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Chapter 1 
Amino Acids: Versatile Chiral Synthons in Organic Synthesis 
1.1  Background 
-Amino acids are among the most widely used single class of chiral pool materials in 
contemporary organic synthesis. In addition to their utility as enantiopure starting materials for 
various synthetic targets, amino acids are also often used as chiral catalysts in a number of 
asymmetric synthetic methodologies.
1,2
  Some of the advantages as associated with the use of -
amino acids in asymmetric synthesis include, 
 easy availability in both enantiomeric forms 
 possible incorporation as a chiral fragment into target products 
 utilization of the inherent chirality to induce asymmetry in the formation of new 
stereocenters  
 presence of both nucleophilic (-NH2) and electrophilic (-CO2H) functional groups in the 
molecule allowing for a variety of regioselective synthetic transformations 
 utility of the side chain as an additional site for further chemical transformations 
Accordingly, amino acids continue to be an important source of enantiopure starting 
materials, chiral auxiliaries, and chiral catalysts in the stereoselective synthesis of a variety of 
organic molecules of structural, biological, and pharmaceutical importance.   
In previous research from our group, amino acids have been extensively utilized as 
versatile chiral starting materials in the stereoselective syntheses of a variety of natural and non-
natural products of medicinal chemical significance.
3-28
 Representative examples of some of the 
compounds thus synthesized are shown below (Figure 1).
7,9-14,18-20,23,24
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Figure 1. From amino acids to bioactive compounds: A chiral pool approach 
1.2. Amino acid-derived advanced chiral intermediates in organic synthesis 
In addition to their direct use as chiral materials in organic synthesis, chemically 
modified ‘second generation’ products obtained from amino acids are also a valued reservoir of 
chiral molecules with wide-ranging applications as enantiopure building blocks (chirons), chiral 
auxiliaries, and catalysts in contemporary asymmetric/stereoselective synthetic protocols. 
Representative examples of some of the amino acid-derived chiral molecules, with varied 
applications as mentioned above, are shown in the figure below (Figure 2). Thus, Garner’s 
aldehyde (I),
29
 easily available from serine, has proven to be a versatile intermediate in numerous 
synthetic endeavors, and is an especially valuable chiral precursor for the rapid synthesis of a 
variety of amino acids, amino alcohols, amino sugars, azacarbohydrates, and many other 
biologically important compounds.
30
 Along similar lines, pyroglutamic acid (II) and azetidinone 
3 
 
carboxylic acid (III) as shown below (Figure 2) have been gainfully employed as advanced 
chiral building blocks for the stereoselective syntheses of a number of natural and non-natural 
products of medicinal chemical significance.
1
  
 
Figure 2. Amino acid-derived '2nd generation' chiral building blocks, auxiliaries, and catalysts 
On the other hand, the valine-derived oxazolidinone chiral auxiliary IV is a critical 
component in Evans aldol and alkylation protocols, providing the respective products in a highly 
stereoselective manner.
31
 Similarly, employing the proline-derived RAMP or SAMP (V) as 
chiral auxiliaries, Enders has developed a versatile method for the stereoselective -alkylation of 
aldehydes and ketones.
32,33
 In further illustration of the utility of chemically modified amino 
acids in asymmetric synthesis, the proline-derived CBS-oxazaborolidine VI, as developed by 
Corey’s group, has been shown to be a highly efficient catalyst for the rapid and enantioselective 
reduction of achiral ketones in the presence of borane as the reducing agent.
34
  
Syntheses of amino acid-derived strategically functionalized advanced chiral building 
blocks, and their further utilization in various synthetic endeavors have also been the focus of 
investigations in our own research group. Towards this end, starting from L-, or D-serine and 
following a concise and efficient synthetic protocol we have developed synthetic routes to the 
enantiopure 5- and 6-member amino lactones (1) as shown below (Figure 3).
26
 In subsequent 
research, these chiral lactones have proven to be versatile structural platforms for the 
stereoselective synthesis of a variety of more complex molecules. For example, the amine 
functionality in the side chain is a potentially useful site for nucleophilic modifications, whereas, 
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the protected terminal primary hydroxy group is a masked precursor for a carbonyl group and 
can also be easily manipulated towards nucleophilic displacement reactions. The ring olefinic 
linkage provides a convenient handle for carrying out both nucleophilic and electrophilic 
modifications at this site.  Similarly, the lactone carbonyl can be utilized for introduction of 
various nucleophiles, especially carbon- and nitrogen-based, as desired.  Importantly, the 
inherent chirality of the lactones can be easily utilized to control and introduce asymmetry in 
subsequent reactions, thereby providing access to various stereoisomeric products. In subsequent 
studies demonstrating the utility of the above chirons, our group has also achieved the syntheses 
of several natural and non-natural compounds of biological importance (Figure 3).
21,26,35
  
 
 
 
 
 
 
 
 
Figure 3. Serine-derived chiral lactones (1) and selected synthetic applications thereof 
 
In continuation of the above studies, in my doctoral research, I have initiated further 
exploration of the chiral aminobutenolide 1 (n 0) in the syntheses of selected targets of 
medicinal chemical significance. The details of the studies are described in the following 
chapters. 
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Chapter 2 
HIV Protease Targeted Synthesis of Conformationally–Rigid Hydroxyethylene 
Dipeptide Isosteres: A Combinatorial approach 
2.1  Background 
Acquired immunodeficiency syndrome (AIDS) was first reported in 1981 in a small 
cohort of individuals, but soon thereafter developed into a major health concern of epidemic 
proportions.
36-38
 AIDS is caused by infection with the retrovirus, Human Immunodeficiency 
Virus (HIV), and the infected patients can exhibit a variety of symptoms such as fever, 
lymphadenopathy, sore throat, rash, myalgia/arthralgia, and headache. Although these are not 
specific for acute HIV infection only, prolonged duration of the above symptoms with 
mucocutaneous ulcers recommends for immediate diagnosis and initiation of appropriate 
treatment.
39-41
 The HIV retrovirus can be divided into two major subtypes, HIV-1 and HIV-2, 
with HIV-1 being the more common and pathogenic strain. Latest statistical analysis by World 
Health Organization (WHO) indicates that more than 34 million people are currently living with 
HIV, the highest rate being observed in Sub-Saharan Africa (69%), with 1.8 million deaths 
worldwide in 2010 alone.
42
 Thus, HIV infection and AIDS continue to be a global health concern 
with huge impacts on social, economic, and ethical issues.  
Since the first clinical detection of HIV in 1981, there have been substantial 
advancements in the understanding of the HIV life cycle, infection prevention, and its treatment. 
Currently, there are 37 FDA approved drugs/drug regimens for the treatment of AIDS.
43
 The 
available AIDS drugs target different stages of the HIV life cycle, and are useful in preventing 
the increase in viral load. At the beginning of the AIDS epidemic, early mortality was very 
significant, however, subsequent advancements in the development of new drugs and the 
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introduction of combination therapeutic strategies, also known as Highly Active Antiretroviral 
Therapy (HAART), have resulted in profound reductions in morbidity and mortality.
44-46
  
 Zidovudine (also known as azothymidine or AZT), clinically introduced in 1987, is the 
first FDA-approved drug for HIV treatment.
47
 A synthetically modified nucleoside analog, the 
prodrug AZT is an inhibitor of HIV-reverse transcriptase, an essential enzyme in the viral life 
cycle. Since then, extensive drug discovery efforts have continued to add new drugs towards the 
HIV drugs armamentarium. Depending on their binding targets and function, the currently 
available AIDS therapeutic agents can be categorized into seven different categories (Table 1).  
The first column in the table lists the various drug classes and their mode of action, while the 
second column provides representative examples of drugs belonging to each class.
43
  
Table 1.  Anti-HIV drug classes and representative agents in current clinical use 
Drug Classes Representative Drugs 
Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Zidovudine; Emtricitabine 
Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Delaviridine; Nevirapine 
Nucleotide Reverse Transcriptase Inhibitors (NtRTIs) Tenofovir disoproxil fumarate 
Protease Inhibitors (PIs) Darunavir; Ritonavir 
Fusion Inhibitors Enfuvirtide 
Entry Inhibitors Maraviroc 
HIV Integrase Strand Transfer Inhibitors  Raltegravir; Dolutegravir 
2.1.1 HIV protease structure, function and mechanism 
 Among the various anti-HIV drugs, the HIV protease inhibitors (PI) comprise the single 
largest class of drugs in current clinical use.
43,48
 HIV protease is a homodimeric aspartyl 
protease, wherein each of the identical monomeric units consists of 99 amino acid residues. The 
catalytic active site of this C2-symmetric enzyme is located at the dimeric interface, with each 
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protein subunit contributing the tripeptide sequence, Asp-Thr-Gly. The HIV protease is closely 
related to the other retroviral proteases, with similar amino acid sequences and molecular 
structures.
49,50
 The enzyme has broad substrate specificity, however, unlike mammalian 
proteases, the HIV protease can also hydrolyze peptidic bonds formed between proline and 
aromatic amino acid residues (Figure 4). Additionally, the symmetrical nature of this viral 
enzyme and its active site also represents structural features that are absent in mammalian 
proteases. The above structural and functional differences between the HIV protease and its 
mammalian counterparts thus provide an opportunity for the design of drugs selective against the 
viral enzyme. 
 
Figure 4. The polypeptide substrate of HIV protease and the cleavage site [showing 6 of the 
binding subsites (S1 etc.), and the corresponding amino acid residues (P1 etc.) of the substrate] 
In further illustration of the HIV protease structure and function, a ribbon diagram of 
HIV protease (PR), bound to the peptidomimetic protease inhibitor Amprenavir, is shown below 
(Figure 5).
51
  Apart from the catalytic tripeptide sequence Asp-Thr-Gly, the retroviral PR also 
has a conserved Gly-Arg-Asn/Asp near the C-terminus and a Gly-rich sequence in the middle of 
the protein structure. The main function of this enzyme involves the proteolytic cleavage of 
precursor proteins Pr55
Gag 
and Pr160
Gag-Pol
 using two aspartates located at D25 and D25’.
52,53
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Figure 5. HIV protease bound to the protease inhibitor Amprenavir (adapted from Ref. 51) 
The ceiling of the active site of the enzyme is formed by two beta-hairpin structures or flaps 
that are highly flexible, and can undergo large localized conformational changes during the 
binding and release of substrates. The body of the enzyme contains β-sheet and α-helical 
segments defining an extended hydrophobic core with a curved tubular shape. Embedded in the 
convex region of this core lies the catalytic Asp25 and Asp25’ residues.  
Mechanistically, the above-mentioned aspartate residues and a bridging water molecule 
at the active site of the HIV protease are responsible for hydrolysis of the substrate peptide bond 
(Figure 6: Panel A).  Subsequent to activation of the water molecule, the reaction proceeds via 
formation of a tetrahedral gem-diol as a transition-state (TS) intermediate (Figure 6: Panel B), 
followed by cleavage of the amide linkage and regeneration of the catalytic enzyme (Figure 6: 
Panel C).
53-57
 Breaking of the tetrahedral intermediate is reversible at a low level as established 
by 
18
O exchange into reformed substrates.
58
 Enzyme kinetic studies of the reaction mechanism 
provided evidence that the dissociation of tetrahedral intermediate is the rate-determining step 
(RDS).
58-61
   A non-chemical slow step was also observed for the substrate with P’2 Gln instead 
of Glu.
60,62
 An alternate RDS was proposed to be the conformational change of the two flaps 
during the entry of the substrate.  
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Figure 6. HIV protease catalyzed hydrolysis of the viral polypeptide substrate 
2.1.2. Transition State Mimicry in the Design of HIV Protease Inhibitors 
In 1989, Wlodawer et al reported the first X-ray co-crystal structure of HIV protease bound to a 
non-hydrolysable peptide analog.
63,64
 Structural and binding interaction data gleaned from this 
and several subsequent studies provided crucial information towards rational design and 
development of various HIV protease inhibitors. The first generation HIV protease inhibitors 
were developed based on the TS peptidomimetic principles in which the hydrolyzable P1-P1’ 
amide bond was replaced by non-hydrolysable TS isosteres.
52
 As illustrated in the HIV protease 
catalyzed peptide hydrolysis mechanism (Figure 6), the transition state involves the formation of 
a gem-diol tetrahedral intermediate. However, the inherent chemical instability of such a 
tetrahedral intermediate necessitates the design of inhibitors incorporating transition state 
mimicry, while being stable to hydrolysis. Several such isosteres meeting the above structural 
guidelines have been investigated in the design and development of inhibitors of renin, a 
mammalian aspartyl protease. Representative examples of peptide hydrolysis transition state 
isosteres thus explored include methyleneamine, hydroxyethylene, dihydroxyethylene, 
hydroxyethylamine, ketomethylene, and phosphonamide etc. (Figure 7). As non-hydrolysable 
structural mimics of the transition state gem-diol, the strategic secondary hydroxy (or a related) 
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 group in these isosteres (colored blue) are expected to participate in hydrogen-bonding 
interactions with the two aspartates in the HIV protease active site, leading to enzyme inhibition. 
 
Figure 7. Transition-state isosteres of peptide bond hydrolysis 
Structures of protease inhibitor anti-HIV drugs in clinical use, incorporating some of the 
above transition-state mimic structural components (color coded in red), are shown below 
(Figure 8). FDA-approved in 1995, Saquinavir as the first protease inhibitor drug in AIDS 
treatment, and served as a benchmark for all the subsequently introduced PIs. Several other PIs, 
such as Indinavir, Ritonavir, Nelfinavir and Amprenavir, and their utility in various combination 
therapy regimens have significantly contributed towards the success of the Highly Active Anti-
Retroviral Therapy (HAART).
65-69
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Figure 8. FDA-approved HIV protease inhibitors in AIDS therapy 
2.1.3. HIV Protease inhibitors: Design, development and concerns 
Having identified appropriate transition-state isosteres, the design of the first generation 
PI’s were based on the natural peptidic substrates of the enzyme, targeting binding interactions 
spanning the S1/S1’, S2/S2’, and S3/S3’ subsites (Figure 4).  Thus, Saquinavir, a 
hydroxyethylamine transition-state isostere analog, flanked by amino acid units phenylalanine 
and aspargine at P1 and P2 respectively (Figure 8), is the first clinically approved HIV protease 
inhibitor drug, displaying strong enzyme inhibitory activity (IC50 < 0.4 nm).  However, the 
resulting peptide-like character and relatively high molecular weight of this and similar drugs 
results in poor pharmacokinetic properties, while also contributing to some of the deleterious 
side effects.
70,71
 Addressing the above limitations, the more recent generation of PI’s were 
developed with an emphasis on the reduction of peptidic features, lowering of molecular weight, 
and the introduction of novel structural entities capable of strong binding interactions with the 
enzyme. The second generation PI’s thus developed include Lopinavir,
72
 Atazanavir,
73
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Amprenavir,
74
 Fosamprenavir (a prodrug),
75
 Tipranavir,
76
 and the most recently approved drug 
Darunavir
77
 (Figure 8). All of these agents demonstrate superior antiviral activities, including 
activity against resistant viral strains, and also have better oral bioavailability. For example, in 
the design of Darunavir (Figure 8), the decahydroisoquinoline carboxamide group of Saquinavir 
has been replaced by an N-isopropyl-N’-p-aminosulfonamide group, thereby improving water 
solubility (enhanced oral bioavailability). Similarly, replacement of the P2 and P3 groups of 
Saquinavir by the bistetrahyrdofuryl ring-fused carbamate group in Darunavir reduced the 
peptidic character in this molecule, while also providing a better space-filling group at the 
hydrophobic S2 binding pocket. It was also found that the oxygen atoms of the bicyclic furan 
substituent of Darunavir participate in potent hydrogen bonding interactions with the peptide 
backbone of the target enzyme. Such binding interaction with the peptidic backbone of the 
enzyme, rather than with an amino acid residue, reduces the likelihood of mutation-influenced 
development of drug resistance. 
Although each successive generation of drugs for anti-retroviral therapy (ART) has been 
associated with an overall improved activity profile, toxic side effects, and development of drug 
resistance however continues to be of concern. For example, Tenofovir, an NRTI class of first-
line drug, commonly used in various combination regimens, has small but measureable adverse 
effects on kidney function.
78-80
 A rapidly growing and consistent evidence base suggests that 
many markers of inflammation are higher in ART adults than in age-matched uninfected 
individuals.
81,82
 Liver toxicity has also been observed in HIV patients receiving novel second 
generation non-nucleoside reverse transcriptase inhibitors etravirine and rilpivirine.
83,84
   
Apart from the toxicity issues, development of viral resistance against the HIV drugs is 
also a growing concern. According to a recent report, usage of HIV-1 reverse transcriptase (RT) 
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inhibitors have been found to contribute towards the development of resistance by introducing 
mutations into the viral genome.
85,86
 Gratifyingly, the current treatment regimens of HAART, in 
which multiple classes of anti-HIV-1 drugs are employed, have been shown to significantly 
increase the life expectancy of HIV-1 infected patients. Additionally, first-line HAART with 
boosted protease inhibitor (PI)-based regimens resulted in less resistance within and across drug 
classes.
87-90
 However, the ability to provide effective long-term anti-HIV therapy is complicated, 
as 40-50% of those patients, who initially achieved favorable viral suppression to undetectable 
levels, subsequently experienced treatment failure.  Between 10-40% of antiviral therapy-naïve 
individuals with HIV-1 infection have shown persistent viral replication (plasma HIV RNA > 
500 copies/mL) under HAART regimens.
91
 Possibly due to the transmission of drug-resistant 
HIV-1 regimens, only partial immunologic reconstitution is attained in patients with advanced 
HIV-1 infections or AIDS.
51
   
With the above concerns in HIV therapy, there is a continuing need for further 
development of more active / less toxic anti-HIV drugs, identification of novel targets, and new 
treatment strategies / regimens to combat resistance.
92,93
   
2.2. Present work 
In addition to identification of important binding elements required for biological 
activity, the pharmacophore of a drug molecule is also defined by its bioactive conformation at 
the receptor-binding site.  Elucidation of the bioactive conformation, the conformation adopted 
by an otherwise structurally flexible compound upon binding to its biomacromolecular target, is 
a critical element in successful drug discovery efforts. An important strategy in such 
investigations include strategic introduction of conformational restraints in the structural 
framework of the compound of interest, resulting in the locking of the molecule into a more rigid 
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conformation. As a conformationally more flexible bioactive compound has an increased 
likelihood of interacting with multiple biological receptors, locking the compound to a more 
rigid active conformation can lead to selective binding to the desired receptor while avoiding off-
target interactions. From an entropic viewpoint too, compared to a flexible molecule, a rigidified 
analog in its bioactive conformation is expected to have better overall binding affinity.  
Molecules incorporating structural features capable of causing decreased freedom of 
intramolecular motion, particularly of rotation around single bonds, exhibit conformational 
restriction.
94
 Some of the common strategies towards introduction of conformational restriction 
in an otherwise flexible structural scaffold include, incorporation of olefinic linkages or cyclic 
moieties, extended networks of intramolecular hydrogen bonding, and bulky substituents 
preventing free rotations across single bonds. However, in designing conformationally rigid 
analogs, it is an important criterion that, in terms of size, shape, and molecular weight, the 
designed analogs retain similarity to the parent (lead) compound to a certain extent, so as not to 
compromise critical structural features associated with desirable activity.
 
Following the above 
strategy and approach, rational design of agents for various therapeutic areas has been 
investigated.
62-66
 
Among the various structural motifs useful in imparting conformational rigidity, 
cyclopropane rings remain a popular choice. The characteristically rigid and small structure of a 
cyclopropane ring is highly effective in restricting the conformation of a molecule while 
retaining the chemical and physical properties of the parent compound. Cyclopropane ring-
rigidified peptidomimetics have been found to be very useful in the strategic design of 
conformationally pre-organized analogs imitating turns or helices of the peptide secondary 
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structure. In another study, it has been shown that by controlling the cyclopropane ring 
substitution pattern (cis/trans) in a peptide backbone, in addition to attaining conformational 
rigidity, it is also possible to simultaneously project the amino acid side chains in defined 
orientations. Cyclopropane-containing conformationally rigid analogs have thus been variously 
investigated in designing inhibitors of renin,
95,96
 HIV-1 protease,
97
 Ras farnesyltransferase,
98
 
enkephalin analogues,
99
 SH2 antagonists,
100
  and H3 and/or H4 receptor ligands.
101
 Development 
of selective α4β2-nicotinic acetylcholine receptor partial agonists exhibiting an antidepressant 
profile in which cyclopropane-induced rigidity improved metabolic stability and provided 
directionality towards H-bonding have also been reported.
102
  
 In a pioneering example, Martin and co-workers have investigated cyclopropane-
containing peptidomimetic analogs (B) designed along the lines of known C2-symmetric 1,2-
dihydroxyethylene dipeptide isosteric HIV protease inhibitors (A) (Figure 9).
97
     
 
 
Figure 9. An HIV Protease inhibitor C2-symmetric dihydroxyethylene peptide isostere (A), and 
peptide backbone rigidified cyclopropane analogs (B) thereof (Ref. 97) 
 Some of the noteworthy inhibitor design features (B) in the above study include: 
installation of two cyclopropane rings spanning the P2 and P2’ subsites, resulting in local 
rigidification of the peptidic backbone; peptide hydrolysis transition-state mimicry via the 
incorporation of a 1,2-dihydroxyethylene structural motif; and retention of the overall C2 
symmetry as in the parent compound (A). The trans-1,2 substitution pattern across the two 
cyclopropane rings are meant to orient the resulting peptidic substrate in an extended 
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conformation. Several of the rigid analogs (B) thus synthesized were found to be competitive 
inhibitors (Kis in sub-nM range) of the wild-type-HIV-1 protease, and were approximately 
equipotent to the known lead compound (A).
97
   
 The above study demonstrates the promise of conformationally rigid peptide isosteres in 
probing the bioactive conformation of HIV-protease inhibitor peptidomimetics, and potential 
application thereof in the design and development of a new class of agents for AIDS therapy.        
Intrigued by the above observations, we decided to initiate a study aimed at the design, 
synthesis and evaluation of a hitherto unexplored class of analogs combining conformational 
rigidity and peptide hydrolysis transition state mimicry in a common structural framework. 
Based on the above design elements, the general structural scaffolds of two hypothetical analogs 
we envisioned are shown below (Figure 10).  
 
 
Figure 10. Proposed cyclopropane ring-constrained hydroxyethylene dipeptide isosteres 
 Mimicking relevant structural features of some of the known HIV protease inhibitors 
(e.g. Ritonavir and Lopinavir: Figure 8), we conceptualized the above analogs combining the 
functionally critical hydroxyethylene transition-state isostere moiety, and the introduction of a 
strategically placed cyclopropane ring to impart conformational rigidity in the peptide-like 
backbone. It is noteworthy that, depending on the 1,2-substitution pattern (cis/trans) across the 
cyclopropane ring, the above analog design offers the additional possibility of spatial placement 
of the two substituents either in a folded (cis), or an extended (trans) conformation.  Side chain 
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orientations of peptides/pseudopeptides are often critical determinants of enzymatic binding 
interactions and specificity, therefore, the ability to control the orientations of the above 
appendages is a highly desirable feature in the strategic design of the above analogs.  With the 
above aims, the details of the synthetic studies undertaken by me are described below. 
2.2.1. Retrosynthetic strategy and combinatorial synthetic approach towards a new class of 
cis-1,2-disubstituted cyclopropane ring-containing hydroxyethylene dipeptide isosteres   
Initiating the desired study, we began our pursuit by targeting the synthesis of 
conformationally rigid hydroxyethylene dipeptide isosteres containing a cis-1,2-cyclopropane 
ring in the structural backbone. Accordingly, utilizing a versatile chiral aminobutenolide 1  
[reported previously from our laboratory (vide infra)] as an advanced building block, we 
envisioned the following combinatorial synthetic approach towards rapid and efficient synthesis 
of a select library of the desired dipeptide isostere analogs 4 (Figure 11). 
Figure 11. Retrosynthetic strategy and approach towards conformationally-restricted hydroxy- 
ethylene dipeptide isosteres: A combinatorial approach 
 As evident, the strategically functionalized aminobutenolide 1 already incorporates two 
of the required stereogenic centers of the final product. Through asymmetric induction, the 
existing chiral center of the butenolide ring is expected to allow stereoselective installation of the 
cyclopropane ring in compound 2 (Figure 11) as shown. Exploiting the inherent ring-strain of the 
[3, 5]-bicyclic scaffold 2, the subsequent lactone ring-opening with amines will easily furnish the 
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corresponding cis-1,2-disubstituted cyclopropane carboxamide derivatives 3, with simultaneous 
unmasking of the desired hydroxyethylene isostere structural motif.  Employing a chosen set of 
amines in the above lactone aminolysis step, this reaction will also provide the first 
diversification point (color coded red) towards the intended synthesis of the combinatorial library 
of target analogs.  Finally, N-Boc deprotection and standard coupling of the resulting amine with 
various amino acids (second diversification step in the library synthesis; colored blue) will 
culminate in the target cyclopropane ring-containing hydroxyethylene dipeptide isosteres (4). 
Although not included in the present study, appropriate functionalization and nucleophilic 
substitution involving the primary hydroxyl group of 3 could easily provide a third possible 
diversification site in further combinatorial library construction efforts. 
Accordingly, acquisition of the aminobutenolide (1) was initiated following a previously 
developed synthetic route from our laboratory as shown below (Scheme 1).
26  
Scheme 1 
Starting from L-serine, the key steps in the synthesis involved, conversion of the Weinreb 
amide 1.1 to the strategic enone 1.2, followed by a chelation-controlled reduction of the ketone 
to the corresponding anti-aminoalcohol 1.3 in a highly stereoselective manner.
103
 Subsequent 
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derivatization of 1.3 to form the diene 1.4, and subjecting it to Grubbs ring-closing metathesis 
provided the desired enantiopure lactone 1 (Scheme 1).
104
 Some of the salient features of the 
above synthesis involve: 
 A practical, efficient, and reproducible reaction sequence 
 Good overall yield, and easy scalability to obtain multi-gram quantities (15–20g) of the 
product lactone in each reaction batch 
 The product lactone obtained as a stable, crystalline solid, and can be stored indefinitely 
without any apparent decomposition 
 Starting from D-serine, the above route also provides an equally efficient protocol 
towards obtaining ent-1  
It is worth mentioning that, in several other previous, and ongoing research projects in 
our group, the above lactone has proven to be a highly valuable chiral building block in the 
synthesis of a variety of natural and non-natural products of biological significance. 
Having synthesized sufficient quantities of the lactone 1 for the proposed study, 
introduction of the cyclopropane moiety to form the desired bicyclic lactone 2 was next 
investigated. Cyclopropanation of olefins with diazoalkanes in the presence of transition metal 
catalysts is a widely used synthetic protocol.
105-111
 The simplest diazoalkane used in such 
cyclopropanation reactions is diazomethane (CH2N2). Although several metal catalysts (e.g. Ni, 
Pd, Cu, Fe, Co, Rh etc.)
112
 have been found to be useful in performing the above 
cyclopropanation reaction, palladium catalysts are generally among the most effective.
113-116
  A 
probable mechanistic pathway explaining the palladium-catalyzed cyclopropanation of olefins in 
the presence of diazomethane is shown below (Figure 12). 
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Figure 12.  Cyclopropanation of olefins in the presence of diazomethane and palladium 
The overall reaction involves initial coordination of diazomethane to the palladium 
catalyst to form the metal-carbenoid species I, with concomitant extrusion of nitrogen. 
Subsequent concerted addition of the metal-carbenoid to the olefin results in the formation of the 
palladocyclobutane II. This unstable intermediate on further reductive elimination affords the 
cis-cyclopropane derivative in a stereospecific manner (Figure 12).
94-117
   
Accordingly, following the above method, the aminobutenolide 1 was reacted with 
freshly prepared diazomethane ethereal reagent
118
 in the presence of a catalytic amount (10 
mol%) of Pd(OAc)2.  Subsequent work-up and chromatographic purification of the reaction 
mixture afforded the cyclopropane ring-fused bicyclic lactone 2.1 as the only product (Scheme 
2), along with the recovery of minor quantities of unreacted starting material. During efforts to 
optimize the above reaction, it was found that addition of the diazomethane in two batches (0 h 
and after 24 h) afforded the best product yield. The structure of the product 2.1 was confirmed on 
the basis of high-resolution NMR and mass-spectrometric studies. To further confirm the 
assigned stereochemistry of the newly formed cyclopropane stereocenters, the N,O-acetonide 
linkage of 2.1 was subjected to cleavage so as to simplify the 
1
H NMR spectrum (to eliminate 
peak-broadening caused by the presence of rotamers in 2.1).  Accordingly, employing a mild and 
efficient reaction protocol previously developed in our laboratory,
119
 selective removal of the 
N,O-acetonide protecting group cleanly afforded the aminoalcohol 2.2 (Scheme 2) in high yield.  
In subsequent high-resolution NMR experiments, significant nOe enhancement was observed 
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between the Hd and Hc protons, while there was no such effect involving the Hd and Hb protons 
(Scheme 2), thereby confirming the assigned stereochemistry at the cyclopropane stereocenters. 
True to expectation, the observed stereoselectivity in the above reaction is influenced by the 
chiral center adjacent to the olefin directing the approach of the incoming reagent from the less 
hindered -face (propagation of asymmetry).
120,121
  
 
 
 
Scheme 2 
 Continuing with our studies, the next step in the synthesis involved aminolysis of the 
bicyclic lactone to form the cis-1,2-disubstituted cyclopropane containing hydroxyethylene 
isostere segment of the target compound. Accordingly, refluxing a solution of the lactone 2.1 
with an excess of n-butylamine in the presence of i-propanol as solvent cleanly afforded the 
corresponding ring-opened cyclopropane carboxamide 3.1a (Scheme 3). 
 
 
Scheme 3 
In addition to formation of the right-hand side portion of the carboxamide functional 
group, the above reaction also simultaneously unveiled the critical ‘warhead’ hydroxyethylene 
isostere component as designed in the target conformationally rigid dipeptide analogs. 
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A potential concern in this reaction has been the possibility of stereochemical inversion at 
the chiral center adjacent to the carboxamide group, so as to orient the two bulky substituents at 
the 1,2-position of the cyclopropane ring in a more favorable trans-relationship. Gratifyingly, 
1
H 
NMR spectrum of the above product (3.1a) indicated the coupling constant between the 
respective methine protons (JHa,Hb=8.1Hz) of the cyclopropane ring to be in the desired cis-
relationship, thereby confirming the assigned product structure and stereochemical integrity. 
Subsequently, in a parallel combinatorial synthetic approach, a select set of representative 
amines with different steric, electronic, and lipophilic properties were also employed in the 
above aminolysis reaction to obtain a total of eight different carboxamide analogs 3.1a-h as 
shown (Scheme 3).  In addition to belonging to either to a primary or secondary amine class, the 
chosen amines can also be broadly classified into aliphatic, cyclic and heterocyclic categories. 
Moreover, the tetrahydroisoquinoline, and the aminoindanol-derived carboxamide moieties in 
two of the above analogs (3.1g–h) have also been deliberately designed so as to mimic similar 
structural components as present in some of the known HIV protease inhibitors (Figure 8).  
In continuation of the studies, incorporation of the remaining peptidic core in the above 
structural scaffold was next undertaken. Towards this goal, selective removal of the N,O-
acetonide linkage of 3.1 was performed using a mild and efficient protocol developed previously 
in our laboratory.
119
 Accordingly, treatment of the oxazolidines 3.1a-h with TMSOTf at ambient 
temperature resulted in rapid formation of the corresponding aminodiol derivatives 4.1a-h in 
uniformly high yields (Scheme 4). Subsequent hydrogenolytic removal of the N-Cbz-protecting 
group, followed by reaction of the resulting free amines with a chosen set of six N-Boc-
aminoacids (A–F) under standard peptide coupling conditions
122
 led to the uneventful formation 
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of a combinatorial library of the desired dipeptide isosteres 4.2aA–4.2hf (Scheme 4, and Figure 
13). Thus, following a concise and efficient combinatorial synthetic route, a 32-member library 
of a novel class of conformationally rigid hydroxyethylene dipeptide isosteres was successfully 
constructed. 
 
 
 
Scheme 4 
 
 
 
 
 
 
 
 
Figure 13. Representative examples of the conformationally-rigid hydroxyethylene dipeptide 
isostere combinatorial library of compounds 
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As the Boc-protected amine functional groups in this library of compounds represent a 
potential diversification site in future library design, it was considered worthwhile to investigate 
the possibility of removal of this group without compromising the structural or stereochemical 
integrity of the above dipeptide isosteres. 
Accordingly, two representative analogs from the library, 4.2gE and 4.2hF (Figure 13), 
were selected for Boc-deprotection study. Thus, treatment of the above compounds with 
trifluoroacetic acid (neat) at ambient temperature, followed by removal of the excess acid under 
high vacuum cleanly afforded the respective amines 5.1 and 5.2 (Scheme 5) as the corresponding 
TFA-salts. Spectral and analytical data confirmed the assigned structure and purity of the 
products formed.  
 
 
 
 
Scheme 5 
2.3. Concluding remarks 
Structural inspection of the various HIV protease inhibitor dipeptide isosteres (Figure 8) 
indicates the presence of a linear peptide isosteric backbone to be a common motif, with 
individual compounds differing mostly with respect to their side chain functionalities. 
Surprisingly, modifications involving the conformational features of the peptidic backbone of the 
HIV protease inhibitors have remained relatively scarce. Contemporary studies have shown that 
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preorganization of otherwise flexible peptidic molecules in a structurally rigid conformation can 
result in higher target binding affinity and improved selectivity. In such studies, strategies for 
introduction of conformational restrain on peptidic backbones generally involved incorporation 
of olefin motifs, or the formation of cyclic framework. 
 In view of the above observations, our present study was initiated to investigate the 
design and synthesis of a new class of conformationally-restricted hydroxyethylene dipeptide 
isosteres as potential HIV-protease inhibitors. Accordingly, utilizing an L-serine-derived 
polyfunctional chiral lactone as a strategic building block, we have developed an efficient 
combinatorial synthetic route to construct a unique library of the above dipeptide isosteres. In the 
structural design of these analogs, local conformational rigidity on the dipeptidic backbone has 
been achieved by stereoselective incorporation of a strategic 1,2-disubstituted cyclopropane 
structural motif.  Utilizing two diversification sites in the target analogs, and employing select 
sets of amines and amino acids as the diversity elements, a parallel synthetic approach has been 
followed towards rapid construction of a demonstration combinatorial library of 32 analogs.  
The synthetic route designed also offers additional flexibility in terms of further 
diversification. For example, the primary hydroxy and the amine functional groups in the 
molecule (Figure 14) can be easily manipulated to incorporate appropriate functionalities to 
optimize interactions at the S1–S3 subsites of the enzyme binding pocket. 
 
 
 
 
Figure 14. Further diversification sites towards future combinatorial libraries  
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Continued synthetic studies along the above lines, and biological evaluation of the 
analogs will be the target of future investigations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
27 
 
Chapter 3 
Total Synthesis and Structure-Activity Relationship Studies of the Cytotoxic 
Anhydrophytosphingosine Jaspine B   
3.1. Introduction  
Cancer, a broad group of diseases characterized by uncontrolled cell growth, is a leading 
cause of death in the United States, accounting for more than 580,000 deaths in 2013 alone.
123,124
 
According to Weinberg et al, the major hallmarks of cancer include: sustained proliferative 
signaling, evasion of growth suppressors, cell death resistance, enabled replicative immortality, 
induction of angiogenesis, activation of invasion, metastasis, reprogrammed energy metabolism, 
and evasion of immune-destruction
125
.  
Despite major breakthroughs in many areas of medicine over the past century, successful 
treatment of cancer remains a daunting challenge. Thus, advances in the elucidation of molecular 
mechanisms that promote cancer, and identification of small molecules that modulate these 
mechanisms are providing new insights into potential therapeutic targets for cancer 
chemotherapy.  
Natural products have a long history of use in the treatment of cancer and many other 
diseases. Discovery of several effective anti-cancer agents from natural products, or leads 
thereof, may be attributed directly or indirectly, to a history of use of the relevant plants in 
traditional medicine.  Representative examples of some of the natural product-inspired drugs in 
contemporary cancer chemotherapeutic use include the taxanes, camptothecins, and vinca 
alkaloids etc. Thus, natural products continue to be a rich resource for the discovery and 
development of new chemotherapeutic agents.
126,127 
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3.2. Background 
3.2.1. Isolation of marine natural product Jaspine B and biological significance 
Jaspine B (Figure 15), also known as Pachastrissamine, is a marine natural product 
initially isolated from the Okinawan marine sponge Pachastrissa sp. (family Calthropellidae) in 
2002.
128
 It is the first example of a cyclic anhydrophytosphingosine structural feature in a natural 
product. In cell cytotoxicity studies, Jaspine B exhibited an IC50 value of 0.01 μg/mL against 
P388, A549, HT29 and SK-Mel28 cancer cell lines.
128
  
 
 
 
 
Figure 15. Structure of the cytotoxic marine natural product Jaspine B 
Shortly thereafter, Debitus et al have independently reported the isolation of the same 
bioactive natural product from a different marine sponge Jaspis sp. in Vanuatu, New Zealand. 
129
 
In their biochemical studies, Jaspine B exhibited toxicity towards brine shrimp, Artemia salina, 
at a concentration as low as 0.1 μg/mL. In another cell-based cytotoxicity study, Jaspine B 
exhibited an IC50 value of 0.24 μM against A549 human lung carcinoma cell line. 
129
  
Since its isolation, there has been a keen interest in identifying the molecular mechanisms 
by which Jaspine B exhibits cytotoxicity in cancer cell lines. One such study by Salma et al have 
reported that time and dose-dependent cell growth inhibition was exhibited by Jaspine B in 
murine B16 and human SK-MEL28 melanoma cells.
130
 In their studies, exposure of these 
melanoma cells to Jaspine B triggered cell death by typical apoptosis involving phosphatidyl 
serine externalization, release of cytochrome C, and caspase processing.
130
 These biochemical 
events were associated with increased intracellular ceramide levels, owing to perturbed ceramide 
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metabolism caused by strong inhibition of sphingomyelin synthase (SMS). SMS belongs to a 
transferase enzyme family, which catalyzes the transfer of phosphatidyl choline to the primary 
hydroxyl of ceramide to form sphingomyelin (Figure 16).  
In another study by Delgado et al, exposure of lung cancer cells to Jaspine B suggested 
that dihydroceramide-mediated autophagy might be involved in its observed cytotoxicity.
131
  
Autophagy (self-eating) is a survival pathway responsible for the breakdown of damaged 
organelles, protein aggregates, and long-lived proteins towards recycling during periods of 
starvation in an effort to maintain cellular homeostasis.
132
 During tumorigenesis, cancer cells 
need a continuous supply of nutrients. However, solid tumor cancer cells are deprived of 
nutrients due to poor vascularization. Under these metabolic stressful circumstances cells initiate 
autophagy as a survival mechanism.
133
  
Recently, Kim et al reported that Jaspine B induces apoptosis in melanoma cells and 
inhibits cell cycle progression by activating Forkhead box O3 (FOXO3) via suppression of the 
Extracellular Regulatory Kinase (ERK) pathway and inhibiting Cyclin-Dependent Kinase (CDK) 
production.
134
   FOXO3 is a tumor suppressor transcription factor that negatively regulates 
melanoma tumorigenesis.
135
  It has been identified as a component of phytosphingosine (PS)-
induced cell death machinery.
136
 FOXO3 induces apoptosis by upregulation of genes necessary 
for cell death, such as BIM (BCL2 Family member that promotes apoptosis); PUMA (p53 
Upregulated Modulator of Apoptosis)
137
 or down regulation of anti-apoptotic proteins such as 
FLIP (FLICE Like Inhibitory Protein).
138
 
Though the exact mechanism of action of Jaspine B is not yet fully understood, 
preliminary biochemical studies supporting its involvement in ceramide metabolism pathways 
and anti-cancer potential offers an interesting lead for further investigation.
139
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3.2.2. Sphingolipids biosynthesis, metabolism and biological significance 
 Sphingolipids (SLs) constitute a heterogeneous class of lipids derived from aliphatic 
amino alcohol sphingosine (Figure 16). In mammalian cells, SLs play key role both as ubiquitous 
component of cellular membrane, circulating lipoproteins, and as bioactive lipids involving in a 
variety of fundamental processes including cell growth, cell death, cell differentiation, cell 
senescence, migration, angiogenesis, inflammation and immune response.
140-151
  Their functional 
diversity is related to their structural complexity and is reflected by their implication in numerous 
human pathological processes.  
Among the SLs, ceramide (Figure 16) is the central precursor of sphingolipid metabolism 
and has been studied extensively for its pro-apoptotic and anti-proliferative effects. 
Pharmacological approaches targeting ceramide metabolism in apoptosis-related diseases such as 
cancer have been proposed.
140-142,148-154
 The three major biosynthetic pathways leading to 
ceramide formation (Figure 16) include: (1) de novo synthesis from serine and palmitoyl CoA; 
(2) SMase pathway: sphingomyelinase assisted catabolism of Sphingomyelin, and (3) Salvage 
pathway: where more complex sphingolipids are metabolized to sphingosine followed by re-
acylation to form ceramide (Figure 16). Ceramide thus formed is subject to various metabolic 
pathways such as, C-1-O-functionalization into several metabolites such as: sphingomyelin 
(catalyzed by sphingomyelin synthase, SMS); glucosyl ceramide (glycosylated by glucosyl 
ceramide synthase, GlcCer); ceramide-1-phosphate (C1P) (phosphorylated by ceramide kinase, 
CERK); and 1-O-acyl ceramide (acylated by 1-acyl ceramide synthase).  In another important 
metabolic pathway, Sphingosine-1-phosphate (S1P) is derived from ceramide by the actions of 
the enzymes ceramidase followed by sphingosine kinase. In contrast to ceramide, S1P is a key 
facilitator of pro-cancerous cellular events such as proliferation, migration, angiogenesis, as well 
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as resistance to apoptosis.
 140-142,148-151 155-158    
In view of the opposing actions of ceramide and 
S1P, it has been suggested that the cellular balance between these two sphingolipids could be an 
important determining factor in cell survival or death.
 141-143,149-152,159,160   
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Ceramide biosynthesis and metabolism: An overview 
As evident, ceramide is ultimately at the crux of sphingolipid metabolic pathways, and 
modulating these metabolic pathways will significantly contribute towards controlling 
intracellular ceramide concentration.  
Among the various biological functions of ceramide, of particular relevance is its 
apoptotic potency and specificity.
140-142,148-153,161-165
 Administration of exogenous ceramides to 
cells in vitro has been shown to cause apoptosis, whereas, reducing cellular ceramide levels lead 
to drug resistance. Modulation of ceramide-induced apoptosis is therefore a viable strategy for 
sensitizing neoplastic cells to anticancer agents.
140-142,148-151,166
 The table shown below (Table 2) 
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lists several sphingolipid pathway-associated enzymes as potential targets for ceramide-based 
therapeutics.
142,166,167
  
Table 2. Sphingolipid biosynthetic pathways-associated enzymes as potential anticancer targets 
 
As shown in the table, manipulation of the above biosynthetic pathways can provide a 
means for enhancing drug action, overcoming drug resistance, protecting normal cells from 
cytotoxic actions, and even creation of new chemoprevention possibilities.  
 In view of the anti-tumor role of ceramide, enhancement of endogenous ceramide levels 
is considered an effective way to regulate cell growth. Several anticancer drugs, such as 
Daunorubicin, Camptothecin, Etoposide, Fludarabine, and Gemcitabine promote de novo 
synthesis of ceramide, whereas, Ara-C increases the cellular ceramide level through a SMase 
activation pathway.
146
 
168-170
 An alternative strategy to prolong ceramide half-life is the inhibition 
of the enzymes responsible for its metabolism or activation of enzymes involved in the 
Enzyme Known Modulators Action 
Serine palmitoyl transferase (SPT) 4-HPR; PSC 833 Activation 
Ceramide synthase (CS) 4-HPR; Daunorubicin Activation 
Ceramidase B13; D-MAPP Inhibition 
Ceramide kinase (CERK) K1; NVP-231 Inhibition 
Sphingomyelinase (SMase) Many cancer drugs Activation 
Sphingomyelin synthase (SMS) D609 and prodrugs; Jaspine B Inhibition 
Sphingosine kinase (SK) Safingol; DMS Inhibition 
Sphingosine-1-phosphatase (S-1-P) - - 
Glucosyl ceramide synthase (GCS) P-drugs; NBDJ Inhibition 
1-O-Acylceramide synthase (ACS) PPMP Inhibition 
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biosynthesis of ceramide (Table 2). For example, when tested in a murine model of metastatic 
colon cancer, as well as a prostate cancer xenograft model, B13 (a potent ceramidase inhibitor) 
was found to prevent tumor growth via accumulation of ceramide without affecting the normal 
ceramide level or survival of normal liver cells.
171,172
 Inhibition of Sphingomyelin synthase 
(SMS) has been shown to increase ceramide accumulation in cancer cells.
173,174
 In one particular 
study, a synergistic combination of exogenous ceramide and paclitaxel was found to enhance 
apoptotic death of Tu 138 head and neck cancer cells.
142
  
Strategies leading to agonism/antagonism of these sphingolipids, or modulation of their 
levels could provide attractive cancer therapeutic approaches. Though the study of the bioactive 
sphingolipids is of relatively recent origin, an increased understanding of the specific functions 
of these bioeffector molecules, and rational modulations of these functions could provide novel 
avenues for cancer therapy. The growing body of ongoing investigation suggests that ceramide-
related pathways are a fertile area for the identification and development of novel cancer 
chemotherapeutic agents.  
Encouraged by the above observations, and the promising activity of Jaspine B in 
enhancing cellular ceramide level (via inhibition of sphingomyelin synthase), I initiated a study 
aimed at the synthesis and structure-activity relationship investigation of this novel natural 
product. Details of the studies thus undertaken are reported in the following sections.  
3.3 Previous syntheses of Jaspine B 
For a relatively small molecule (mol. wt. 299), the structural features of Jaspine B are 
somewhat challenging. Aside from three contiguous asymmetric centers, the sterically 
unfavorable all-syn substitution pattern as present in this molecule is also a potential concern in 
any synthetic efforts. The appealing structural / stereochemical challenges and the biological 
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significance of Jaspine B have resulted in more than 20 total syntheses since its isolation 
(2002).
175-198
 The various approaches employed in these synthetic endeavors include chiral pool 
approach, asymmetric synthesis, and organocatalysis. Among these approaches, the chiral pool 
strategy utilizing naturally available enantiopure starting materials such as L-serine and various 
carbohydrates have been the most popular. Among the asymmetric synthetic methods, Sharpless 
asymmetric dihydroxylation of appropriate achiral precursors were the most commonly 
employed approaches.
193,194,197 
The following section briefly reviews a representative cross-
section of the total synthetic endeavors towards Jaspine B. 
L-Serine-based syntheses: 
B.V. Rao’s approach 
The first total synthesis of Jaspine B as reported by Rao in 2005, utilizes L-serine derived 
Garner’s aldehyde 6.1 as the source of chirality (Scheme 6).
179
 Thus, Garner’s aldehyde 6.1 was 
subjected to Grignard addition using vinyl magnesium bromide to afford a mixture of separable 
diastereomeric alcohols (anti:syn = 86:14). The enantiopure major diastereomeric alcohol was 
protected as its benzyl ether derivative 6.2. Ozonolysis of olefin in 6.2 to the corresponding 
aldehyde, followed by its reaction with tetradecylmagnesium bromide afforded an inseparable 
(70:30) mixture of diastereomeric alcohols 6.3. Acetonide deprotection of 6.3 followed by 
selective protection of primary alcohol as TBS ether gave a mixture of the corresponding 
diastereomeric D-ribo- and D-lyxo-phytosphingosines 6.4. Mesylation of secondary alcohol in 
6.4 followed by TBAF promoted TBS deprotection and concomitant cyclization afforded a 
separable mixture (70:30) of the desired tetrahydrofuran 6.5. Subsequent debenzylation followed 
by Boc-deprotection afforded Jaspine B as its TFA salt. 
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Scheme 6 
Ohno’s approach 
In the synthesis by Ohno et al,
184
  starting from (S)-Garner’s aldehyde 6.1, an initial step 
in the synthesis involved formation of the intermediate diol 7.1 (Scheme 7) by a sequence of 
Wittig olefination
199
 using pentadecyl triphenylphosphoniumbromide to form the corresponding 
olefin (as a mixture of Z:E = 13:1), followed by its osmium tetroxide mediated dihydroxylation 
providing the product diol 7.1 as a diastereomeric mixture (77:23). 
 
Scheme 7 
Separation of the enantiopure major diol 7.1 and its derivatization to a ditosylate, 
followed by subsequent removal of the acetonide and Boc-protecting groups and resulting 
cyclization led to the required tetrahydrofuran intermediate 7.2. Finally, cleavage of the tosyl- 
protection completed the synthesis of Jaspine B. 
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Passiniemi’s approach 
In Passiniemi and Koskinen’s synthesis of Jaspine B, addition of the lithiated vinylic 
species 8.1 to Garner’s aldehyde (6.1) afforded a separable diastereomeric mixture (92:8) of 
secondary alcohol intermediate 8.2 (Scheme 8)
180
 . Benzyl protection of the secondary hydroxy 
group of 8.2, and silyl-deprotection formed the allylic alcohol intermediate 8.3. Acetonide 
deprotection forming the diol 8.3 and subjecting it to a Pd (0)-mediated intramolecular 1, 5-
cyclization afforded a separable diastereomeric mixture (2:1) of tetrahydrofuran derivative 8.5. 
Grubbs catalysis assisted cross-metathesis of 8.5 with 1-tetradecene afforded the C2-alkenyl 
adduct 8.6. Tandem hydrogenation and hydrogenolysis of 8.6 with Pd (OH)2/C under H2, 
followed by treatment with dry HCl afforded Jaspine B. 
 
 
 
 
 
Scheme 8 
Shaw’s approach 
Shaw et al have reported a stereoselective total synthesis of Jaspine B utilizing 
iodocyclization as a key reaction key step.
185
 Thus, the allylic alcohol derivative 9.1 (Scheme 9) 
was obtained by a sequence of reactions involving: addition of vinyl magnesium bromide to (S)-
Garner’s aldehyde (6.1) to afford a mixture of the corresponding anti and syn allylic alcohols 
(6:1), followed by separation of the desired anti-isomer and O-benzyl protection of the hydroxy 
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group. Subjecting 9.1 to olefin cross-metathesis with 1-pentadecene in the presence of Grubbs’ 
second generation catalyst, and subsequent acetonide deprotection provided a mixture of the 
olefins 9.2 (E:Z=94:6). The 1, 2-amino alcohol 9.2 on iodocyclization with I2 and N-iodosuccin-
imide (NIS), furnished a diastereomeric mixture (10:1) of the tetrahydrofuran intermediates 9.3a 
(major) and 9.3b (minor). Separation of the major diastereomer 9.3a, its reductive de-iodination 
using n-Bu3SnH/AIBN,
200
 followed by subsequent debenzylation and N-Boc-deprotection 
afforded Jaspine B as a TFA salt.  
 
 
 
 
 
 
 
Scheme 9 
Fujii and Ohno’s approach 
 In Fujii and Ohno’s total synthesis of Jaspine B, a palladium-catalyzed bis-cyclization of 
bromoallene 10.1 (Scheme 10) was utilized as a key reaction step.
201
 The bromoallene 10.1, 
derived from (S)-Garner’s aldehyde,
29,202
  when subjected to palladium-catalyzed reaction using 
Pd(PPh3)4 and Cs2CO3, resulted in a cascade cyclization to form the bicyclic product 10.2. 
Hydroboration-oxidation of the exocyclic olefin in 10.2 afforded primary alcohol 10.3 with the 
desired stereochemistry. Triflation of the alcohol 10.3 followed by copper-catalyzed alkylation 
with a Grignard reagent gave tetrahydrofuran intermediate 10.4 bearing all the requisite 
functionalities. Finally, acidic hydrolysis of 10.4 afforded Jaspine B. 
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Scheme 10 
Phytosphingosine-based approaches: 
Overkleeft’s approach 
 Overkleeft et al have reported the synthesis of Jaspine B, utilizing D-ribo-phyto-
sphingosine (11.1) as a chiral precursor (Scheme 11).
177
 Standard functional group 
transformation of the amine 11.1 resulted in the corresponding azide 11.2.   
 
 
 
 
 
 
 
Scheme 11 
Treatment of 11.2 with trimethylorthoacetate in the presence of a catalytic amount of 
Lewis acid afforded the desired tetrahydrofuran intermediate 11.4. The process is believed to 
proceed through a 5-exo-tet cyclisation involving the ortho ester-derived oxonium intermediate 
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11.3b. Base catalyzed acetate hydrolysis followed by Staudinger reduction of azide in 11.4 gave 
Jaspine B.  
Delgado’s approach 
Delgado et al have reported the total synthesis of Jaspine B involving a key 
intramolecular cyclization of protected N-Boc-phytosphingosine 12.1 (Scheme 12).
131
 The 
primary hydroxy group of N-Boc-phytosphingosine 12.1 was tosylated to afford 12.2, which 
upon intramolecular SN2 displacement afforded the required tetrahydrofuran intermediate. 
Deprotection of N-Boc using TFA afforded Jaspine B as its TFA salt. 
 
Scheme 12 
Kim’s approach 
Kim et al have reported a stereodivergent synthesis of Jaspine B utilizing a D-ribo-phyto-
sphingosine-derived key cyclic sulfate intermediate 13.3 (Scheme 13).
203
 
 
 
 
Scheme 13 
Thus, starting from D-ribo-phytosphingosine, its conversion to the corresponding TBS-
protected azido alcohol 13.1 was achieved following standard reaction procedures. Subsequent 
treatment of 13.1 with SOCl2 provided the cyclic sulfite 13.2. Desilylative cyclisation of 13.2 
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with TBAF forming the desired tetrahydrofuran core, and subsequent reduction of azide afforded 
Jaspine B. 
Sanghee Kim’s approach 
In Sanghee Kim’s total synthesis of Jaspine B, N-Boc-phytosphingosine 14.1 was 
initially converted to the corresponding orthogonally protected oxazolidinone derivative 14.1 
(Scheme 14).
186
 Subsequent deprotection of O-trityl ether and concomitant spontaneous 
intramolecular cyclization provided the required tetrahydrofuran oxazolidinone intermediate 
14.2. Treatment of 14.2 under alkaline conditions afforded Jaspine B. 
 
Scheme 14 
Carbohydrates as starting materials: 
Shaw’s approach 
 Several carbohydrate starting materials have also been utilized as chiral starting materials 
for the enantiospecific syntheses of Jaspine B. Thus, in Shaw’s total synthesis of Jaspine B,
181
 
the D-galactose-derived 3,4,6,-tri-O-benzyl-galactal (15.1) was initially converted to α,β-
unsaturated aldehyde 15.2 (Scheme 15). Luche reduction of the α,β-unsaturated aldehyde 15.2 to 
the corresponding allylic alcohol, subsequent Sharpless asymmetric epoxidation, and 
intramolecular ring opening of the resulting epoxide resulted in the tetrahydrofuran diol 
intermediate 15.3. Acetonide protection of the side chain diol of 15.3 and mesylation of the 
secondary hydroxy group in the tetrahydrofuran ring, followed by its SN2 displacement with 
azide provided 15.4. Deprotection of the acetonide linkage in 15.4 and oxidative cleavage of the 
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diol formed the C2 formyl tetrahydrofuran intermediate 15.5. Wittig olefination of 15.5 using 
tridecyltriphenylphosphoniumbromide to form the corresponding olefin, and global reduction via 
transfer hydrogenation afforded Jaspine B. 
 
 
 
 
 
 
 
Scheme 15 
Du and Linhardt’s approach 
Starting from D-xylose, Du and Linhardt have reported a total synthesis of Jaspine B 
(Scheme 16).
182
 The synthetic sequence started with structural rearrangement of D-xylose (16.1) 
into the corresponding pentose, followed by acetonide protection to afford the acetal 16.2 
(Scheme 16). Subsequent regioselective tosylation of the primary hydroxyl group and 
benzylation of the secondary alcohol afforded 16.3. Acid catalyzed furan ring reconstruction then 
afforded the 2,5-anhydro intermediate 16.4. The secondary hydroxyl of 16.4 was then converted 
to the corresponding azide with inversion of stereochemistry followed by acetal deprotection to 
form the 4-azido-aldehyde intermediate 16.5. Wittig olefination of 16.5 with a C-13 alkyl donor 
provided an inseparable mixture of E- and Z- isomers of the corresponding C-14 olefinic side 
chain derivative 16.6. Finally, in a single step, conversion of azide to amine, O-benzyl 
deprotection, and hydrogenation of the olefinic side chain furnished Jaspine B. 
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Scheme 16 
Du’s approach 
Soon after the above synthetic endeavor, Du et al have described a further refined 
synthesis of Jaspine B.
204
 The key intermediate in this route involved the development of a 
closely related formylfuran intermediate 17.2 via an iodine-induced diastereoselective 
cyclization of an appropriately functionalized olefinic intermediate 17.1 (Scheme 17). 
 
 
 
Scheme 17 
The olefinic triol 17.1 was obtained by oxidative degradation and subsequent Wittig 
olefination of a D-xylose-derived precursor. Subsequently, an iodine promoted olefin activation/ 
debenzylation/cyclization cascade involving 17.1, and further functional group transformation 
led to the 2-formyl tetrahydrofuran derivative 17.2. Employing a similar sequence of reaction as 
in the previous route (Scheme 16) a total synthesis of Jaspine B was achieved. 
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Ramana’s approach 
Ramana et al have reported the synthesis of Jaspine B starting from D-Glucose.
188
 A key 
intermediate in this route involved the formation of a strategic C-2 alkyne substituted 
tetrahydrofuran 18.4 (Scheme 18). Following a literature procedure,
205,206
 conversion of D-
Glucose to the aldehyde 18.1 and its conversion to the corresponding tosylate 18.2 was followed 
by acidic hydrolysis of the acetonide linkage with concomitant cyclization to the tetrahydrofuran 
acetal 18.3. Unmasking of the aldehyde, and an Ohira-Bestmann alkynation
207,208
 afforded the 
key intermediate 18.4. Conversion of the secondary hydroxy group to azide with inversion of 
stereochemistry to form 18.5, and base promoted alkylation of the terminal alkyne with dodecyl 
bromide provided the penultimate alkynyl tetyrahydrofuran 18.6. Global hydrogenolysis 
completed the synthesis of Jaspine B. 
 
Scheme 18 
 
Miscellaneous chiral starting materials: 
Marco’s approach 
Marco et al have reported an enantiospecific synthesis of Jaspine B starting from 
commercially available (R)-glycidol (Scheme 19).
189
 Thus, O-TBDPS protected (R)-glycidol 
19.1 was treated with tridecylmagnesium bromide to afford the corresponding alcohol, which 
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was then protected as its O-methoxymethyl (O-MOM) derivative followed by O-desilylation to 
afford the mono-protected diol 19.2. Swern oxidation of the primary alcohol in 19.2 followed by 
HWE olefination and DIBAL reduction of the resulting α,β-unsaturated ester afforded the allylic 
alcohol intermediate 19.3. Sharpless asymmetric epoxidation of allylic alcohol 19.3 using (-)-
DET afforded the epoxy alcohol which on further treatment with trichloroacetonitrile formed the 
acetimidate 19.4. Structural rearrangement leading to the oxazoline 19.5 and its subsequent 
hydrolysis followed by N-Boc protection afforded the phytosphingosine derivative 19.6. 
Tosylation of the primary alcohol in 19.6 followed by base induced cyclization afforded the 
tetrahydrofuran 19.7 Boc-deprotection of 19.7 completed the synthesis of Jaspine B. 
 
 
 
 
 
 
 
Scheme 19 
Chandrakumar’s approach 
 Chandrakumar et al have reported synthesis of Jaspine B utilizing D-tartaric acid 
(Scheme 20).
190
 Starting with addition of tetradecylmagnesium bromide to tartaric acid 
bisdimethylamide (20.1) provided the corresponding ketoamide, which was subjected to 
stereoselective reduction furnishing a mixture of diastereomeric alcohols (dr = 95:5) with 20.2 as 
the major diastereomer. Treatment of 20.2 with excess 2,2-dimethoxyropane and p-TSA resulted 
in the acetonide rearranged methyl ester derivative 20.3. Subsequent reduction of the methyl 
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ester to primary alcohol and selective O-TBDMS and O-tosyl protections afforded the fully 
protected tetraol derivative 20.4. Displacement of the tosylate with azide with concomitant 
inversion of stereochemistry, and deprotection of the primary hydroxyl group yielded the 
azidohydrin 20.5. Tosylation of hydroxyl group of 20.5 and hydrolysis of the acetonide linkage 
unveiled the diol 20.6. A base promoted cyclization to form the trisubstituted tetrahydrofuran 
core and subsequent azide reduction led to Jaspine B. 
 
Scheme 20 
Ichikawa’s approach 
Ichikawa et al have reported the synthesis of Jaspine B employing a highly 
stereocontrolled [3,3] sigmatropic rearrangement of an allyl isocyanate intermediate as a key 
reaction step (Scheme 21).
191,209
 Thus, following a four-step reaction sequence, the L-tartaric 
acid-derived tetraol 21.1 was converted to the long-chain alkylated triol 21.2. Subsequent 
oxidation of the primary hydroxyl group to aldehyde, its HWE olefination, DIBAL-H reduction 
of the resulting α,β-unsaturated ester, and oxidation of the resulting primary alcohol provided the 
aldehyde 21.3. Enantioselective addition of Et2Zn to the aldehyde 21.3, in the presence of 3-exo-
morpholinoisoborneal (MIB) as a chiral ligand, to form the corresponding carbinol adduct, 
conversion of the resulting hydroxyl group to a trichloroacetimidate, and subsequent hydrolysis 
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yielded the allyl carbamate 21.4.  Triphenyl phosphine promoted conversion of the allyl- 
carbamate 21.4 to the allyl cyanate 21.5 as a transient intermediate, followed by its spontaneous 
[3,3]-sigmatropic rearrangement to the allylisocyanate 21.6, and quenching of the reaction with 
methanol afforded the methyl carbamate 21.7. Acetonide deprotection of 21.7 and base promoted 
intramolecular cyclization afforded the oxazolidinone 21.8. Ozonolytic cleavage of the olefin in 
21.8 led to the formation of a lactol, which on treatment with acetic anhydride provided the 
acetylated derivative 21.9. Reductive cleavage of the acetoxy group, and alkaline hydrolysis of 
the cyclic carbamate culminated in Jaspine B. 
 
Scheme 21 
Asymmetric synthetic approaches: 
Yakura’s synthesis 
The first asymmetric synthesis of Jaspine B was reported by Yakura et al and utilized a 
Sharpless asymmetric dihydroxylation protocol as a key reaction step.
210
 Thus, Sharpless 
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asymmetric dihydroxylation of α,β-unsaturated ester 22.1 provided the diol 22.2 (Scheme 22). 
Acetonide protection of the diol and partial reduction of the methyl ester with DIBAL afforded 
the formyl intermediate 22.3. Subsequent Wittig olefination of the aldehyde 22.3, followed by 
hydrogenation of the resulting olefin and PMB-deprotection in a one-pot reaction resulted in the 
hydroxy alkane 22.4. Conversion of the primary hydroxy group of 22.4 to the iodoalkane 22.5, 
and acid-catalyzed acetonide deprotection followed by intramolecular cyclization formed the 
tetrahydrofuran intermediate 22.6. Subsequent reaction with trichloroacetyl isocyanate, and Rh-
mediated C-H amination gave a diastereomeric mixture, from which the desired enantiopure 
bicyclic carbamate 22.7 was isolated. Hydrolysis of the carbamate linkage completed the 
synthesis of Jaspine B. 
 
 
 
 
 
 
 
 
Scheme 22 
Génisson’s approach 
The synthesis of Jaspine B as developed by Génisson et al started with the easily 
available mono-benzylated trans-butenediol 23.1 (Scheme 23).
193,194
 Thus, Sharpless’ 
asymmetric epoxidation of 23.1 delivered the key epoxide 23.2, which upon ring opening with p-
methoxybenzylamine provided the regioisomeric aminoalcohols 23.3a and 23.3b as an 
inseparable mixture of products (70:30). However, treatment of the above product mixture with 
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methyl chloroformate allowed the separation of the desired oxazolidinone 23.4. Dess-Martin 
oxidation of 23.4 to the corresponding aldehyde 23.5, and its anti-selective addition with a 
vinylcerium reagent afforded the allylic alcohol 23.6. Subsequent conversion of the secondary 
hydroxy group to its mesylate resulted in spontaneous cyclization to form the all-cis-
tetrahydrofuran 23.7. Cross-metathesis of 23.7 with 1-tetradecene using Grubbs second-
generation catalyst, and subsequent hydrogenation of the product olefin resulted in the 
oxazolidinone derivative 23.8 Subsequent PMB deprotection and hydrolytic cleavage of the 
cyclic carbamate afforded Jaspine B. 
 
 
 
 
 
 
 
 
 
 
Scheme 23 
Enders’ approach  
Ender’s asymmetric synthesis of Jaspine B involved a (R)-proline catalyzed diastereo- 
and enantioselective aldol condensation of dioxanone 24.1 and 1-pentadecanal as a key reaction 
step towards the stereoselective formation of the anti-diol 24.2 (Scheme 24).
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secondary alcohol derivative 24.3 with high selectivity. Conversion of the resulting hydroxy 
group to its mesylate and its SN2 displacement with NaN3 with concomitant inversion of the 
stereocenter, followed by a two-step conversion of the silyl-protected hydroxy group to the 
corresponding tosylate afforded the azidotriol 24.4. Acetonide deprotection under acidic 
conditions followed by an intramolecular SN2 displacement of the tosylate afforded the all-syn-
trisubstituted tetrahydrofuran 24.5. Finally, hydrogenation of the azide 24.5 afforded Jaspine B. 
 
 
 
 
 
 
 
Scheme 24 
Britton’s approach 
In Britton’s synthesis of Jaspine B, the first step involved an asymmetric chlorination of 
1-heptenal (Scheme 25). Thus, following McMillan’s method,
211
 1-heptenal (25.1) was 
converted to α-chloro-6-heptenal (25.2) with high selectivity (>99% ee).
196
 A subsequent aldol 
reaction of 25.2 with Boc-protected hydantoin afforded a mixture of diastereomeric 
chlorohydrins (dr= 10:1:1:1), with the desired aldol adduct 25.3 being the major diastereomer. 
Heating a solution of 25.3 in aq. methanol under microwave conditions resulted in the formation 
of the bicyclic lactone 25.6 in moderate yield. The formation of the bicyclic lactone (25.6) has 
been explained via a reaction cascade, wherein initial cleavage of the O-Boc linkage resulted in 
the chlorohydrin intermediate 25.4. Subsequent nucleophilic attack at the highly activated 
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hydantoin carbonyl by the hydroxy group to generate the ring-opened carbamate 25.5, followed 
by N-Boc deprotection and intramolecular displacement of the chloride in 25.5 by amide 
carbonyl oxygen and hydrolysis of the resulting imine ultimately led to the lactone 25.6. 
Subjecting olefin 25.6 to cross-metathesis with 1-undecene and hydrogenation of the resulting 
alkene installed the tetradecyl side chain in compound 25.7. Subsequent conversion of the 
lactone carbonyl to methylene and alkaline hydrolysis of the cyclic carbamate completed the 
synthesis of Jaspine B.  
 
 
 
 
 
 
 
 
 
Scheme 25 
3.4. Structure-activity relationship (SAR) studies of Jaspine B  
As described in the previous section, since its isolation in 2002, several total and formal 
syntheses of Jaspine B have been reported in the literature.  In contrast, despite its known 
anticancer potential, any systematic or detailed studies aimed at co-relating the structural 
elements and biological activity of this unique natural product remains relatively scarce. Based 
on the available information from the reported studies, the major structure-activity relationships 
(SAR) of Jaspine B are summarized below (Figure 17).
129,131,193,194,203,212,213
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Figure 17. Jaspine B structure-activity relationships: An overview 
Evidently, the cyclic form of Jaspine B is essential for biological activity as the 
corresponding open chain analog (D-ribo-phytosphingosine) was found to be inactive. It was 
observed that, the epimeric analogs at various stereocenters were partially active. The alkyl chain 
at C2 is amenable to minor modifications with the resulting analogs retaining activity. However, 
any modifications of the C3-hydroxy group were found to be detrimental to activity. 
Interestingly, bioisosteric replacements of the core tetrahydrofuran ring oxygen atom with amine 
(NH), sulfur (S), and selenium (Se) groups resulted in activity retention. However, all the Jaspine 
B analogs reported thus far have been found to be less active than the natural product. 
With the aim to carry out a detailed SAR investigation of Jaspine B, we initiated the 
present study, wherein, development of a flexible synthetic route to the natural product, and 
further application of the method for systematic structural modification studies were targeted. 
Results of the studies thus undertaken are described hereunder.      
3.5. Towards Jaspine B: Previous studies from our research group  
Soon after the isolation and biological activity of Jaspine B (2002–2003) were reported, 
our research group undertook a preliminary study aimed at the total synthesis of this bioactive 
natural product. The retrosynthetic strategy for the intended synthesis envisioned utilization of 
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the serine-derived chiral aminobutenolide 1 (Figure 18) as a strategic chiral platform towards 
rapid construction of the all syn-2,3,4-trisubstituted structural framework of Jaspine B. 
 
 
 
 
Figure 18. Jaspine B: Retrosynthetic strategy 
 As mentioned previously, the aminobutenolide 1 has been shown to be a highly versatile 
and useful chiral building block in our research. In further utilization of this multifunctional 
lactone, it was proposed that, starting from 1, selective deprotection of the N, O-acetonide 
linkage of 1 and possible Michael addition of the resulting primary hydroxy group into the -
carbon of the butenolide should provide the bicyclic lactone 6 (Figure 18). Stereoselective 
formation of the cis-fused [5,5]-bicyclic scaffold of 6 is expected due to the highly unfavorable 
ring strain associated with the alternative trans-ring junction between the two five-membered 
rings. The formation of the bicyclic lactone 6 should also install the C2, C3, and C4-stereo-
centers as present in Jaspine B. Standard functional group transformations involving the right 
hand side lactone moiety will complete the synthesis of the desired all syn-tetrahydrofuran 
natural product 5. 
Accordingly, acid catalyzed hydrolysis of the N,O-acetonide linkage of 1, followed by 
treatment of the crude product with aqueous bicarbonate directly afforded the bicyclic lactone 6 
(Scheme 26) as the only product. The assigned stereochemistry and the all syn-relationship 
between the three contiguous asymmetric centers as present in 6 were confirmed on the basis of 
its X-ray crystal structure.  As expected, the favorable energetics involved in the cis-fused [5,5] 
bicyclic ring forming reaction during the above intramolecular Michael addition contributed to 
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the exclusive formation of product 6 as shown. Towards introduction of the C2-tetradecyl side 
chain, DIBAL-assisted partial reduction of the lactone carbonyl to the lactol derivative 26.1 and 
its standard condensation with a Witting reagent derived from dodecylphosphoniumbromide 
resulted in the corresponding olefins 26.2 as an inseparable mixture of E- and Z-isomers. 
Interestingly, the C3-secondary oxyanion generated during the Wittig reaction mediated ring 
opening of the lactol underwent intramolecular addition to the favorably disposed N-Cbz-
carbonyl group, resulting in the concomitant formation of the cyclic carbamate protected 
tetrahydrofuran derivative 26.2.  Hydrogenation of the side chain olefin of 26.2 to the 
corresponding saturated alkane 26.3, followed by alkaline hydrolysis of the cyclic carbamate 
culminated in the synthesis of Jaspine B (Scheme 26). A manuscript detailing the results of the 
above study was subsequently published (early 2005),
28
 and became only the second reported 
total synthesis of ‘Jaspine B’ at that time. 
 
 
 
 
 
 
 
Scheme 26 
However, in a subsequent study (2008), Davies and co-workers found that, the product 
formed in our above reported synthesis is not the natural (2S,3S,4S) Jaspine B, but the 
corresponding C2- epimeric analog  27.5 instead (Scheme 27).
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Scheme 27 
Davies’ reassignment of the above stereochemistry was based on comparison of the 
spectroscopic data of Jaspine B and the C2-epimer 27.5, as available from several studies 
published subsequent to our publication. To rationalize the formation of this unexpected product, 
Davies also suggested an alternative reaction pathway, wherein the in situ formed aldehyde 
intermediate 27.1 (Scheme 27), generated from the lactol 26.1 under the base mediated Wittig 
olefination reaction condition, undergoes facile C2-epimerization via a retro-Michael–Michael 
addition sequence (through intermediacy of 27.2), resulting in the sterically more favorable C2–
C3 trans-substituted 2-formyl tetrahydrofuran intermediate 27.3. Subsequent transformations 
involving the (2R)-aldehyde 27.3 ultimately led to the C2-epi-Jaspine B as obtained. 
3.5.1. Present research: A revised total synthetic route to Jaspine B 
  In view of the rather surprising and unexpected outcome of the above Jaspine B synthetic 
endeavor, in my present research, I decided to investigate an alternative reaction strategy to 
circumvent the undesired C2-epimerization.  
Accordingly, starting from the advanced bicyclic lactone 6, exhaustive reduction of the 
ester functionality provided the diol 28.1 in good yield (Scheme 28). Although the above 
55 
 
reduction could also be achieved using an excess of DIBAL alone, the recovery of the product 
diol was found to be poorer compared to the two step sequence involving initial DIBAL (1.2 
equiv) reduction of the lactone to the corresponding lactol, followed by further reduction of the 
crude reaction product with sodium borohydride. Subsequent regioselective protection of the C3-
C4 amino alcohol functionalities as the oxazolidine 28.2, and conversion of the free primary 
hydroxy group to the corresponding tosylate 28.3 was achieved in good overall yield. 
 
 
 
 
 
 
 
Scheme 28 
Towards installation of the natural tetradecyl substituent at C2, facile SN2 displacement 
of the tosylate with an in situ generated dodecyl organocuprate reagent as shown, uneventfully 
provided the fully protected Jaspine B derivative 28.4. Finally, global deprotection of 28.4 under 
acidic conditions afforded Jaspine B as its HCl Salt. 
The specific rotation {[ ]D = 2.5 (c 0.46, MeOH); lit.
175
 [ ]D = 2.6 (c 0.4, MeOH)}, and 
the NMR spectral data of the Jaspine B salt as obtained above, are in good agreement with the 
literature reported values,
175
 thereby unambiguously confirming the product structure.
 
As reported by the Davies study,
175
 a major difference in the 
1
H-NMR spectra between 
Jaspine B and its diastereoisomeric 2-epi-analog is the chemical shift pattern involving one of the 
C5-protons. Thus, in the proton NMR spectrum of 2-epi-Jaspine B, the above diagnostic peak is 
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observed at  4.14 ppm, whereas the corresponding spectrum of the natural, all cis Jaspine B is 
characterized by the absence of any peaks above  4.0 ppm. In accordance with the above 
observations, comparison of the 
1
H-NMR spectra of Jaspine B from the present study (in the free 
amine form, obtained by neutralization of the corresponding salt), and the corresponding 2-epi-
analog (as obtained by us previously), displayed the characteristic chemical shift differences as 
expected (Figure 19), confirming the structural identity and stereochemical integrity of the 
products obtained (full spectra data provided in the Experimental Section). 
 
 
 
 
 
 
 
Figure 19. Comparison of the 1HNMR spectra (  3–5 ppm) of Jaspine B and 2-epi-Jaspine B 
 In conclusion, starting from the same bicyclic lactone 6 as in the previous effort from our 
research group, but employing a modified synthetic route, a stereoselective total synthesis of 
enantiopure Jaspine B has been accomplished.   
3.5.2. Wittig olefination approach to Jaspine B: A reinvestigation of our initial synthesis 
While pursuing the above synthesis, it was considered worthwhile to also reinvestigate 
the earlier reported synthetic route (Scheme 26) from our initial studies, as it could provide a 
complimentary method towards synthesizing 2-epi-Jaspine B analogs for possible SAR studies. 
Accordingly, following the previously developed synthetic route from our group (Scheme 26), 
the bicyclic lactone 6 was subjected to DIBAL reduction to form the lactol 26.1. Subsequent 
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Wittig olefination, followed by employment of the same reaction protocol as earlier completed 
the purported total synthesis of 2-epi-Jaspine B. However, to my utter surprise, spectral and 
analytical data of the product thus obtained was found to be identical to the natural Jaspine B 
stereoisomer, and not the expected 2-epi-analog. As the C2-epimerization in our previous 
synthesis of Jaspine B step was suspected to have taken place under the basic reaction conditions 
of the Wittig olefination (27.1  27.3: Scheme 27), I therefore repeated the sequence once 
again, and performed the Wittig reaction in the presence of an excess amount of base (5 equiv). 
However, the product Jaspine B ultimately obtained from this effort too was found to be the 
natural stereoisomer, and not the C2-epimer thereof. The above experiments point to the fact 
that, the epimeric Jaspine B, as obtained during our previous synthetic endeavor, did not result 
from the proposed base mediated epimerization of the transient aldehyde intermediate 27.3. 
While we were pondering the implications of the above study, an interesting publication 
appeared, adding another intriguing element to the overall mystery.
186
 In this study, pursuing the 
total synthesis of Jaspine B and its 2-epi-analog, Kim et al developed a route, wherein a strate-
gically functionalized common precursor I was utilized to selectively obtain either the all-syn-
substituted bicyclic oxazolidinone II, or the corresponding 2-epi-analog III (Figure 20). 
Subsequent oxazolidinone ring cleavage led to Jaspine B, and 2-epi-Jaspine B respectively. 
 Surprisingly, while comparing the spectral and analytical data of the above 
oxazolidinones I and II with the corresponding intermediate as reported in the earlier synthesis 
from our group, Kim observed that the oxazolidinone formed during our study is indeed the 
initially assigned all-syn compound 26.3 (Scheme 26), and not the subsequently suggested C2-
epimeric analog 27.5 (Scheme 27) thereof.   
58 
 
 
 
 
 
 
 
 
 
Figure 20. Kim’s bicyclic oxazolidinones I and II en route Jaspine B and 2-epi-Jaspine B186
 
 The above observations from Kim’s study, and our own studies repeating the Wittig 
olefination sequence therefore confirmed that, while the final product obtained from our initial 
synthesis is indeed 2-epi-Jaspine B, the epimerization could not have been caused by base/basic 
conditions of the Wittig reaction process. 
In view of the above conclusion, we herein propose an alternative mechanistic pathway 
rationalizing the epimeric Jaspine B formation in our previously reported synthesis. It is possible 
that, an acid catalyzed epimerization occurring during the lactone to lactol reduction step could 
be responsible for the C-2 epimeric Jaspine B in our previous synthesis. In a probable scenario, 
during the material build-up process of the synthesis, use of an older/improperly stored lot of 
DIBAL-H, contaminated with partially decomposed reagent as impurities, could have provided 
the Lewis acidic metal ion responsible for catalyzing the epimerization of the lactol intermediate 
(Figure 21).  Thus, it can be postulated that, in the presence of a Lewis acidic contaminant 
present in the DIBAL reagent used, the hydroxyaldehyde A in equilibrium with the lactol 26.1, 
undergoes a tetrahydrofuran ring-opening reaction via a -elimination process (Figure 21). 
Recyclization involving an intramolecular Michael addition of the alkoxide B onto the , -
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unsaturated aldehyde then results in the sterically more favorable 2,3-trans-substituted C2-
epimeric aldehyde (Figure 21), leading to the subsequently obtained 2-epi-Jaspine B. 
 
 
 
 
 
 
 
Figure 21. Formation of 2-epi-Jaspine B: An alternative mechanistic rationale 
Accordingly, it is possible that, during the previously reported synthesis from our group, 
the compound characterization data as reported for the bicyclic oxazolidinone 26.3 was obtained 
from an initial batch of reaction product (standardization step), wherein non-contaminated 
DIBAL was used as the reducing agent. However, in moving forward with the total synthesis 
endeavor, in the subsequent scaled-up version of the reaction, possible use of a contaminated 
reagent bottle could have led to the formation of the epimeric aldehyde, ultimately leading to 2-
epi-Jaspine B.  
However, future studies, involving carefully designed experiments mimicking the 
postulated acid catalyzed reaction conditions, will have to be performed to confirm (or disprove) 
the above-suggested alternative mechanistic pathway (Figure 21).      
3.5.3. Structure-activity relationship studies of Jaspine B 
 In devising the total synthetic route to Jaspine B during my present studies, we also 
intended to utilize the method developed to investigate structure-activity relationships of this 
bioactive natural product. Thus, following the above synthetic approach, and utilizing various 
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advanced intermediates from the total synthesis endeavor, I embarked on the following SAR-
targeted modifications of Jaspine B. Unfortunately, there are no X-ray crystal structures of 
Sphingomyelin synthase, limiting any structural information of the target-binding site of the 
enzyme. Therefore, the present structural modification studies have been devised basing on 
classical medicinal chemistry approaches.     
3.5.3.1. C2-Side chain modified analogs of Jaspine B 
C2-Alkyl analogs:  
Jaspine B has a long lipophilic alkyl chain at the C2-position. Although some of the 
previous studies have targeted modification of this tetradecyl side chain, there has been no 
systematic study co-relating optimum chain length and bioactivity. Accordingly, our first SAR 
aim has been the identification of optimum chain length required for activity. Thus, replacement 
of the tetradecyl side chain of Jaspine B with a short chain (propyl); medium chain (hexyl) and a 
benzylic functionality was planned for the present study. In addition to its lipophilicity, the 
benzyl functional group containing analog was also intended to probe possible π-π interactions 
with any suitably disposed aromatic amino acid residues at the enzyme-binding pocket. 
Syntheses of the designed analogs (Scheme 29) were initiated from an advanced chiral 
intermediate 28.3 from our total synthetic route. Thus, following the same reaction protocol as in 
 the synthesis of Jaspine B, displacement of the tosylate 28.3 with in situ generated alkyl 
magnesiocuprates as shown, afforded the corresponding C2 alkylated analogs 29.1-29.3 (Scheme 
29) in good yields. One-pot removal of both the acetonide, and the carbamate protecting groups 
under acidic conditions provided the three desired analogs 29.4-29.6 as the corresponding 
hydrochloride salts. 
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Scheme 29 
C2-Ether analogs:  
 The natural tetradecyl side chain of Jaspine B renders the molecule highly lipophilic 
(CLogP = 6.21). Aiming to modulate the lipophilicity of the above substituent, we decided to 
investigate analogs wherein a methylene group in the C2-alkyl chain will be subjected to 
bioisosteric replacement with a more polar oxygen functionality. It was reasoned that, in addition 
to increased polarity of the intended analogs, the oxygen atom in the side chain could also serve 
as a potential H-bond acceptor at the target-binding site. 
Once again, utilizing an advanced intermediate 28.2 from our total synthesis, the desired 
analogs could be accessed in a rapid and efficient manner (Scheme 30). 
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Thus, starting from the bicyclic tetrahydrofuran intermediate 28.2, deprotonation of the 
primary hydroxyl group and subsequent O-alkylation with appropriate alkyl halides led to the 
formation of the corresponding alkoxy analogs 30.1-30.3 (Scheme 30) in good yields. Following 
a two-step deprotection sequence, initial hydrolytic cleavage of the oxazolidine ring forming the 
N-Cbz-protected amino alcohols 30.4-30.6, followed by hydrogenolytic removal of the amine 
protecting group yielded the target C2-alkyloxyalkyl analogs 30.7-30.9 in good overall yields. 
C2-Alkylamine analogs:  
In continued studies aimed at bioisosteric modification of the C2- alkyl chain of Jaspine 
B, bioisosteric replacement of one of the side chain methylene groups with an amine (NH) group 
(Scheme 31) was undertaken. In addition to increasing the hydrophilicity of the molecule, it was 
also envisioned that, the amine moiety thus introduced in the side chain could provide a 
favorable tool towards probing potential H-bond interactions (both as donor and acceptor) with 
appropriate amino acid residues at the enzyme-binding pocket.  
The syntheses of the intended analogs were initiated with the bicyclic lactol intermediate 
26.1 from our total synthesis route. Thus, subjecting the lactol 26.1 to standard reductive 
amination with selected primary amines in the presence of sodium acetoxyborohydride provided 
the corresponding C2-alkylamino tetrahydrofuran derivatives 31.1-31.3 (Scheme 31) in good 
yields. Subsequent hydrolytic removal of the Cbz-protecting group uneventfully resulted in the 
desired C2-alkylamine substituted Jaspine B analogs 31.4-31.6 as the corresponding HCl salts. 
 
 
 
 
Scheme 31 
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3.5.3.2. C4-Amine modified analogs of Jaspine B 
 Except for a surprisingly few reports involving functionalization of the C4-amine group 
of Jaspine B, there have been no SAR studies to determine the role, or effect of the above amine 
in the biological activity of this cytotoxic natural product. We therefore decided to carry out 
strategic modification of the C4-amine and evaluate the effect on biological activity. 
C4-Guanidine analog:  
 In addition to strong H-bond forming capabilities, the relatively higher basicity and 
increased affinity for ionic interactions with appropriate counter anions at enzyme binding 
pockets render the guanidine moiety a preferred replacement for amine groups in investigational 
bioactive molecules. The potent neuraminidase inhibitor anti-influenza drug Zanamavir is an 
example of such an approach, wherein, an amine to guanidine modification of a previous 
generation lead compound resulted in several fold increase in binding affinity of the drug.
214
  
Accordingly, with an aim to probe/modulate the possible biological role of the C4-amine 
of Jaspine B in ionic, or salt-bridge forming interactions, we decided to investigate the synthesis 
of the corresponding C4-guanidine analog of Jaspine B. Thus, staring from Jaspine B, as 
obtained from our total synthesis, its reaction with the known guanidine transfer reagent 32.1 
(Scheme 32) under standard conditions cleanly provided the corresponding di-Boc-protected 
guanidine derivative 32.2. Removal of the Boc-protecting groups with trifluoroacetic acid 
resulted in the desired C4-guanidino Jaspine B analog 32.3.  
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C4-Azide analog:  
 Replacement of the C4-amine of Jaspine B with a polar and linear azide moiety was next 
investigated. Thus, in a one-step process, reaction of Jaspine B with freshly prepared triflic azide 
(Scheme 33) directly provided the corresponding C4-4-azido-Jaspine B (33.1) in good yield. 
 
 
 
 
Scheme 33 
C4-Triazolo analogs:  
 Having easy access to the above C4-azide analog (33.1) also created an opportunity to 
investigate replacement of the amine group of Jaspine B with a biologically relevant triazole 
motif. Structurally, the triazole moiety possesses a large dipole, is capable of H-bond 
interactions, and is a mimic of amide bond planarity. In drug design strategies, the triazole 
moiety is often used as a bioisosteric replacement for amides, and also to modulate polarity and 
bioavailability via H-bond interactions of the analog.
215
  
 Installation of the target triazole group at the C4-position of Jaspine B was accomplished 
following a Sharpless click reaction.
216
 Thus, subjecting the azido analog 33.1 to a Cu (I) 
catalyzed 1,3 dipolar cycloaddition with 1-pentyne led to the regioselective formation of the 
corresponding 4-(1,4-disubstituted-triazolo) Jaspine B analog 34.1 (Scheme 34) in good yield.  
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Similarly, employing the Fokin protocol,
217
 1,3-dipolar cycloaddition of the azide 33.1 
with 1-butyne in the presence of catalytic RuCp*Cl(PPh3)2 afforded the regioisomeric 4-(1,5-
disubstituted-triazolo)Jaspine B analog 34.2 (Scheme 34).   
3.5.3.3. C2, C4 Modified Analogs: Synthesis of ‘Jaspine B–Ceramide’ hybrids 
A free amine or amide thereof is an integral structural component of the bioactive 
sphingolipids (Figure 16). For example, in ceramide, the amine group is derivatized to a fatty 
acid amide. Considering the ceramide and Jaspine B structural similarities (highlighted red in 
Figure 22 below), it is considered worthwhile to investigate whether the attachment of 
appropriate acyl/alkyl groups onto the C4-amine of Jaspine B, matching the 
lipophilic/steric/electronic features of ceramide even more closely, would result in derivatives 
with improved interactions at the various ceramide processing enzyme binding site(s). 
Accordingly, we performed a molecular modeling study to probe the possible structural overlaps 
among: (i) ceramide, (ii) Jaspine B, and two hypothetical analogs, (iii) 4-N-palmitoyl Jaspine B 
(mimicking the corresponding amide functionality of ceramide), and (iv) a C2, C4 doubly 
modified  ‘ceramide-Jaspine B hybrid’ (Figure 22). 
 
Figure 22. Ceramide, Jaspine B, and hypothetical analogs iii and iv. Similarities and overlap 
The structures were optimized in SYBYL according to default optimization thresholds 
and were then overlaid according to positions of functionally conserved heteroatoms. As evident, 
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in addition to the excellent overlap among the central structural cores of all the above four 
molecules, the close spatial orientation of the lipophilic C2/C4 functionalities of these 
compounds provide a strong incentive to investigate the proposed ‘ceramide-mimic’ Jaspine B 
analog as a potential chemical tool towards beneficial modulation of ceramide action. 
C4-Fatty acid amide analog: 
Based on the above premise, synthesis of a C4-caboxamide analog was undertaken. 
Accordingly, Jaspine B was reacted with tridecanoyl chloride in the presence of sodium 
bicarbonate in a biphasic medium, providing the corresponding Jaspine B carboxamide analog 
35.1 (Scheme 35).  
 
 
 
Scheme 35 
Jaspine B – Ceramide hybrid: 
 The synthesis of the desired Jaspine B–Ceramide hybrid was initiated from the same 
lactol intermediate 26.1 as obtained from our total synthetic route. Accordingly, Wittig 
olefination of the masked aldehyde 26.1 with a methyl triphenylphosphonium bromide derived 
reagent, formed the corresponding C2-allyl-substituted bicyclic oxazolidinone 36.1 (Scheme 36). 
Installation of the desired tetradecenyl side chain at C2 was accomplished by subjecting 36.1 to 
an olefin cross-metathesis reaction in the presence of Grubbs second- generation catalyst, 
selectively affording the corresponding E-alkene derivative 36.2. Alkaline hydrolytic cleavage of 
the oxazolidinone ring afforded the free amine 36.3. Finally, treatment of the amine 36.3 with 
palmitoyl chloride culminated in the novel Jaspine B–Ceramide hybrid 36.4. 
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Scheme 36 
3.5.4. Cytotoxic activity assays of the Jaspine B analogs against B16 melanoma cells 
To determine the effects of C2-side-chain modifications on cytotoxic activity, the C2-
alkyl chain modified analogs (29.4-29.6; 30.7-30.9; 31.4-31.6) were evaluated in murine B16 
melanoma cells by resazurin assay (the details of the assay protocol are described in the 
experimental section). Jaspine B and the anticancer drug paclitaxel (Taxol
®
) were also included 
as references in this assay. As can be seen from the figure below (Figure 23), the synthetic 
Jaspine B exhibited a dose-dependent cytotoxicity comparable to the natural product (IC50 = 
0.56 M), and is 20 times more potent than Taxol
®
 (IC50 = 10.2 M). In an interesting trend, it 
was observed that, shortening of the tetradecyl side chain of the natural product to a hexyl analog 
(29.5) retained substantial activity (IC50 = 3.3 M), whereas further shortening to a propyl side 
chain (29.4), or incorporation of a benzylic moiety (29.6) resulted in significant activity loss 
(IC50> 25 M). It is worth noting that, the CLogP value (1.978) of the C2 hexyl analog 29.5 
indicates a substantial improvement in its hydrophilicity compared to Jaspine B (CLogP 6.21). In 
the C2-alkoxy series, the bioisosteric replacement of an internal methylene group with oxygen, 
the long chain alkyloxy analog 30.8 retained substantial activity (IC50 2.04 M), while the 
corresponding shorter chain (30.7), or the benzyloxy analog (30.9) are devoid of activity (IC50> 
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25 M). In C2-alkylamine series, the long chain alkyl amine derivative 31.6 (IC50 1.7 M) is the 
most active compound among all the analogs synthesized. The other congeners in this series are 
inactive (IC50> 25 M). 
 
 
 
 
 
 
 
 
 
 
Figure 23. Murine B16 melanoma cell cytotoxic activities of Jaspine B, Taxol, and the 
C2-side chain modified Jaspine B analogs in Resazurin assay (active analogs shown) 
 
The results from the above preliminary studies clearly indicate that the C2-alkyl 
substituent of Jaspine B could be a potentially beneficial site for a more detailed and systematic 
SAR investigation towards improvement of its anticancer activity and efficacy. The encouraging 
activity of the alkylamino analog 31.6 also points towards a possible approach towards 
improving the hydrophilicity of these compounds. While the cytotoxic activities of the remaining 
C4-, and C2, C4-modified analogs (33.1, 34.1, 34.2, 35.1, and 36.4) are yet to be determined, it 
is expected that, once available, the results from these assays too will provide important 
directions towards future design of analogs with improved activity.    
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3.5.5. Synergistic cytotoxic effect of Jaspine B-Paclitaxel combination against B16 
melanoma cells 
 
As discussed earlier, various anticancer drugs (including Taxol
®
) are known to cause 
cellular accumulation of ceramide and, malignant cells appear to be more sensitive to the effects 
of ceramide perturbation and/or generate ceramide more selectively in response to drugs. Thus, 
in a potential synergistic scenario, increased ceramide generation with concomitant inhibition of 
its metabolism could provide an even more efficient and cancer cell selective approach to 
chemotherapy with reduced collateral toxicity to normal tissues. As a proposed inhibitor of 
sphingomyelin synthase, Jaspine B action is expected to prolong the half-life of cellular ceramide 
via prevention of its metabolic conversion to sphingomyelin. It was therefore considered 
worthwhile to study the effect of a systematic combination of Jaspine B and Taxol
®
 and 
investigate any potential synergism. The single-agent IC50 value of Jaspine B and Taxol
®
 were 
determined to be approximately, 0.6 g/mL and 10 g/mL, respectively, against murine B16 
melanoma cells in conventional cytotoxicity assays (using resazurin readouts as in figure 23 
above). In experiments designed to test whether the presence of both compounds would result in 
additive or synergistic effects, a ‘checkerboard titration’ experiment was performed where both 
Jaspine B and Taxol
®
 concentrations were simultaneously varied using an automated liquid 
handling program implemented on a Bio-Tek Precision 2000 XS instrument, wherein one 
compound is diluted ‘down’ the plate, while the other compound is diluted ‘across’ the plate. As 
shown below (Figure 24), gradual increase in Taxol
®
 concentration results in progressive 
increase in the cytotoxicity of Jaspine B; and, sub-inhibitory concentrations of Taxol
®
 (0.892 
g/mL) drastically reduces the viability of the melanoma cells when incubated with even <10 ng/ 
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mL of Jaspine B (Fig. 24, left panel). A Schild-type plot of IC50 attributable to Jaspine B as a 
function of concomitant Taxol
®
 concentration (Fig. 24, right panel) also indicated a potential 
synergistic effect of the two compounds. 
Figure 24. Inhibition of murine B16 melanoma cells as a function of simultaneous variation of 
Taxol® and Jaspine B concentrations (left panel), and, plot of Jaspine B-induced melanoma cell 
growth inhibition as a function of Taxol® concentration (right panel). 
 
The above experiments point towards a potentially beneficial chemotherapeutic approach, 
wherein, combination of Jaspine B with cellular ceramide level enhancing known anti-cancer 
agents, could provide a synergistic pathway in triggering ceramide-induced apoptotic events in 
cancer cells. Such a strategy could also offer potential means to avoid/overcome development of 
drug resistance otherwise caused by evasion of apoptosis.  
3.6. Concluding remarks 
 An efficient and practical total synthetic route to Jaspine B has been developed during the 
present research. Easy amenability of the above method towards strategic structural 
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modifications has also allowed easy access to a number of unique Jaspine B analogs for hitherto 
unknown SAR investigations. Simultaneously to the above studies, a previously reported 
synthetic route to Jaspine B from our group has also been reinvestigated in order to help clarify 
some unanswered questions. Gratifyingly, the results from the above study have also confirmed 
the utility of the previous route in stereoselective synthesis of enantiopure Jaspine B.  
 Results of the SAR investigations from the present study have contributed useful 
structural information towards future design and development of further improved analogs based 
on the Jaspine B structural lead.  Results from the studies investigating potential synergism 
involving Jaspine B and Taxol
®
 combination have been very promising. In future studies, this 
approach will be further investigated to study possible synergistic combinations of other 
ceramide level enhancing anticancer drugs (Paclitaxel, Camptothecin, Vincristine, Doxorubicin, 
Etoposide, Tamoxifen etc), with Jaspine B/active analogs thereof. These studies will be 
performed in cell lines relevant for Taxol (Breast cancer cell lines) and Taxol-resistant cell lines. 
The effect of combination (both Taxol and Jaspine B) on normal growing cell lines and in vivo 
xenograft model studies will also be pursued. 
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Chapter 4 
A Rapid Approach Towards Diastereoselective Synthesis of Azacarbohydrate Scaffolds of 
Biological Significance 
4.1 Introduction 
A wide range of monocyclic and bicyclic polyhydroxylated alkaloids (Figure 25), 
commonly termed as iminosugars/azacarbohydrates, has been isolated from various plants, 
insects and microorganisms. Acting as carbohydrate mimics, many of these compounds have 
been found to be potent inhibitors of glycosidase and glycosyl transferase enzymes.
218-220
  Since 
the initial discovery of the glycosidase inhibitory activities of the azacarbohydrates in the 1970’s, 
the promising potential of these compounds as a new generation of therapeutics for the treatment 
of diseases such as diabetes,
221
 viral infections,
222,223
 cancer,
224
 and metabolic disorders
225
 has 
opened up exciting new opportunities in various drug discovery endeavors.  
 
Figure 25. Representative examples of natural azacarbohydrates and analogs thereof 
During the last few decades, rapid advancements in the fields of iminosugar chemistry 
and biology have also extended the scope of this class of compounds as inhibitors of a number of 
other enzymes such as phosphorylases, metalloproteinases, and glycosyltransferases. In recent 
years, the azacarbohydrate analogs, Miglitol/Glyset
®
 (N-hydroxyethyl-1-deoxynojirimycin), and 
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Miglustat/Zavesca
®
 (N-butyl-1-deoxynojirimycin) (Figure 25) have received FDA-approval for 
use in patients with type II diabetes,
226
 and type I Gaucher’s disease,
227
 respectively.    
The interest in iminosugars stems from the fact that, both conformationally
228
 and 
electronically
228
 they resemble the proposed transition state structure of the enzyme-catalyzed 
hydrolysis of glycoconjugates (Figure 26). During glycoside hydrolysis, protonation of the 
anomeric ether linkage is followed by formation of an oxocarbenium ion intermediate that adopts 
a half-chair conformation and possesses a positively charged endocyclic oxygen atom (A: Figure 
26). Similarly, iminosugars bear a structural resemblance to the enzyme’s natural substrate and 
mimic this oxocarbenium ion transition state, as the amino group exists as protonated form under 
physiological conditions. (B: Figure 26).
228-230
  
 
 
 
 
Figure 26. Structural mimicry between oxonium ion transition-state of glycoside hydrolysis (A), 
and protonated deoxynojirimycin (B) 
 
Thus, as transition-state mimetics, iminosugars are often capable of binding more tightly 
in the enzyme active site than the natural substrate. For example, 1-deoxynojirimycin (Figure 25) 
has 5 fold greater binding affinity to α-glucosidase than the natural substrate glucose.
228
 The 
anomeric carbon in iminosugar is still sp
3
 hybridized and they do not adopt a half-chair 
conformation as expected for oxocarbenium transition-state analogs of glycosidase cleavage 
processes.
229
 Importantly, the replacement of the endocyclic oxygen atom of carbohydrates with 
a nitrogen atom in iminosugars renders the latter compounds metabolically inert, but does not 
affect their recognition by glycosidases.
228
 Structural resemblance of the iminosugars to 
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carbohydrates also endows them with unique properties such as, transportation by carbohydrate 
transporters, and the ability to cross the blood-brain barrier etc, while the polar nature of the 
molecules helps retain their water-solubility and normal, unchanged excretion from the body.
231
 
Broad range of biological activities, and challenging structural features of the 
azacarbohydrates have thus attracted growing interest in the synthesis, structural modifications, 
and biological evaluations of this class of compounds. In the following section, I will briefly 
discuss the recent literature reports on the synthesis of representative azacarbohydrates. 
4.2. Overview of azacarbohydrate synthesis 
Azacarbohydrates, with multiple chiral centers, several polar hydroxy functionalities, and 
lack of a chromophore in the structural core, present considerable challenges in any synthetic 
endeavor. Accordingly, application of chiral pool materials, orthogonal protection-deprotection 
protocols, and use of specialized techniques for analysis and separation have been some of the 
useful strategies/tools employed in the synthesis of the various azacarbohydrates.
232-237
 
 
  A common synthetic approach for this class of compounds has been the utilization of 
readily available carbohydrate starting materials, wherein, initial introduction of an amine 
functional group in the sugar core is followed by aminocyclization towards formation of the 
piperidine/pyrrolidine ring structure of the target iminosugar.
232-237
 Some of the strategies 
employed for the performance of the above aminocyclization reaction include intramolecular 
versions of: reductive amination of aldehydes/ketones, SN2 displacement of suitably located 
leaving groups by amines, or, addition of amines onto activated olefins. Alternatively, 
simultaneous amination and cyclization have also been achieved employing a one-pot protocol, 
via reaction of ammonia (or a primary amine) with a di-functionalized sugar.
232-237
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In addition to carbohydrates, other chiral pool starting materials such as amino acids,
238-
241
 and tartaric acid
242
 etc. have also been utilized in a number of other synthetic approaches to 
iminosugars. Some of the other reported approaches leading to the azacarbohydrates include, 
construction of the nitrogen containing cycle via Diels-Alder reactions of appropriate substrates, 
Grubbs olefin metathesis, asymmetric synthetic methodologies towards stereoselective 
installation of hydroxy and amine bearing functionalities etc.
237,243-251 
Representative synthetic 
routes to various azacarbohydrates are briefly reviewed in the following section. 
Fleet’s approach 
In extensive studies, Fleet and co-workers have reported the syntheses of azacarbohydrate 
scaffolds utilizing monosaccharides as starting material.
235
 1-Deoxynojirimycin, an analog of D-
glucose in which the ring oxygen has been replaced by nitrogen, is the archetypal azasugar 
(Scheme 37). In the described synthesis, the formation of the piperidine ring of the 
azacarbohydrate core has been achieved by connection of nitrogen either through, (a) connection 
of C-1 and C-5 via an amine bridge, with inversion of configuration at C-5, or (b) installation of 
the amine between C-2 and C-6, with inversion of configuration at C-2. Accordingly, starting 
from the D-glucose-derived di-acetonide 37.1, a common epoxide intermediate 37.2 has been 
utilized in both of the above ring-forming strategies. Thus, subjecting 37.1 to regioselective 
acetonide deprotection followed by activation of primary alcohol towards SN2 displacement by 
the secondary alcohol at C-5 afforded the 5,6-epoxide intermediate 37.2. Ring opening of the 
epoxide 37.2 with benzyloxy anion (path a) and subsequent SN2 displacement of the resulting C-
5 secondary alcohol with an azide nucleophile afforded the glucoazide derivative 37.3, with 
concomitant inversion of the C5-stereocenter. Hydrolysis of the acetonide to form the lactol, and 
its selective oxidation formed the corresponding hydroxy lactone 37.4. Reduction of the azide to 
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amine and its subsequent intramolecular cyclization to the lactam, followed by removal of the 
benzyl protecting groups resulted in the nojirimycin -lactam 37.5.  
 
Scheme 37 
Alternatively, opening of the epoxide 37.2 with an azide nucleophile (path b), and benzyl 
protection of the resulting secondary hydroxy group yielded the azide 37.6 (Scheme 37). 
Opening of the acetonide with methanolic HCl to form the corresponding methyl furanoside, and 
reaction of the resulting secondary hydroxy group with triflic anhydride led to the triflate 
derivative 37.7. Reductive conversion of the azide to amine led to its spontaneous cyclization to 
the bicyclic amine 37.8, with inversion of the stereocenter at C2. Protection of the amine as its 
carbamate, subsequent acid hydrolysis of the methyl furanoside to the corresponding lactol, and 
its reduction with sodium borohydride formed the tri-protected 1-Deoxynojirimycin derivative 
37.9. Global removal of the protecting groups completed the synthesis of 1-Deoxynojirimycin.       
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Martin’s approach 
 Starting from the D-glucose-derived 3,4,6-Tri-O-benzyl-D-glucal (38.1), Martin’s 
synthesis of α-1-C-substituted fagomine derivatives involved initial conversion of the glucal 38.1 
to the ring-opened terminal olefin 38.2 (Scheme 38).
236
 Thus, treatment of 38.1 with NIS, 
followed by removal of the iodide with sodium dithionate, and subjecting the resulting 2-
deoxysugar to Wittig methylenation afforded 38.2. Mitsunobu inversion of the free hydroxy 
group of 38.2 to form the corresponding epimer and subjecting the resulting hydroxy group to a 
second Mitsunobu inversion with phthalimide, followed by cleavage of the phthalimido 
protection generated the amine 38.3. NIS mediated activation of terminal alkene in 38.3 followed 
by an intramolecular cyclisation afforded iminosugar intermediate 38.4 as a mixture of products, 
with the -anomer being the major product. Treatment of the iodo intermediate 38.4 with 
Me2CuLi and chromatographic separation of the desired stereoisomeric product, followed by 
removal of the benzyl protecting groups afforded α-1-C-ethyl fagomine 38.5. 
Scheme 38 
Hirai’s approach 
Hirai has reported an original synthesis of 1-deoxymannojirimycin starting from D-
mannitol.
252
 A key reaction in this route involved a Pd-catalyzed intramolecular cyclization. 
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Thus, following a known procedure, D-mannitol was initially converted to the tetra-protected 
polyol 39.1 (Scheme 39). Oxidative cleavage of the diol and HWE reaction of the resulting 
aldehyde provided the , -unsaturated ester 39.2. Reduction of the ester to alcohol and its 
protection as a pivalate, followed by acetonide deprotection and conversion of the diol moiety to 
the epoxide 39.3 was achieved via standard functional group transformations. Regioselective 
opening of the epoxide with azide anion, MOM-protection of the resulting secondary hydroxyl, 
conversion of the azide to amine and its Boc-protection, followed by selective pivaloyl 
deprotection provided the allylic alcohol 39.4. The intramolecular cyclization of 39.4 was 
achieved via a Pd(II) catalyzed reaction, forming the piperidine 39.5 with high selectivity. 
Ozonolysis of the terminal olefin to aldehyde, its reduction with sodium borohydride, and 
removal of the protecting group completed the synthesis of 1-deoxymannojirimycin. 
 
 
 
 
 
 
 
Scheme 39 
Takahata’s approach 
Takahata and co-workers have reported the synthesis of iminosugar analogs using D-
serine-derived Garner’s aldehyde as a chiral building block. Thus, Wittig olefination of Garner’s 
aldehyde, acetonide deprotection, and re-protection of the primary hydroxy group as its TBS 
ether formed the allylamine intermediate 40.1 (Scheme 40).
238
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dialkylated diene 40.2, and subjecting it to a ring-closing metathesis with Grubbs’ second 
generation catalyst formed the piperidine derivative 40.3. Dihydroxylation of 40.3 employing 
modified Upjohn conditions resulted in the stereoselective formation of the diol 40.4. Subsequent 
removal of the protecting groups afforded 3-epi-fagomine (40.5).  
 
 
 
 
 
 
 
Scheme 40 
Knight’s approach 
 Knight and co-workers have reported a total synthesis of 1-deoxymannojirimycin starting 
from the amino acid D-serine. A key reaction in the synthesis involved palladium-catalyzed 
decarboxylative carbonylation of 5-vinyloxazolidine-2-one intermediate 41.2 to afford δ-lactam 
intermediate 41.3 (Scheme 42).
253
 Thus, the D-serine-derived aldehyde intermediate 41.1 on 
reaction with vinyl Grignard reagent, followed by treatment with potassium tert-butoxide 
furnished a mixture of the anti- and syn-5-vinyloxazolidin-2-ones 41.2 (2:1 dr). This mixture 
was heated under CO pressure in the presence of a Pd catalyst to form, via a π-allylpalladium 
intermediate, the unsaturated δ-lactam 41.3. Subsequent treatment of 41.3 with Oxone
®
 resulted 
in a 4:1 mixture of the corresponding anti-and syn-epoxides, from which the major epoxide 41.4 
was isolated. A base-mediated ring opening of the epoxide 41.4 and benzyl protection of the 
resulting hydroxyl led to the corresponding allylic alcohol 41.5.  Dihydroxylation of the olefin 
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resulted in the diol 41.6 with high selectivity. Reduction of the lactam carbonyl to form the 
piperidine ring, and removal of the protecting groups afforded 1-deoxymannojirimycin.  
 
 
 
 
 
 
 
 
Scheme 41 
Kazmaier’s approach 
In Kazmaier’s synthesis of an unnatural iminosugar, aldol reaction between a protected 
threose derivative 42.1 and the metal-chelated N-protected alanine tert-butyl ester 42.2 (Scheme 
43) constituted a key reaction step.
242
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The above aldol condensation provided a mixture of three diastereomers, with the desired 
2,3-anti-3,4-anti isomer 42.3 being the major isomer. Removal of benzyl group in 42.3 followed 
by cyclization under Mitsunobu conditions formed the pipecolic acid derivate 42.4. Subsequent 
cleavage of the acetonide linkage and benzylic protection of the free hydroxy groups afforded the 
tribenzyl- protected derivative 42.5. Subsequent reduction of ester to primary alcohol, and 
removal of the protecting groups completed the synthesis of the iminosugar 42.6.  
O’Doherty’s approach  
In an asymmetric synthetic approach, O’Doherty et al have employed the Sharpless 
Asymmetric Aminohydroxylation (SAA) as a key reaction in their synthesis of chiral azasugars. 
Thus, vinyl furan 43.1 (Scheme 43), obtained from furfural, was subjected to SAA to provide a 
mixture of the regioisomeric amino alcohols 43.2a and 43.2b (1:2 dr).
243
 
 
 
 
 
 
 
 
 
 
 
Scheme 43 
Selective silyl-protection of the primary hydroxy group of 43.2a allowed efficient 
separation of the desired aminoalcohol derivative 43.3. Subsequent aza-Achmatowicz 
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rearrangement of 43.3 in the presence of m-CPBA  afforded the hemiaminal 43.4. Acid catalyzed 
conversion of 43.4 to the corresponding ethylaminal, followed by stereoselective Luche 
reduction of the ketone, and diastereoselective OsO4 dihydroxylation yielded the triol 43.5.  
Hydrogenolysis of 43.5 in the presence of TsOH completed the synthesis of 1-deoxygulo-
nojirimycin 43.6. Following a similar reaction sequence, the intermediate 43.4 was converted to 
the epimeric allylic alcohol 43.7 (via a Mitsunobu inversion of the Luche reduction product), 
followed by its eventual transformation to 1-deoxymannojirimycin 43.9 as shown. 
Chemla’s approach 
 Chemla and co-workers have reported a stereoselective synthesis of (–)-swainsonine by 
employing the addition of allenylmetals to chiral , -dialkoxy N-Boc-sulfinylimines as a key 
reaction step. Thus, commercially available D-erythronolactone was initially converted to the 
fully protected Weinreb amide 44.1 (Scheme 44).
254 
Reduction of the amide to aldehyde, 
followed by its condensation with enantiopure N-tert-butanesulfinamide led to the formation of 
the sulfinylimine adduct 44.2. Reaction of imine 44.2 with the in situ generated allenylzinc 44.3 
provided the corresponding adduct 44.4 as the major diastereoisomer (major/minor = 4:1). Mild, 
base-catalyzed cleavage of the C-Si bond of 44.4, and partial reduction of the alkyne afforded the 
olefin 44.5. A two-step conversion of the TBS-ether to the mesylate 44.6, and its subsequent 
treatment with base resulted in an intramolecular cyclization to form the pyrrolidine 44.7. 
Selective removal of the sulfinyl chiral auxiliary, and alkylation of the resulting free amine with 
allyl bromide led to the formation of the diene 44.8. Ring-closing metathesis of 44.8 with 
Grubbs’ catalyst (2
nd
 generation) yielded the bicyclic amine 44.9. Removal of the protecting 
groups, and hydrogenation of the olefin provided (–)-swainsonine. 
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Scheme 44 
Ojea’s approach 
Ojea et al have utilized a diastereoselective aldol addition of SchÖllkopf’s bislactim ether 
45.2 to acetonide protected L-threose 45.1 (Scheme 45) in constructing a key precursor in their 
synthesis of various piperidine imino sugars.
250
 The group has reported seven types of piperidine 
imino sugars by selecting different reaction partners. A representative aldol reaction used 
towards synthesis of D-galacto-deoxynojirimycin (45.7) is described below (Scheme 45).
250
 2,3-
O-isopropylidene derivative of L-threose 45.1 on stereoselective aldol reaction with a metalated 
azaenolate of bislactim ether 45.2 afforded the adduct 45.3 as a major isomer, along with 
formation of two other minor diastereoisomers. Benzyl-protection of the free hydroxy group of 
45.3 followed by a two-step conversion of the TBS-ether to the corresponding mesylate, and 
selective hydrolysis of the pyrazine moiety unmasked the amine 45.4. Treatment of the amino 
mesylate 45.4 with triethylamine led to an intramolecular cyclization to yield the pipecolate 45.5. 
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Subsequent ethyl ester reduction forming the primary alcohol intermediate 45.6, followed by 
debenzylation and acetonide deprotection afforded D-galacto-deoxynojirimycin 45.7. 
 
 
 
 
 
 
 
 
 
Scheme 45 
Overkleeft’s approach 
Overkleeft et al have synthesized eight diastereomeric 1-deoxynojirimycins starting from 
a single chiral cyanohydrin 46.1 (Scheme 46).
255
 Cyanohydrin derivate 46.1 was synthesized by 
the reaction between crotonaldeyde and HCN in the presence of purified enzyme paHNL,
256
 a 
hydroxynitrile lyase derived from almonds, affording the enantiopure (99% ee) secondary 
alcohol which was subsequently protected as its TBS ether to afford 46.1. Cyanohydrin 46.1 
was converted to the secondary amine adduct 46.3 via a one-pot, three step reaction sequence 
involving DIBAL reduction of 46.1, transamination with 46.2 and NaBH4 reduction of the 
adduct imine.
257
 Subsequent N-Boc protection and ring-closing metathesis yielded 46.4. Upjohn 
dihydroxylation of 46.4 afforded a separable mixture of the diols 46.5 and 46.6 (1:1 ratio). 
Finally, deprotection of the purified products 46.5 and 46.6 led to a straightforward synthesis of 
the corresponding iminosugars D-galactodeoxynojirimycin and (46.7) and D-talo-deoxynojiri-
mycin (46.8) respectively. 
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Scheme 46 
Jayathirtha Rao’s approach 
 Starting from a D-mannitol-derived advanced chiral intermediate, Jayathirtha Rao et al 
have reported a synthetic route to 1-deoxynojirimycin.
237
 Thus, the (E)-allylic alcohol 47.1, 
obtained from D-mannitol in 4-steps, on Sharpless asymmetric epoxidation, followed by C-2 
selective endo-mode epoxide opening with an azide afforded the azido alcohol intermediate 47.2 
(Scheme 47). Benzylic ether protection of the free hydroxy groups of 47.2 followed by cleavage 
of the cyclohexylidene protection yielded the 1,2-diol 47.3. Oxidative cleavage of the diol with 
NaIO4 followed by HWE olefination of the resulting aldehyde selectively formed the , -
unsaturated ester 47.4. Upjohn dihydroxylation of electron deficient olefin 47.4, forming the 
corresponding diol with high selectivity (dr 99:1), followed by acetonide protection afforded the 
fully functionalized azido ester derivative 47.5. Reduction of ethyl ester 47.5 to the primary 
alcohol, its conversion to a mesylate, reductive cleavage of the azide to an amine, base catalyzed 
intramolecular cyclization forming the piperidine ring, and removal of the protecting groups 
completed the synthesis of 1-deoxynojirimycin. 
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Scheme 47 
Crich’s approach 
Crich et al have reported an asymmetric synthetic route to polyhydroxylated piperidines, 
as exemplified by the synthesis of isofagomine shown below (Scheme 48).
251
 Thus, starting with 
cyclopentadiene, generation of the corresponding sodium cyclopentadienylide and its reaction 
with benzyloxymethyl chloride formed the corresponding alkylated analog 48.2. Subjecting 48.2 
to a desymmetrizing enantioselective hydroboration with (+)-Ipc2BH, followed by standard 
oxidative workup formed the corresponding 1,2-trans-substituted cyclopentenol 48.3 with high 
stereoselectivity (99% ee). Hydroxyl-directed m-CPBA oxidation of the olefin 48.3 and 
subsequent conversion of the hydroxy group to mesylate provided the epoxide 48.4 as the major 
product. Lewis acid catalyzed regioselective opening of the epoxide ring with benzyl alcohol 
yielded the tetra-substituted cyclopropane derivative 48.5. Base-assisted elimination of the 
mesylate resulted in the olefin 48.6 as the major regioisomeric product. Subjecting the olefin 
48.6 to oxidative cleavage with OsO4/NMO/PIDA resulted in the hydrated dialdehyde 48.7. 
Ring-closing double reductive amination of 48.7 with O-benzylhydroxylamine in the presence of 
sodium cyanoborohydride yielded the N-benzyloxypiperidine 48.8 in high yield. Finally, 
treatment of 48.8 with BBr3 afforded isofagomine (48.9). 
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Scheme 48 
 To date, the most commonly used approach for the synthesis of various iminosugars have 
involved modification of readily available carbohydrate precursors. Close structural similarities 
between the above two compound classes, and resident chirality of the starting sugars are the 
major advantages of the above approach. However, when the target azacarbohydrate contains 
unusual / non-natural residues or stereochemistry, the above synthetic strategy often suffers from 
lengthy reaction sequence and necessitates extensive protection-deprotection of functional 
groups. In our present studies, we therefore propose to explore and develop an alternative 
reaction strategy involving stereoselective de novo construction of the azacarbohydrate structural 
scaffold, starting from a more simple non-carbohydrate synthon. Besides circumventing the 
disadvantages inherent in the carbohydrate-based approach, our alternative strategy will also 
make the method more flexible towards potential structural modifications towards detailed SAR 
investigations of this biologically important class of compounds. The details of my studies 
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involving the development of a rapid and flexible synthetic route to representative 
azacarbohydrate structural scaffolds are described in the following section.   
4.3 Present Research 
In continuation of our research interest in bioactive natural products, I initiated a study 
aimed at the development of a flexible synthetic route to variously functionalized 
azacarbohydrates. In this endeavor, the previously described aminobutenolide 1 from our 
research appeared to be an ideal building block for the proposed studies. Accordingly, starting 
from the chiral aminobutenolide 1 as a common building block, the retrosynthetic plan (Figure 
27) envisioned utilization of the enone moiety of the butenolide towards stereoselective 
incorporation of appropriate functional groups as present in the target azacarbohydrates. 
Similarly, the conveniently located amine group in 1 should allow its intramolecular nucleophilic 
addition to the lactone carbonyl, leading to a rapid construction of the desired piperidine 
structural core. 
 
 
 
 
Figure 27. Aminobutenolide (1) to azacarbohydrates (9): Retrosynthetic strategy and approach 
4.3.1. Stereoselective synthesis of a 2,3,4-trideoxyazacarbohydrate 
 Based on the retrosynthetic strategy described above, the synthesis of a dihydroxylated 
iminosugar was investigated. Accordingly, the L-serine-derived aminobutenolide 1 was treated 
with formic acid in methylene chloride to form the acetonide deprotected primary alcohol 
derivative 49.1 (Scheme 49). After removal of solvent and excess reagent, the crude product was 
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directly subjected to a further two-step reaction sequence, wherein, hydrogenation of 49.1 
resulted in a one-pot N-Cbz-deprotection and saturation of the olefin, forming the corresponding 
free amine derivative. Removal of the hydrogenation catalyst by filtration and solvent removal, 
followed by subjecting the resulting amino lactone to a base-catalyzed intramolecular cyclization 
provided the desired piperidinone 49.2 in good overall yield. Borane-mediated standard 
reduction of the lactam 49.3 to the corresponding piperidine derivative 49.4, followed by 
standard removal of the protecting groups provided the target 2,3,4-trideoxyazacarbohydrate 
analog 49.5. 
 
 
 
 
 
 
 
 
Scheme 49 
Successful attainment of our initial synthetic goal towards rapid and efficient conversion 
of the aminobutenolide 1 to a functionalized azacarbohydrate scaffold encouraged us to further 
explore the above approach in the synthesis of tri-, and tetra-substituted azacarbohydrates.  
4.3.2. Stereoselective synthesis of 4-epi-fagomine 
 Aiming to synthesize a 3,4,5-trihydroxylated azacarbohydrate, the aminobutenolide 1 was 
subjected to epoxidation at the enone moiety. Accordingly, following a known procedure,
258
 
reaction of the butenolide 1 with NaOCl led to the stereoselective formation of the epoxide 50.1 
(Scheme 50) in moderate yield. Analysis of the crude reaction mixture showed the presence of a 
polar product in addition to the epoxide 50.1. Concomitant to epoxide ring formation, the above 
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epoxidation condition is also known to cause lactone ring opening of the bicyclic epoxylactone 
to form the corresponding hydroxy carboxylic acid derivative.
258
 Accordingly, suspecting the 
polar product in our reaction mixture to be the lactone ring-opened epoxide, in a subsequent 
reaction, the crude reaction mixture, obtained after epoxidation of 50.1, was subjected to re-
cyclization of the lactone ring by treatment with EDCI (1.2 equiv), and stirring at room 
temperature for 1 hr. TLC monitoring of the reaction mixture showed clean and complete 
disappearance of the polar spot, with increased intensity of the product spot corresponding to the 
epoxide. Gratifyingly, standard work-up of the reaction mixture, and purification of the crude 
product afforded the desired epoxide (50.1) with an improved yield (76%).  
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 50 
The assigned stereochemistry of epoxide 50.1 was based on literature precedence,
258
 as 
well as our analogous observation involving cyclopropanation of the butenolide 1 (Chapter 2), 
wherein approach of the incoming nucleophile from the sterically less-hindered face of the olefin 
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leads to the stereoselective formation of the product. Proceeding with the synthesis, regio-
selective ring-opening of the epoxide with an in situ generated phenylselenium hydride (PhSeH) 
formed the β-hydroxy lactone 50.2 in high yield. The structure and purity of the product was 
confirmed on the basis of its spectral and analytical data. The observed regioselectivity in the 
above epoxide ring-opening reaction can be attributed to the attack of the hydride at the more 
reactive (electron deficient), and less sterically hindered α-carbon adjacent to the carbonyl 
group.
259-263
 Removal of the acetonide protection of the β-hydroxy lactone 50.2, followed by 
silyl-protection of the free hydroxy groups afforded the di-silyl lactone 50.3. Hydrogenolysis of 
the Cbz-protecting group, and exposure of the resulting amine to base catalyzed intramolecular 
cyclization uneventfully afforded the desired piperidinone 50.4 in good overall yield. Subsequent 
acidic cleavage of the silyl-protecting groups afforded the trihydroxy- substituted -lactam 50.5. 
On the other hand, borane reduction of the lactam carbonyl affording the corresponding 
trisubstituted piperidine 50.6, followed by removal of the silyl-protecting groups resulted in 4-
epi-fagomine (50.7). 
4.3.3. Stereoselective synthesis of talo-1-deoxynojirimycin 
 The next target in our studies involved the synthesis of the tetra-substituted structural 
framework of the 1-deoxynojirimycins. Thus, following a previously reported synthesis from our 
group, 
26
 the aminobutenolide 1 was stereoselectively converted to the corresponding diol 51.1 in 
good yield (Scheme 51). The high stereoselectivity observed in this reaction is once again 
attributable to the approach of the oxidizing reagent from the less hindered -face of the olefin. 
Subsequent removal of the acetonide protection, and silyl-protection of all the free hydroxy 
groups provided the tri-silyloxylactone 51.2. Unmasking of the amine 51.3, via hydrogenolytic 
removal of the Cbz-protecting group, followed by treatment of the resulting amino lactone with 
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catalytic sodium methoxide yielded the expected piperidinone 51.4 in good overall yield. 
Cleavage of the silylether linkages led to the tetrasubstituted δ-lactam 51.5. Whereas, initial 
borane-mediated conversion of the lactam 51.4 to the corresponding pyrrolidine derivative 51.6, 
and global deprotection completed a straightforward synthesis of talo-1-deoxynojirimycin (51.7). 
 
 
 
 
 
 
 
 
 
 
 
Scheme 51 
5.2.Conclusions 
Continuing with the utilization of a highly functionalized aminobutenolide as a versatile 
chiral building block, the present research describes a general and highly efficient protocol for 
the rapid construction of variously substituted enantiopure azacarbohydrate structural scaffolds 
of biological significance. In terms of brevity, ease of reactions, and overall yields, the present 
method compares well with the literature reported syntheses of the above class of compounds. 
From a future structure-activity relationship investigation perspective, the versatility of the key 
lactone intermediate 1 towards easy structural modifications and consequent possible access to a 
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variety of natural and non-natural azacarbohydrate analogs is also expected to be an added 
advantage of the present route.  
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Chapter 5 
Experimental Procedures and Data 
5.1 Materials and Methods 
Proton and carbon nuclear magnetic resonance spectra were recorded using Bruker DRX 
400 MHz, or Bruker DRX 500 MHz, or Avance AV-III 500 MHz spectrometers. All chemical 
shifts were recorded as parts per million (ppm), and all samples were dissolved in CDCl3 using 
residual solvent peak as internal standard unless otherwise noted. Mass spectra were obtained 
from a ZAB HS mass spectrometer (VG Analytical Ltd., Manchester, U.K.) equipped with a 
11/250 data system. Fast-atom bombardment mass spectrometry (FAB-MS) experiments were 
performed with a Xenon gun operated at 8 Kev energy and 0.8 mA emission at the MS 
laboratory at the University of Kansas. Fast-atom bombardment high-resolution mass spectra 
(FAB-HRMS (ESI-TOF) m/z:) were recorded at 1:10,000 resolution analyzer mode (MCA). 
HPLC analyses were carried out using a Shimadzu LC-6AL liquid chromatograph coupled to a 
SPD 20A prominence UV/VIS detector. All columns were purchased from Agilent. A Shimadzu 
FTIR 8400S spectrophotometer was used to record infrared spectra. Optical rotations were 
obtained using an Autopol IV Automatic Polarimeter at rt. Melting points were obtained using a 
Thomas Hoover Uni-melt capillary melting point apparatus and are uncorrected. All moisture-
sensitive reactions were performed using either oven or flame dried glassware under a positive 
pressure of argon unless otherwise noted. Solvents and reagents that are commercially available 
were used without further purification unless otherwise noted. Tetrahydrofuran and diethyl ether 
were freshly distilled from sodium benzophenone ketyl under argon. Methylene chloride was 
distilled freshly from calcium hydride under argon. Starting from L-serine the aminobutenolide 1 
was prepared following an earlier reported procedure from our laboratory.
26
 The silica gel (230-
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400 mesh) used for column chromatography was purchased from Sorbent Technologies, while 
thin layer chromatography was performed using Silica Gel HLF Uniplates
TM
, purchased from 
Analtech, Inc. All the compounds were concentrated using standard rotavap and high-vacuum 
techniques. 
5.2. Biological Procedures 
Cytotoxicity assays were performed in the laboratory of our collaborator Dr. Sunil David, 
in the Medicinal Chemistry Department at the University of Kansas. Jaspine B analogs were 
evaluated in murine B16 melanoma cells by using a homogeneous resazurin (Alamar Blue) 
assay,
264
 which has been shown to be more sensitive.
265
 Resazurin detects cell viability by 
converting from a nonfluorescent dye to the highly red fluorescent dye resorufin in response to 
chemical reduction of growth medium resulting from cell growth. Continued cell growth 
maintains a reduced environment while inhibition of growth maintains an oxidized environment. 
Reduction related to growth causes the REDOX indicator to change from the oxidized 
(nonfluorescent, purple color) form to the reduced (fluorescent, red color) form.
264,266,267
  
Stock solutions (1mM) of compounds are first serially diluted in cell-culture medium 
(RPMI-1640 supplemented with 10 mM L-glutamine, 10% fetal bovine serum, and antibiotics) 
across a 384-well plate, resulting in 40 L in each well. 40 L aliquots of cells suspended in 
cell-culture medium at a density of 10
6
 cells/well are added to the plate and incubated for 48 h in 
a humidified atmosphere (37 °C, 5% CO2). At the end of the incubation period, 40 L of the 
supernatant is removed and an equal volume of 2X resazurin (200 g/mL) was added and 
incubated for an additional 4 h. Conversion of resazurin to resorufin is quantified by ratiometric 
absorptimetry at 570/610 nm and plotted as a function of the concentration of compounds, from 
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which IC50 values are derived by conventional four-parameter logistic curve-fitting using 
GraphPad Prism. 
5.3. Experimental Procedures   
5.3.1. Chapter 2:  HIV Protease Targeted Synthesis of Conformationally-Rigid Hydroxy-  
          ethylene Dipeptide Isosteres: A Combinatorial approach  
 
(S)-Benzyl 2,2-dimethyl-4-((1R,2R,5S)-4-oxo-3-oxabicyclo[3.1.0]hexan-2-yl)oxazolidine-3-
carboxylate (2.1). To a stirred solution of the aminobutenolide 1 (1.5 g, 4.8 mmol) in anhydrous 
diethyl ether (70 mL) was added Pd(OAc)2 (0.106g, 10 mol %) and cooled to 0 
o
C, followed by 
the addition of freshly prepared diazomethane solution in ether [prepared from 5 g of 
commercially available N-methyl-N’-nitrosoguanidine (NNMG) as described below]. The 
resulting solution was allowed to attain room temperature, and stirring continued for 24 h. A 
second lot of diazomethane (prepared from 5 g of MNNG) was added to the reaction mixture and 
stirred for an additional 24 h. Excess diazomethane was removed by bubbling nitrogen into the 
reaction mixture for 15 min. The reaction mixture was filtered over celite, and the residue 
washed with ether (4 x 10 mL). The combined filtrate was concentrated under vacuum, and the 
crude product purified by flash column chromatography (hexanes : EtOAc = 1 : 3) to afford the 
cyclopropane ring-fused bicyclic lactone 2.1 as a white solid (1.19g, 75 % ):  [α]D  - 3.8 (c 0.6, 
CH2Cl2);  
1
H NMR
 
(400 MHz, CDCl3, mixture of rotamers):  7.41-7.29 (m, 5H), 5.31-4.91 (m, 
2H), 4.41-4.21 (m, 1H), 4.18-3.91 (m, 3H) 2.21-2.01 (m, 1H) 1.81-1.41 (m, 7H) 1.31-1.01 (m, 
1H), 0.91-0.68 (m, 1H); 
13
C NMR (125.8 MHz, CDCl3; mixture of rotamers)  175.6, 175.4, 
155.1, 152.4, 135.7, 128.7, 128.6, 128.5, 128.4, 128.2, 95.1, 94.7, 82.2, 79.7, 67.7, 67.2, 65.6, 
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64.7, 60.5, 59.9, 29.7, 27.5, 26.8, 24.4, 22.8, 20.3, 19.8, 17.4, 12.4, 12.3;  HRMS (ESI-TOF) 
m/z: [M+H] + Calcd for C18H22NO5 332.1498; Found 332.1484. 
 [CAUTION: Diazomethane (CH2N2) is an explosive and a highly toxic gas. Explosions may 
occur if the substance is dried and undiluted. All operations involving diazomethane should be 
carried out in an efficient fume hood following appropriate precaution]. To a biphasic solution of 
KOH (20 g) in H2O (50 mL) and ether (120 mL) at 0 °C was added N-methyl-N’-nitrosogua-
nidine (MNNG, 5 g) in one lot. The organic layer turned bright yellow. The ethereal layer was 
separated into an ice-cooled Erlenmeyer flask containing KOH pellets. The aqueous layer was 
carefully washed with ether (3 x 10 mL), and the ethereal layers were combined for use in the 
cyclopropanation reaction as described above]. 
 
Benzyl ((S)-2-hydroxy-1-((1R,2R,5S)-4-oxo-3-oxabicyclo[3.1.0]hexan-2-yl)ethyl)-carbamate 
(2.2). The cyclopropane ring-fused bicyclic lactone 2.1 (0.03 g, 0.091 mmol) was dissolved in 
anhydrous CH2Cl2 (5 mL) and cooled to 0 °C. TMSOTf (0.067 mL, 0.039 mmol) was added to 
the solution and continued stirring at 0 °C for 6 h. The reaction was quenched with saturated aq. 
NaHCO3 solution, and extracted with EtOAc (3 x 10 mL). The combined extracts washed with 
brine, dried over anhydrous Na2SO4 and concentrated under vacuum. The residue was purified 
by flash chromatography (hexanes:EtOAc = 1:4) to afford the aminoalcohol 2.2 as a viscous 
liquid (0.025 g, 81 %): [α]D  - 0.32 (c 0.655, CH3OH); 
1
H NMR (500 MHz, DMSO-d6):  7.42-
7.36 (m, 5H), 5.18 (brs, 2H), 4.91-4.81 (m, 1H), 4.52-4.48 (m, 1H), 3.81-3.61 (m, 1H), 3.59-3.41 
(m, 2H), 2.18-2.11 (m, 1H), 2.01-1.97 (m, 1H), 1.28-1.20 (m, 1H), 0.85-0.75 (m, 1H); 
13
C NMR 
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(125.8 MHz, CDCl3) 175.7, 156.2, 135.5, 126.8, 126.4, 126.2, 78.7, 65.1, 58.8, 54.5, 18, 15.8, 
10.0;  HRMS (ESI-TOF) m/z: [M + H]
+
 Calcd for C15H18NO5 293.1185; Found 293.1203.  
General procedure for the synthesis of cyclopropyl carboxamide analogs 3.1a-h. 
A solution of the bicyclic lactone 2.1 (1 equiv.) in i-propanol (10% solution w/v), and the 
respective amine (a-h: 4 equiv.) was refluxed for 5-18 h (tlc monitoring). The reaction mixture 
was concentrated under vacuum and the residue purified by flash chromatography (hexanes : 
EtOAc = 9/1 to 1/2) affording the cyclopropane carboxamides 3.1a-h.  
 
(S)-Benzyl 4-((R)-((1R,2S)-2-(butylcarbamoyl)cyclopropyl)(hydroxy)methyl)-2,2-dimethyl-
oxazolidine-3-carboxylate (3.1a). Obtained as white solid (54 mg, 87 %): 
1
H NMR (400 MHz, 
CDCl3; mixture of rotamers):  7.41-7.28 (brs, 5H), 6.21-6.05 (m, 0.5H), 5.71-5.51 (m, 0.5H), 
5.21-5.01 (m, 2H), 4.61-4.42 (m, 0.5H), 4.41-3.55 (m, 4.5 H), 3.31-3.08 (m, 2H), 2.15-2.04 (m, 
0.5H), 1.65-1.11 (m, 13H), 0.99-0.81 (m, 3H), 0.75-0.66 (m, 0.5H); 
13
C NMR (125.8 MHz, 
CDCl3; mixture of rotamers)  172.9, 172.6, 154.1, 152.7, 136.2, 136.1, 128.6, 128.5, 128.2, 
128.1, 128, 127.9, 94.4, 94.1, 70.9, 70.7, 67.2, 66.8, 65.2, 62.2, 61.2, 39.6, 31.4, 29.6, 27.3, 26.7, 
24.5, 23.5, 23.3, 23, 19.9, 19.8, 13.6, 10.7;  HRMS (ESI-TOF) m/z: [M+H]
+
 Calcd for 
C22H33N2O5 405.2389; Found 405.2378.   
 
 
 
 
(S)-Benzyl 4-((R)-((1R,2S)-2 (cyclopropylcarbamoyl)cyclopropyl)(hydroxy) methyl)-2,2-di-
methyloxazolidine-3-carboxylate (3.1b). Obtained as a white solid (0.9 g, 82%): 
1
H NMR (500 
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MHz, CDCl3; mixture of rotamers)  7.41-7.29 (m, 5H), 6.09 and 5.52 (2s, 0.5H and 0.5H), 5.18-
4.91 (m, 2H), 4.44-4.36 (brs, 0.5H), 4.21-3.80 (m, 3.5H), 3.73-3.64 (brs, 1H), 2.69 & 2.52 (2s, 
1H), 1.71-1.41 (m, 6H), 1.40-1.00 (m, 3H), 0.99-0.81 (m, 1H), 0.71-0.61 (m, 2H), 0.51-0.25 (m, 
2H); 
13
C NMR (125.8 MHz, CDCl3; mixture of rotamers)  174.8, 174.4, 154.2, 152.8, 136.3, 
136.2, 128.7, 128.6, 128.4, 128.2, 128, 94.5, 94.2, 70.9, 70.6, 67.6, 67.3, 66.9, 66.6, 65.3, 64.3, 
62.3, 61.2, 30.9, 30.6, 29.7, 27.4, 27.2, 26.8, 24.5, 24.3, 23.9, 23.8, 23.5, 23, 22.8, 22.6, 19.8, 
19.6, 19.1, 6.7, 6.5;  HRMS (ESI-TOF) m/z: [M+H]
+
 Calcd for C21H29N2O5 389.2076; Found 
389.2065.   
 
 
 
 
(S)-Benzyl 4-((R)-((1R,2S)-2-(cyclohexylcarbamoyl)cyclopropyl)(hydroxy)methyl)-2,2-di-
methyloxazolidine-3-carboxylate (3.1c). Obtained as a white solid (0.12 g, 99 %):  
1
H NMR 
(500 MHz, CDCl3; mixture of rotamers):  7.34 (brs, 5H), 5.71 (brs, 0.5H) and 5.41 (brs, 0.5H),  
5.21-4.95 (m, 2H), 4.45 (brs, 0.5H), 4.29-3.88 (m, 3.5H),  3.79-3.62 (m, 2H), 1.95-1.76 (m, 2H), 
1.75-1.01 (m, 17.5H), 0.79-0.61 (m, 0.5H); 
13
C NMR (125.8 MHz, CDCl3 ; mixture of rotamers) 
 172.1, 171.7, 154.2, 152.8, 136.4, 136.3, 128.7, 128.6, 128.4, 128.2, 94.6, 94.2, 71.2, 67.3, 
66.8, 65.3, 64.4, 62.3, 61.2, 48.7, 33.1, 32.9, 29.7, 25.5, 24.8, 23.5, 23.3, 23, 20.2, 20, 10.8;  
HRMS (ESI-TOF) m/z: [M + H]
+
 Calcd for C24H35N2O5 431.2546; Found 431.2526.   
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(S)-Benzyl 4-((R)-((1R,2S)-2-(dimethylcarbamoyl)cyclopropyl)(hydroxymethyl)-2,2-di-
methyloxazolidine-3-carboxylate (3.1d). Obtained as a white solid (0.118 g, 80 % ):  
1
H NMR 
(400 MHz, CDCl3; mixture of rotamers ):  7.41-7.29 (m, 5H), 5.21-5.01 (m, 2H), 4.88 (brs, 
0.5H), 4.55 (brs, 0.5H) 4.29-4.01 (m,  2H), 3.96-3.86 (m, 1H), 3.51-3.31 (m, 1H), 3.21 and 3.01  
(2s, 3H), 2.99 and 2.85 (2s, 3H), 1.71-1.41 (m, 7.5H), 1.31-1.18 (m, 0.5H), 0.99-0.81 (m, 1H), 
0.71-0.51 (m, 1H); 
13
C NMR (125.8 MHz, CDCl3 ; mixture of rotamers)  172.1, 171.7, 154.1, 
152.7, 136.3, 128.6, 128.2, 128, 94.5, 94.2, 72.9, 72.6, 67.2, 66.8, 65.4, 65.2, 62.2, 60.9, 37.6, 
37.5, 35.7, 35.5, 27.3, 26.7, 24.6, 23.1, 23, 17.6, 11, 10.9;  HRMS (ESI-TOF) m/z: [M + H]
+
 
Calcd for C20H29N2O5 377.2076; Found 377.2066.  
 
 
 
 
(S)-Benzyl 4-((R)-hydroxy((1R,2S)-2-(pyrrolidine-1-carbonyl)cyclopropyl)methyl)-2,2-di-
methyloxazolidine-3-carboxylate (3.1e) Obtained as a white solid (320 mg, 88%): 
1
H NMR 
(400 MHz, CDCl3; mixture of rotamers)  7.41-7.29 (m, 5H), 5.21-5.09 (m, 2H), 5.04-4.89 (m, 
0.5H), 4.41-4.19 (m, 0.5H), 4.28-4.05 (m, 2H), 3.95-3.85 (m, 1H), 3.61-3.59 (m, 1H), 3.58-3.31 
(m, 4H), 1.98-1.75 (m, 4H), 1.71-1.41 (m, 7.5H), 1.41-1.21 (m, 0.5H), 1.11-0.89 (m, 1H), 0.81-
0.65 (m, 1H); 
13
C NMR (125.8 MHz, CDCl3 ; mixture of rotamers)  171.2, 170.5, 154.1, 152.7, 
136.3, 136.2, 128.5, 128.4, 128.3, 128.2, 128.1, 127.9, 94.4, 94.1, 72.3, 71.8, 67.2, 66.8, 66.7, 
65.8, 65.4, 65.3, 64.9, 64.1, 62.2, 61, 46.8, 46, 45.9, 45.7, 27.9, 27.4, 26.7, 26, 25, 24.6, 23.4, 
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23.2, 23, 22.6, 18.2, 11, 10.8; HRMS (ESI-TOF) m/z: [M + H]
+
 Calcd for C22H31N2O5 403.2233; 
Found 403.2237. 
 
 
 
 
 
(S)-Benzyl4-((R)-hydroxy((1R,2S)-2-(morpholine-4-carbonyl)cyclopropyl)methyl)-2,2-di-
methyl oxazolidine-3-carboxylate (3.1f). Obtained as a white solid (73 mg, 52 %): 
1
H NMR 
(500 MHz, CDCl3; mixture of rotamers)  7.41-7.29 (brs, 5H),  5.21-5.01 (m, 2H) 4.65-4.58 (m, 
0.5H), 4.29-4.01 (m, 2.5H), 3.97-3.88 (m, 1H), 3.71-3.31 (m, 10H), 1.71-1.41 (m, 6H) 1.38-1.21 
(m, 1H), 1.01-0.89 (m, 1H), 0.71-0.61 (m, 1H); 
13
C NMR (125.8 MHz, CDCl3; mixture of 
rotamers)  170.5, 170.1, 154.2, 152.6, 136.1, 128.5, 128.2, 128, 94.5, 94.3, 72.9, 72.6, 67.3, 
66.8, 66.7, 66.6, 65.1, 64.3, 62.2, 60.8, 46.2, 42.3, 42.2, 30.6, 29.7, 27.1, 26.7, 24.6, 23, 22.8, 21, 
19.1, 17.2, 17, 16.8, 14.1, 10.7, 10.6; HRMS (ESI-TOF) m/z: [M + H]
+
 Calcd for C22H31N2O6 
419.2182; Found 419.2174.  
 
 
 
(S)-Benzyl 4-((R)-hydroxy((1R,2S)-2-(1,2,3,4-tetrahydroisoquinoline-2 carbonyl) cyclopro-
pyl)methyl)-2,2-dimethyl oxazolidine-3-carboxylate (3.1g). Obtained as a light brown solid 
(0.35 g, 72 %):  
1
H  NMR (400 MHz, CDCl3; mixture of rotamers)  7.48-7.05 (m,  9H), 5.28-
5.05 (m, 2H), 4.91-4.61 (m, 2H), 4.02-3.71 (m, 6H), 3.59-3.31 (m, 1H), 3.01-2.75 (m, 2H), 1.85-
1.77 (m, 0.5H), 1.68-1.54 (m, 7H), 1.48-1.33 (m, 0.5H), 1.05-0.95 (m, 1H), 0.71-0.61 (m, 1H); 
13
C NMR (125.8 MHz, CDCl3; mixture of rotamers)  169.2, 169, 152, 136.6, 136.3, 135.1, 
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134.9, 133.6, 133.4, 128.4, 128.3, 128.1, 127.9, 126.4, 126.2, 126.1, 93.3, 93.1, 69, 68.9, 66.2, 
66, 64.9, 64.4, 63.9, 61.9, 61.1, 46.4, 44.1, 42.8, 28.7, 28.2, 26.9, 26.1, 24.6, 24.2, 24.1, 23.9, 
22.9, 16.5, 16.3; HRMS (ESI-TOF)  m/z: [M + H]
+
 Calcd for C27H33N2O5 465.2390; Found 
465.2231. 
 
(S)-Benzyl 4-((R)-hydroxy((1R,2S)-2-(((1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl) car-
bamoyl)cyclopropyl)methyl)-2,2-dimethyloxazolidine-3-carboxylate (3.1h). Obtained as a 
brown solid (200 mg, 69 %):  
1
H NMR (400 MHz, CD3OD; mixture of rotamers)  7.48-7.15 
(m, 9H), 5.31-5.19 (m, 1H), 5.17-5.01 (m, 2H), 4.61-4.51 (m, 1H), 4.18-3.91 (m, 3H),  3.82-3.61 
(m, 1H), 3.51-3.41 (m, 1H), 3.18-3.01 (m, 1H),  2.94-2.85 (m, 1H), 1.91-1.71 (m, 1H), 1.68-1.38 
(m, 6H), 1.31-1.21 (m, 1H), 1.09-1.01 (m, 1H), 0.81-0.61 (m, 1H); 
 13
C NMR (125.8 MHz, 
CDCl3; mixture of rotamers)   174.6, 174.1, 155.5, 154.5, 141.9, 137.7, 95.6, 74.1, 71.5, 71.1, 
68.4, 68.1, 66.9, 66.2, 63.4, 62.7, 59.5, 59.3, 40.1, 27.7, 26.9, 25.8, 25.5, 24.9, 23.4, 19.3, 19.1, 
11.1; HRMS (ESI-TOF)  m/z: [M + H]
+
 Calcd for C27H33N2O6 481.2339 ; Found 481.2342. 
General procedure for acetonide deprotected N-Cbz-aminodiol derivatives (4.1a-h): 
To a stirred, ice-cooled solution of cyclopropyl carboxamides 3.1a-3.1h (1 equiv.) in 
anhydrous CH2Cl2 (10% solution w/v) under an inert atmosphere was added TMSOTf (2.2 
equiv.) through a syringe. The resulting solution was stirred at the same temperature for 3-4 h 
(monitored by TLC), followed by quenching the reaction mixture by addition of a saturated 
aqueous NaHCO3 solution. After stirring the mixture for 5 min, the organic layer was separated 
and the aqueous layer was saturated with solid NaCl and extracted with CH2Cl2 (three times). 
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The combined organic layers were dried over anhydrous Na2SO4. Concentration of the solvent 
under reduced pressure and column chromatographic purification of the residue (10 % MeOH in 
EtOAc) provided the pure acetonide-cleaved cyclopropyl aminodiol derivatives 4.1a-h.  
 
Benzyl ((1R,2S)-1-((1R,2S)-2-(butylcarbamoyl)cyclopropyl)-1,3-dihydroxypropan-2-yl)-car-
bamate (4.1a). Obtained as a white solid (100 mg, 96% ):  
1
H NMR (500 MHz, CD3OD)  7.48-
7.30 (m, 5H), 5.21-5.05 (dd, J = 12.5 Hz, 2H), 3.81-3.24 (m, 4H), 3.21-3.05 (m, 2H), 1.61-1.55 
(m, 1H), 1.55-1.41 (m, 2H), 1.38-1.28 (m, 3H), 1.07-0.99 (m, 1H), 0.95-0.88 (t, J = 7.5 Hz, 3H), 
0.87-0.89 (m, 1H);  
13
C NMR (125.8 MHz, CD3OD ):  174.5, 159.1, 138.6, 129.6, 129.2, 129.1, 
129, 71.2, 67.6, 62.9, 59.7, 40.6, 32.7, 25.3, 21.3, 19.4, 14.3, 11.3;  HRMS (ESI-TOF)  m/z: [M 
+ H]
+
 Calcd for C19H29N2O5 365.2076; Found 365.2082.   
 
 
 
 
Benzyl ((1R,2S)-1-((1R,2S)-2-(cyclopropylcarbamoyl)cyclopropyl)-1,3-dihydroxypropan-2-
yl)carbamate  (4.1b). Obtained as a colorless liquid (71 mg, 97 %): 
1
H NMR (400 MHz, 
CD3OD)  7.38-7.21 (m, 5H), 5.21-5.01 (dd, J = 12.5 Hz, 2H), 3.80-3.61 (m, 4H), 2.67-2.58 (m, 
1H), 1.58-1.49 (m, 1H), 1.38-1.21 (m, 1H), 1.11-1.01 (m, 1H), 0.91-0.81 (m, 1H), 0.71-0.61 (m, 
2H), 0.56-0.41 (m, 2H); 
13
C NMR (125.8 MHz, CD3OD)  176.2, 159.2, 138.6, 129.6, 129.4, 
129.2, 129.1,129.0, 71.1, 67.7, 62.9, 59.7, 25.5, 23.7, 19.1, 11.9, 6.7, 6.5; HRMS (ESI-TOF)  
m/z: [M + H]
+
 Calcd for C18H25N2O5 349.1764; Found 349.1760.   
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Benzyl((1R,2S)-1-((1R,2S)-2-(cyclohexylcarbamoyl)cyclopropyl)-1,3-dihydro-xypropan-2-
yl)carbamate (4.1c). Obtained as a white solid (273 mg, 75 %): 
1
H NMR (500 MHz, CD3OD)  
7.48-7.21 (m, 5H), 5.19-5.01 (dd,  J = 12.5 Hz, 2H), 3.81-3.51 (m, 5H), 1.91-1.81 (m, 2H), 1.78-
1.68 (m, 2H), 1.61-1.51 (m, 2H), 1.41-1.11 (m, 6H), 1.05-0.95 (m, 1H), 0.91-0.79 (m, 1H); 
13
C 
NMR
 
(125.8 MHz, CD3OD)  173.6, 159.1, 138.6, 129.6, 129.1, 123.2, 71.2, 63.3, 60.3, 34.1, 
26.8, 26.3, 25.2, 19.5, 14.6;  HRMS (ESI-TOF) m/z: [M + H]
+
 Calcd for C21H31N2O5 391.2233; 
Found 391.2245.   
 
 
 
Benzyl ((1R,2S)-1-((1R,2S)-2-(dimethylcarbamoyl)cyclopropyl)-1,3-ihydroxypropan-2yl) 
carbamate (4.1d). Obtained as a white solid (424 mg, 91% ):  
1
H NMR (400 MHz, CD3OD)  
7.49-7.31(m, 5H), 5.21-5.02 (dd, J = 12.5 Hz, 2H), 3.68-3.51 (m, 3H),  3.28-3.19 (m, 1H), 3.18 
(s, 3H), 2.91 (s, 3H), 1.91-1.81 (m, 1H), 1.49-1.38 (m, 1H), 1.11-1.01 (m, 1H), 0.91-0.78 (m, 
1H);  
13
C NMR (125.8 MHz, CD3OD)   173.7, 159.1, 138.6, 129.6, 129.3, 129.1, 72.3, 67.6, 
62.8, 59.6, 38.1, 36.3, 24.9, 17.8, 11.1;  
13
C NMR (125.8 MHz, CD3OD) HRMS (ESI-TOF)  
m/z: [M + H]
+
 Calcd for C17H25N2O5 337.1764; Found 337.1777. 
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Benzyl((1R,2S)-1,3-dihydroxy-1-((1R,2S)-2-(pyrrolidine-1 carbonyl)cyclopropyl) propan-2-
yl)carbamate (4.1e). Obtained as a white solid (298 mg, 81 %):  
1
H NMR (500 MHz, CD3OD) 
 7.49-7.28 (m, 5H), 5.21-5.02 (dd,  J = 12.5 Hz, 2H), 3.79-3.69 (m, 3H), 3.68-3.51 (m, 2H), 
3.45-3.35 (m, 3H), 2.03-1.75 (m, 5H), 1.51-1.41 (m, 1H), 1.18-1.11 (m, 1H), 0.91-0.81 (m, 1H);  
13
C NMR (125.8 MHz, CD3OD)   172.4, 159.1, 138.7, 129.6, 129.4, 129.3, 129.1, 129, 71.7, 
68.1, 63.2, 59.6, 48.1, 47.4, 27, 25.6, 25.1, 18.8, 11.1;  HRMS (ESI-TOF)  m/z: [M + H]
+
 Calcd 
for C19H27N2O5 363.1920; Found 363.1920.   
 
 
 
 
Benzyl ((1R,2S)-1,3-dihydroxy-1-((1R,2S)-2-(morpholine-4-carbonyl)cyclopropyl) propan-
2-yl)carbamate (4.1f). Obtained as a white solid  (302 mg, 87% ):  
1
H NMR (400 MHz, 
CD3OD)  7.49-7.31 (m, 5H), 5.21-5.02 (dd,  J = 12.5 Hz, 2H), 3.81-3.61 (m, 10H), 3.45-3.39 
(m, 1H), 3.21-3.11 (m, 1H), 1.91-1.85 (m, 1H), 1.49-1.35 (m, 1H), 1.19-1.11 (m, 1H), 0.91-0.81 
(m, 1H);  
13
C NMR (125.8 MHz, CD3OD)   172.2, 159.1, 138.6, 129.6, 129.3, 129.1, 72.3, 
62.8, 60.1, 67.8, 67.7, 67.6, 62.8, 59.7, 47.7, 47.6, 43.9, 25.1, 17.7, 11;  HRMS (ESI-TOF)  m/z: 
[M + H]
+
 Calcd for C19H27N2O6 379.1869; Found 379.1876.  
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Benzyl((1R,2S)-1,3-dihydroxy-1-((1R,2S)-2-(1,2,3,4-tetrahydroisoquinoline-2-carbonyl) 
cyclopropyl)propan-2-yl)carbamate (4.1g). Obtained as a light brown solid (125 mg, 89 % ): 
1
H NMR (400 MHz, MeOD)  7.45-7.21 (m, 5H), 7.19-7.05 (m, 4H), 5.51 (brs, 1H), 5.18-5.01 
(m, 2H), 4.81-4.71 (m, 0.5H), 4.61-4.48 (m, 0.5H), 3.99-3.81 (m, 1H), 3.80-3.61 (m, 4H), 2.95-
2.75 (m, 2H), 2.11-1.91 (m, 1H), 1.51-1.41 (m, 1H), 1.21-1.09 (m, 2H), 0.95-0.81 (m, 1H); 
13
C 
NMR (125.8 MHz, CD3OD)  172.9, 158.5, 138.2, 136.1, 135.8, 134.4, 134, 129.6, 129.5, 
129.4, 129, 128, 127.7, 127.4, 127.3, 67.7, 64.3, 63.9, 48.1, 45.4, 44.5, 41.4, 35.7, 30.1, 29.4, 
28.6, 28.2, 14.5; HRMS (ESI-TOF)  m/z: [M + H]
+
 Calcd for C24H29N2O5 425.2055; Found 
425.2077. 
 
 
 
 
Benzyl ((1R,2S)-1,3-dihydroxy-1-((1R,2S)-2-(((1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-
yl)carbamoyl)cyclopropyl)propan-2-yl)carbamate (4.1h). Obtained as a white solid (190 mg, 
63 %): 
1
H NMR (400 MHz, DMSO-d6)  8.15 (brs, 1H), 7.41-7.25 (m, 5H), 7.21-7.15 (m, 4H), 
6.91 (brs, 1H), 5.18-5.11 (m, 1H), 5.04-4.95 (m, 2H), 4.82-4.78 (m, 1H), 4.61-4.41 (m, 3H), 
3.91-3.71 (m, 3H), 3.20 (brs, 1H),  3.04-2.96 (m, 1H), 2.81-2.78 (m, 1H), 1.91-1.71 (m, 1H), 
1.38-1.21 (m, 1H), 1.05-0.91 (m, 1H), 0.81-0.71 (m, 1H); 
13
C NMR (125.8 MHz, CDCl3)  
174.2, 156.6, 140.9, 139.9, 136.3, 128.5, 128.4, 128.2, 128.1, 127, 125.3, 124.3, 73.1, 69.3, 67.1, 
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62.5, 58.3, 56.3, 38.9, 24.1, 20.1, 10.1;  HRMS (ESI-TOF)  m/z: [M + H]
+
 Calcd for C24H29N2O6 
441.2026; Found 441.2017. 
General procedure for N-Cbz hydrogenolysis of amino diol derivatives (4.1a-h) and 
subsequent peptide coupling towards synthesis of a combinatorial library of dipeptide 
isosteres (4.2aA-4.2hF). 
 
Step 1: Cyclopropyl carboxamide aminodiol derivative  (4.1a-4.1h, 1.0 equiv.) was dissolved in 
methanol (10% solution w/v) and 10% Pd-C (10 mol %) was added under nitrogen blanket. 
Degassed the reaction mixture twice and flushed with hydrogen. Stirred the mixture under H2 
atmosphere at rt until disappearance of the starting material (monitored by TLC). The reaction 
mixture was filtered through a celite pad and the residue was washed with methanol (5x5 mL).  
The combined filtrate was concentrated under vacuum and dried under high vacuum pump for 2 
h.  The crude amine thus obtained was used directly for the next reaction.  
The amine as obtained above was dissolved in anhydrous DMF (10% solution w/v) and the 
respective N-Boc- aminoacid (A-F, 1.2 equiv) was added to it. To the resulting solution was 
added EDCI (1.5 equiv.) and the mixture stirred at rt overnight.  The volatiles were removed 
under high vacuum and the crude product purified by column chromatography (CH2Cl2 : MeOH 
+ 1% NH4OH = 9 : 1) to obtain cis-1,2-disubstituted cyclopropane dipeptide isosteres 4.2aA-
4.2hF respectively. In a combinatorial approach, 6 types of Boc-protected aminoacids were 
utilized for peptide coupling (A-F). 
 
 
 
tert-Butyl((S)-1-(((1R,2S)-1-((1R,2S)-2-(butylcarbamoyl)cyclopropyl)-1,3-dihydroxypropan- 
2-yl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate (4.2aA). Obtained as a white powder (68 
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mg, 51 %):. 
1
H NMR (500 MHz, CD3OD)  7.38-7.11 (m, 5H), 4.41-4.28 (m, 1H), 4.01-3.91 (m, 
1H), 3.81-3.59 (m, 3H), 3.31-3.05 (m, 3H), 2.91-2.71 (t, 1H), 1.61-1.42 (m, 3H), 1.41-1.15 (m, 
12H), 1.11-0.99 (m, 1H), 0.95-0.78 (m, 4H); 
13
C NMR (125.8 MHz, CD3OD)  174.6, 157.8, 
138.9, 130.7, 130.6, 129.5, 127.8, 80.8, 80.7, 70.6, 62.6, 57.9, 40.7, 39.5, 32.7, 28.8, 28.5, 25.3, 
21.2, 19.6, 14.3, 11.6; HRMS (ESI-TOF)  m/z: [M + H]
+
 Calcd for C25H40N3O6 478.2917; Found 
478.2900. 
 
tert-Butyl ((S)-3-(benzyloxy)-1-(((1R,2S)-1-((1R,2S)-2-butylcarbamoyl)cyclopropyl)-1,3-di -
hydroxypropan-2-yl)amino)-1-oxopropan-2-yl)carbamate (4.2aB). Obtained as a white solid 
(139 mg, 74 %):  
1
H NMR (400 MHz, CDCl3)  7.41-7.21 (m, 5H), 6.95-6.85 (m, 1H), 6.05-
5.91 (m, 1H), 5.48-5.38 (m, 1H), 4.99-4.85 (m, 1H), 4.61-4.41 (m, 2H), 4.31-4.21 (m, 1H), 4.05-
3.71 (m, 4H), 3.70-3.51 (m, 2H), 3.31-3.15 (m, 2H), 3.01-2.81 (m, 1H), 1.51-1.49 (m, 3H), 1.51-
1.41 (m, 9H), 1.41-1.28 (m, 3H), 1.27-1.09 (m, 1H), 1.01-0.91 (m, 1H), 0.89-0.81 (m, 3H); 
13
C 
NMR (125.8 MHz, CDCl3):  173.5, 170.2, 155.6, 137.3, 128.5, 127.9, 127.8, 80.3, 73.5, 70.9, 
70.5, 69.8, 62.4, 55.1, 54.8, 39.8, 34.6, 31.4, 28.23, 23.5, 20.1, 13.7, 10.7; HRMS (ESI-TOF)  
m/z: [M + H]
+
 Calcd for C26H42N3O7 508.3023; Found 508.3015. 
 
tert-Butyl ((S)-1-(((1R,2S)-1-((1R,2S)-2-(butylcarbamoyl)cyclopropyl)-1,3-dihydroxypropan 
-2-yl)amino)-4-methyl-1-oxopentan-2-yl)carbamate (4.2aC). Obtained as a white solid (117 
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mg, 71 % ):  
1
H NMR (400 MHz, CDCl3)  6.92 (brs, 1H), 6.01-6.11 (m, 1H), 4.68-5.15 (m, 
2H), 3.95-4.15 (m, 3H), 3.61-3.81 (m, 2H), 3.41-3.52 (brs, 1H), 3.05-3.41 (m, 2H), 1.71-1.91 (m, 
4H), 1.58-1.78 (m, 4H), 1.41-1.52 (m, 9H), 1.21-1.41 (m, 1H), 1.12-1.20 (m, 1H), 0.97-1.08 (m, 
1H), 0.81-0.97 (m, 9H); 
13
C NMR (125.8 MHz, CDCl3):  173.4, 172.8, 155.9, 80, 69.5,  62.3, 
55.1, 54.8, 41.5, 41.2, 31.4, 28.3, 25.2, 21.6, 19.6, 13.7, 11.0; HRMS (ESI-TOF)  m/z: [M + H]
+
 
Calcd for C22H42N3O6 444.3074; Found 444.3077.  
 
 (S)-tert-Butyl 2-(((1R,2S)-1-((1R,2S)-2-(butylcarbamoyl)cyclopropyl)-1,3-dihydroxy propan 
-2-yl)carbamoyl)pyrrolidine-1-carboxylate (4.2aD). Obtained as a white solid (32 mg, 66 %): 
1
H NMR (500 MHz, CD3OD; mixture of rotamers)  4.28-4.11 (m, 1H), 4.01-3.89 (m, 1H), 
3.78-3.61 (m, 3H), 3.52-3.31 (m, 2H), 3.21-3.01 (m, 2H), 2.31-2.09 (m, 1H), 2.04-1.78 (m, 3H), 
1.69-1.51 (m, 1H), 1.51-1.25 (m, 14H), 1.11-1.01 (m, 1H), 0.99-0.81 (m, 4H); 
13
C NMR (125.8 
MHz, CD3OD; mixture of rotamers):  175.5, 174.5, 156.6, 81.8, 70.6, 62.7, 62.6, 58.0, 40.7, 
35.9, 32.9, 31.6, 28.9, 21.2, 14.6; HRMS (ESI-TOF)  m/z: [M + H]
+
 Calcd for C21H38N3O6 
428.2761; Found 428.2748. 
 
tert-Butyl ((S)-1-(((1R,2S)-1-((1R,2S)-2-(cyclopropylcarbamoyl)cyclopropyl)-1,3-dihydroxy  
propan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate (4.2bA). Obtained as a white 
solid (79 mg, 92%): 
1
H NMR (400 MHz, CD3OD)  7.39-7.09 (m, 5H), 4.39-4.25 (m, 1H), 3.95-
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3.85 (m, 1H), 3.79-3.65 (m, 2H), 3.19-3.02 (m, 1H), 2.91-2.71 (m, 1H), 2.64-2.55 (m, 1H), 2.42-
2.30 (m, 1H), 1.85-1.61 (m, 1H), 1.51-1.49 (m, 9H), 1.25-1.11 (m, 3H), 0.72-0.61 (m, 2H), 0.50-
0.40 (m, 1H); 
13
C NMR (125.8 MHz, CD3OD)  176.4, 174.5, 157.8, 138.9, 130.5, 129.6, 127.9, 
80.9. 70.6, 70.3, 62.6, 62.5, 58.2, 58.0, 57.8, 45.5, 45.2, 44.4, 39.6, 39.4, 39.3, 38.8, 36.7, 36.0, 
29.2, 28.8, 28.6, 25.6, 23.6, 19.3, 16, 15, 11.7,6.7, 6.5; HRMS (ESI-TOF)  m/z: [M + H]
+
 Calcd 
for C24H36N3O6 462.2604; Found 462.2601. 
 
tert-Butyl((S)-3-(benzyloxy)-1-(((1R,2S)-1-((1R,2S)-2-(cyclopropylcarbamoyl) cyclopropyl)-
1,3-dihydroxypropan-2-yl)amino)-1-oxopropan-2-yl)carbamate(4.2bB).
 
Obtained as a white 
solid (82 mg, 60%): 
1
H NMR (400 MHz, CD3OD)  7.41-7.29 (m, 5H), 4.51 (s, 2H), 4.32-4.24 
(m, 1H), 4.01-3.89 (m, 1H), 3.81-3.61 (m, 5H), 2.64-2.57 (m, 1H), 1.51-1.47 (m, 1H), 1.45 (s, 
9H), 1.31-1.21 (m, 1H), 1.09-1.01 (m, 1H), 0.91-0.85 (m, 1H), 0.71-0.61 (m, 2H), 0.52-0.39 (m, 
2H);
 13
C NMR (125.8 MHz, CD3OD)  176.4, 172.9, 157.9, 139.4, 130.1, 129.5, 129.4, 129.2, 
129.1, 129, 128.9, 126.4, 81.1, 74.4, 71.3, 70.4, 62.6, 57.9, 56.4, 28.8, 25.6, 23.6, 19.4, 19.3, 
11.7, 8.7, 8.0; HRMS (ESI-TOF)  m/z: [M + H]
+
 Calcd for C25H38N3O7 492.2710; Found 
492.2693. 
 
tert-butyl((S)-1-(((1R,2S)-1-((1R,2S)-2-(cyclopropylcarbamoyl)cyclopropyl)-1,3-dihydroxy 
propan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)carbamate (4.2bC). Obtained as a white solid 
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(32 mg, 66%): 
1
H NMR (500 MHz, CD3OD)  4.11-4.01 (m, 1H), 3.95-3.85 (m, 1H), 3.75-3.61 
(m, 3H), 2.68-2.58 (m, 1H), 1.74-1.61 (m, 1H), 1.58-1.49 (m, 3H), 1.48-1.38 (m, 9H), 1.41-1.28 
(m, 1H), 1.11-1.03 (m, 1H), 0.99-0.91 (m, 7H), 0.71-0.62 (m, 2H), 0.54-0.43 (m, 2H); 
13
C
 
NMR 
(125.8 MHz, CD3OD)  176.3, 158.1, 80.8, 70.6, 62.6, 57.8, 55.1, 42.4, 28.9, 26.1, 25.7, 23.7, 
22, 19.2, 12.0, 6.8, 6.5; HRMS (ESI-TOF)  m/z: [M+H] + Calcd for C21H38N3O6 428.2761; 
Found 428.2742. 
 
 (S)-tert-Butyl2-(((1R,2S)-1-((1R,2S)-2-(cyclopropylcarbamoyl)cyclopropyl)-1,3-dihydroxy- 
propan-2-yl)carbamoyl)pyrrolidine-1-carboxylate
 
(4.2bD). Obtained as a white solid (26 mg, 
23%): 
1
H NMR (500 MHz, CD3OD; mixture of rotamers)  4.25-4.18 (m, 1H), 4.01-3.91 (m, 
1H), 3.85-3.65 (m, 3H), 3.55-3.38 (m, 2H), 2.69-2.59 (m, 1H), 2.29-2.15 (m, 1H), 2.01-1.81 (m, 
3H), 1.61-1.55 (m, 1H), 1.49-1.41 (m, 9H), 1.39-1.28 (m, 1H), 1.17-1.09 (m, 1H), 1.03-0.95 (m, 
1H), 0.73-0.65 (m, 2H), 0.58-0.45 (m, 2H); 
13
C NMR (125.8 MHz, CD3OD; mixture of 
rotamers)  176.4, 176.2, 175.6, 175.4, 156.6, 156.7, 156.3, 81.7, 81.5, 70.7, 70.3, 62.8, 62.7, 
61.9, 57.9, 57.4, 48.1, 32.9, 32.8, 31.7, 30.6, 28.9, 25.7, 25.6, 24.7, 23.6, 19.4, 19.3, 11.8, 11.7, 
6.7, 6.5; HRMS (ESI-TOF)  m/z: [M + H]
+
 Calcd for C20H34N3O6 412.2448; Found 412.2441. 
 
tert-Butyl((S)-1-(((1R,2S)-1-((1R,2S)-2-(cyclohexylcarbamoyl)cyclopropyl)-1,3-dihydroxy- 
propan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate (4.2cA). Obtained as a white solid 
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(75 mg, 53%): 
1
H NMR (400 MHz, CD3OD)  7.35-7.29 (m, 5H), 4.37-4.21 (m, 1H), 3.97-3.85 
(m, 1H), 3.81-3.51 (m, 4H), 3.19-3.05 (m,1H), 2.89-2.71 (m, 1H), 1.99-1.79 (m, 2H), 1.77-1.65 
(m, 2H), 1.63-1.49 (m,2H), 1.35 (s, 9H), 1.33-1.11 (m, 6H), 1.05-0.95 (m, 1H), 0.94-0.79 (m, 
1H); 
13
C NMR (125.8 MHz, CD3OD)  174.5, 174.4, 173.8, 173.7, 157.8, 138.9, 130.6, 129.6, 
127.8, 80.9, 80.8, 70.7, 70.5, 62.6, 62.5, 58.0, 57.9, 50.1, 39.6, 39.4, 34.1, 33.9, 28.8, 26.9, 26.3, 
25.3, 19.7, 11.5  HRMS (ESI-TOF)  m/z: [M + H]
+
 Calcd for C27H42N3O6 504.3074; Found 
504.3078.   
 
tert-Butyl(S)-1-(benzyloxy)-2-(((1R,2S)-1-((1R,2S)-2-(cyclohexylcarbamoyl) cyclopropyl)-1,3 
-dihydroxypropan-2-yl)amino)-2-oxoethyl)carbamate (4.2cB). Obtained as a white solid (66 
mg, 54%): 
1
H NMR (500 MHz, CD3OD)  7.41-7.25 (m, 5H), 4.53-4.45 (m, 2H), 4.33-4.25 (m, 
1H), 3.95-3.85 (m, 1H), 3.78-3.55 (m, 6H), 1.91-1.81 (m, 2H), 1.79-1.68 (m, 2H), 1.67-1.51 (m, 
2H), 1.49-1.41 (m, 9H), 1.38-1.11 (m, 6H), 1.11-1.01 (m, 1H), 0.95-0.81 (m, 1H); 
13
C NMR 
(125.8 MHz, CD3OD)  173.8, 172.9, 157.9, 139.4, 129.5, 129, 128.9, 81.1, 74.3,  71.3, 70.6, 
62.6, 57.9, 56.5, 50, 34.1, 33.9, 28.8, 26.8, 26.3, 25.3, 19.7, 11.6; HRMS (ESI-TOF)  m/z: [M + 
H]
+
 Calcd for C28H44N3O7 534.3179; Found 534.3167. 
 
tert-Butyl((S)-1-(((1R,2S)-1-((1R,2S)-2-(cyclohexylcarbamoyl)cyclopropyl)-1,3-dihydroxy-
propan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)carbamate (4.2cC). Obtained as a white solid 
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(81 mg, 74%): 
1
H NMR (500 MHz, CD3OD)  4.15-4.05 (m, 1H), 3.95-3.85 (m, 1H), 3.81-3.51 
(m, 4H) , 1.95-1.81 (m, 2H), 1.79-1.71 (m, 3H), 1.67-1.58 (m, 2H), 1.56-1.48 (m, 2H), 1.49-1.41 
(m, 9H), 1.38-1.29 (m, 4H), 1.25-1.15 (m, 3H), 1.11-1.03 (m, 1H), 0.99-0.89 (m, 7H);  
13
C NMR 
(125.8 MHz, CD3OD)  176.1, 173.7, 158.11, 80.8, 70.6, 62.7, 57.9, 55.1, 50.2, 42.4, 34.1, 33.9, 
28.9,  26.9, 26.3, 26.1, 25.5, 25.4, 23.7, 22.1, 19.6, 11.7;  HRMS (ESI-TOF)  m/z: [M + H]
+
 
Calcd for C24H44N3O6: 470.3230; Found 470.3211.   
 
 (S)-tert-Butyl 2-(((1R,2S)-1-((1R,2S)-2-(cyclohexylcarbamoyl)cyclopropyl)-1,3-dihydroxy- 
propan-2-yl)carbamoyl)pyrrolidine-1-carboxylate (4.2cD).  Obtained as a white solid (74 mg, 
70%): 
1
H NMR (400 MHz, CD3OD; mixture of rotamers)  4.29-4.21 (m, 1H), 4.03-3.95 (m, 
1H), 3.81-3.61 (m, 4H) 3.58-3.41 (m, 2H), 2.31-2.18 (m, 1H), 2.15-1.85 (m, 4H), 1.81-1.61 (m, 
3H), 1.51-1.41 (m, 9H), 1.40-1.29 (m, 3H), 1.27-1.16 (m, 3H), 1.15-1.09 (m, 1H), 1.03-0.97 (m, 
1H), 0.95-0.88 (m, 2H), 
13
C NMR (125.8 MHz, CD3OD)  175.5, 175.4, 173.8, 173.6, 156.6, 
156.3, 81.7, 81.5, 70.9, 70.4, 62.7, 61.9, 58,  57.4, 50.2,  48.1, 34.1, 33.9, 32.8, 28.8, 26.8, 26.3, 
23.8, 21.7, 19.8, 19.6, 11.9, 11.6, 11.5;  HRMS (ESI-TOF)  m/z: [M + H]
+
 Calcd for C23H40N3O6 
454.2917; Found 454.2904. 
 
tert-Butyl ((S)-1-(((1R,2S)-1-((1R,2S)-2-(dimethylcarbamoyl)cyclopropyl)-1,3-dihydroxypro 
pan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate
 
(4.2dA). Obtained as a white solid 
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(69 mg, 49%): 
1
H NMR (400 MHz, CD3OD)  7.41-7.11 (m, 5H), 4.41-4.21 (m, 1H), 4.09-3.78 
(m, 1H), 3.81-3.61 (m, 2H), 3.41-3.31 (m, 1H), 3.29-3.09 (m, 4H), 2.92 (brs, 3H), 2.71-2.68 (m, 
1H), 1.95-1.81 (m, 1H), 1.31 (brs, 10H), 1.11-1.01 (m, 1H), 0.91-0.81(m, 1H);  
13
C NMR (125.8 
MHz, CD3OD)  174.6, 173.8, 157.9, 138.9, 130.7, 130.5, 129.6, 127.8, 80.8, 71.8, 62.5, 57.8, 
39.5, 38.2, 36.3, 28.7, 25.1, 18, 11.4; HRMS (ESI-TOF)  m/z: [M + H]
+
 Calcd for C23H36N3O6 
450.2604; Found 450.2594. 
 
tert-Butyl ((S)-3-(benzyloxy)-1-(((1R,2S)-1-((1R,2S)-2-(dimethylcarbamoyl)cyclo propyl)-
1,3-dihydroxypropan-2-yl)amino)-1-oxopropan-2-yl)carbamate (4.2dB). Obtained as a white 
solid (87 mg, 58%): 
1
H NMR (400 MHz, CD3OD)  7.41-7.11 (m, 5H), 4.61-4.49 (m, 2H), 4.38-
4.28 (m, 1H), 4.05-3.95 (m, 1H), 3.81-3.61 (m, 4H), 3.38 (brs, 1H), 3.18(s, 3H), 2.92 (s, 3H), 
1.81-1.78 (m, 1H), 1.45 (brs, 10H), 1.15-1.01 (m, 1H), 0.96-0.81 (m, 1H); 
13
C NMR (125.8 
MHz, CD3OD)  173.8, 172.9, 157.9, 139.4, 129.6, 129.3, 128.9, 81.1, 79.6, 74.3, 71.6, 71.5, 
62.5, 57.9, 56.4, 38.2, 36.3, 28.9, 25.1, 17.9, 14.6, 11.5;  HRMS (ESI-TOF)  m/z: [M + H]
+
 
Calcd for C24H38N3O7: 480.2710; Found 480.2718. 
 
tert-Butyl ((S)-1-(((1R,2S)-1-((1R,2S)-2-(dimethylcarbamoyl)cyclopropyl)-1,3-dihydroxy-
propan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)carbamate
 
(4.2dC). Obtained as a white solid 
(59 mg, 45%): 
1
H NMR (400 MHz, CD3OD)  4.19-4.02 (m, 1H), 4.01-3.91 (m, 1H), 3.75-3.61 
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(m, 2H), 3.31-3.22 (m, 1H), 3.21 (s, 3H), 2.92 (s, 3H), 2.01-1.89 (m, 1H), 1.79-1.61 (m, 1H), 
1.58-1.41 (m, 12H), 1.18-1.03 (m, 1H), 0.99-0.85 (m, 7H); 
13
C NMR (125.8 MHz, CD3OD)  
176.0, 173.8, 158.1, 80.8, 71.7, 62.6, 57.8, 55.1, 42.9, 38.2, 36.3, 28.8, 26.1, 25.3, 23.7, 22.0, 
17.9, 11.71; HRMS (ESI-TOF) m/z: [M + H]
+
 Calcd for C20H38N3O6 416.2761; Found 416.2755.  
 
(S)-t-Butyl 2-(((1R,2S)-1-((1R,2S)-2-(dimethylcarbamoyl)cyclopropyl)-1,3-dihydroxyprop-
an-2-yl)carbamoyl)pyrrolidine-1-carboxylate (4.2dD). Obtained as a white solid (54 mg, 
43%): 
1
H NMR (400 MHz, CD3OD; mixture of rotamers)  7.81 (brs, 1H), 4.21-4.18 (m, 1H), 
3.95-3.81 (m, 1H), 3.81-3.61 (m, 2H), 3.51-3.31 (m, 2H), 3.30-3.21 (m, 1H), 3.18 (brs, 3H), 2.91 
(s, 3H), 2.31-2.11 (m, 1H), 1.98-1.65 (m, 4H), 1.49-1.31 (brs, 9H), 1.18-1.05 (m, 1H), 1.01-0.91 
(m, 1H), 0.89-0.78 (m, 1H); 
13
C NMR (125.8 MHz, CD3OD; mixture of rotamers)  175.6, 
175.4, 173.8, 156.6, 156.3, 81.7, 72.0, 71.5, 62.7, 62.6, 61.9, 61.8, 57.9,  57.4, 48.0, 38.1, 36.3, 
32.8, 31.7, 28.9, 25.6, 25.4, 25.2, 24.8, 23.9, 18.0, 17.8, 14.6, 11.6, HRMS (ESI-TOF)  m/z: 
[M+H] + Calcd for C19H34N3O6  400.2448; Found 400.2434. 
 
tert-Butyl ((S)-1-(((1R,2S)-1,3-dihydroxy-1-((1R,2S)-2-(pyrrolidine-1-carbonyl) cyclopropyl) 
propan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate (4.2eA). Obtained as a white solid 
(63 mg, 53%): 
1
H NMR (400 MHz, CD3OD; mixture of rotamers)  7.31-7.09 (m, 5H), 4.38-
4.21 (m, 1H), 3.95-3.85 (m, 1H), 3.78-3.61 (m, 2H), 3.51-3.45 (m, 1H), 3.44-3.31 (m, 2H), 3.15-
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3.01 (m, 1H), 2.81-2.71 (m, 1H), 2.01-1.71 (m, 5H), 1.51-1.43 (m, 1H), 1.41-1.21 (m, 10H), 
1.21-1.01 (m, 1H), 0.98-0.81 (m, 2H); 
13
C NMR (125.8 MHz, CD3OD; mixture of rotamers)  
174.6, 174.5, 157.8, 138.9, 130.5, 129.6, 129.5, 127.8, 80.9, 71.3, 71.1, 62.6, 62.4, 57.9, 57.5,  
57.8, 48.1, 47.4, 39.5, 39.4, 35.8, 32.9, 28.8, 27, 26.4, 25.6, 25.3, 23.9, 18.9, 14.6, 12;  HRMS 
(ESI-TOF)  m/z: [M+H] + Calcd for C25H38N3O6 476.2761; Found 476.2761. 
 
tert-Butyl ((S)-1-(benzyloxy)-2-(((1R,2S)-1,3-dihydroxy-1-((1R,2S)-2-(pyrrolidine-1-carbo-
nyl)cyclopropyl)propan-2-yl)amino)-2-oxoethyl)carbamate (4.2eB). Obtained as a white solid 
(112 mg, 80%): 
1
H NMR (500 MHz, CD3OD, mixture of rotamers)  7.43-7.28 (m, 5H), 4.57-
4.42 (m, 2H), 4.28-4.23 (m, 1H), 4.01-3.91 (m, 1H), 3.78-3.61 (m, 5H), 3.53-3.31 (m, 4H), 2.01-
1.78 (m, 4H), 1.73-1.65 (m, 1H), 1.49-1.35 (m, 10H), 1.15-1.03 (m, 1H), 0.93-0.81 (m, 1H); 
13
C 
NMR (125.8 MHz, CD3OD, mixture of rotamers)  172.9, 172.6, 157.9, 139.4, 129.6, 129.5, 
129.1, 129, 128, 81.1, 74.3, 71.3, 70.1, 62.6, 57.8, 57.7, 56.4, 48.2, 47.4, 28.8, 27.0, 25.5, 25.3, 
18.8, 11.5; HRMS (ESI-TOF)  m/z: [M + H]
+
 Calcd for C26H40N3O7 506.2866; Found 506.2851. 
 
tert-Butyl ((S)-1-(((1R,2S)-1,3-dihydroxy-1-((1R,2S)-2-(pyrrolidine-1-carbonyl)cyclopropyl) 
propan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)carbamate (4.2eC). Obtained as a white solid 
(94 mg, 78%): 
1
H NMR (400 MHz, CD3OD, mixture of rotamers)  4.15-4.01 (m, 1H), 3.98-
3.85 (m, 1H), 3.81-3.61 (m, 3H), 3.59-3.48 (m, 1H), 3.47-3.31 (m, 3H), 2.01-1.75 (m, 5H), 1.73-
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1.61 (m, 1H), 1.57-1.51 (m, 2H), 1.38 (brs, 10H), 1.18-1.11 (m, 1H), 1.11-0.81 (m, 7H); 
13
C 
NMR  (125.8 MHz, CD3OD, mixture of rotamers)  175.9, 172.4, 158.1, 80.7, 71.2, 62.6, 57.7, 
55, 48.1, 47.3, 42.4, 28.9, 27, 26.1, 25.5, 25.4, 23.7, 22, 18.9, 11.6; HRMS (ESI-TOF)  m/z: [M  
+ H]
+
 Calcd for C22H40N3O6: 441.2917; Found 442.2929. 
 
 (S)-tert-Butyl 2-(((1R,2S)-1,3-dihydroxy-1-((1R,2S)-2-(pyrrolidine-1-carbonyl) cyclopropyl) 
propan-2-yl)carbamoyl)pyrrolidine-1-carboxylate (4.2eD). Obtained as a white solid (81 mg, 
70%): 
1
H NMR (500 MHz, CD3OD; mixture of rotamers)  4.28-4.18 (m, 1H), 3.99-3.89 (m, 
1H), 3.85-3.65 (m, 3H), 3.61-3.29 (m, 6H), 2.31-2.01 (m, 1H), 2.11-1.78 (m, 8H), 1.61-1.31 (brs, 
10H), 1.19-1.11 (m, 1H), 1.01-0.91 (m, 1H); 
13
C NMR (125.8 MHz, CD3OD; mixture of 
rotamers)  175.5, 175.4, 172.5, 172.3, 156.6, 156.3, 81.6, 81.5, 71.5, 71, 62.8, 62.6, 61.8, 57.9, 
57.4, 48.1, 48, 47.4, 32.8, 31.6, 28.9, 27,  25.5,  25.4, 24.7, 18.9, 18.8,  11.5, 11.4; HRMS (ESI-
TOF)  m/z: [M + H]
+
 Calcd for C21H36N3O6: 426.2617;  Found 426.2617. 
 
tert-Butyl ((S)-1-(((1R,2S)-1,3-dihydroxy-1-((1R,2S)-2-(morpholine-4-carbonyl)cyclopropyl)  
propan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate (4.2fA). Obtained as a white solid 
(32 mg, 66%): 
1
H NMR (400 MHz, CD3OD)  7.38-7.18 (m, 5H), 4.49-4.47 (m, 1H), 4.05-3.95 
(m, 1H), 3.81-3.61 (m, 9H), 3.50-3.19 (m, 3H), 2.91-2.79 (m, 1H), 1.98-1.81 (m, 1H), 1.41-1.13 
(m, 11H), 1.03-0.81 (m, 1H); 
13
C NMR
 
(125.8 MHz, CD3OD)  171.7, 169.4, 155, 136.2, 127.8, 
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126.8, 125, 78.1, 68.9, 66.2, 65.1, 64.9, 59.7, 55.1, 55.0, 44.8, 41.1, 36.7, 26.1, 23.9, 22.5, 14.9, 
8.6; HRMS (ESI-TOF)  m/z: [M+Na] Calcd for C25H37N3O7Na 514.2529; Found 514.2526. 
 
tert-Butyl ((S)-3-(benzyloxy)-1-(((1R,2S)-1,3-dihydroxy-1-((1R,2S)-2-(morpholine-4-carbon- 
yl)cyclopropyl)propan-2-yl)amino)-1-oxopropan-2-yl)carbamate (4.2fB). Obtained as a 
white solid (69 mg, 56%): 
1
H NMR (400 MHz, CDCl3)  7.41-7.01 (m, 6H), 5.04 (brs, 1H), 4.92  
(brs, 1H), 4.58-4.43 (m, 2H), 4.48-4.34 (m, 1H), 4.09-3.90 (m, 2H), 3.88-3.80 (m, 1H), 3.74-3.57 
(m, 10H), 3.51-3.41 (m, 2H), 1.71-1.51 (m, 1H), 1.35 (brs, 9H), 1.28-1.18 (m, 1H), 0.99-0.91 (m, 
1H), 0.89-0.73 (m, 1H);  
13
C NMR (125.8 MHz, CD3OD)  171.4, 170.8, 156.4, 137.9, 128, 
127.5, 127.4, 79.6, 72.8, 70.2, 69.8, 66.3, 66.2, 60.1, 56.4, 56.2, 54.9, 46.1, 42.3, 27.4, 23.8, 23.7, 
16.1, 10; HRMS (ESI-TOF)  m/z: [M+Na] Calcd for C26H39N3O8Na 544.2635; Found 545.2651. 
 
tert-Butyl ((S)-1-(((1R,2S)-1,3-dihydroxy-1-((1R,2S)-2-(morpholine-4-carbonyl)cyclopropyl) 
propan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)carbamate (4.2fC). Obtained as a white solid 
(48 mg, 45%): 
1
H NMR (400 MHz, CDCl3)  7.16 (brd, J = 8.8 Hz, 1H), 5.41-5.21 (m, 1H), 
4.15-3.81 (m, 3H), 3.77-3.58 (m, 8H), 3.50-3.39 (m, 2H), 1.79-1.51 (m, 3H), 1.49-1.41 (m, 2H), 
1.42 (s, 9H), 1.11-0.99 (m, 1H), 0.93-0.71 (m, 7H); 
13
C NMR (125.8 MHz, CD3OD)  174.4, 
170.7, 156.6, 79.3, 70.2, 66.3, 61, 56.3, 53.5, 46.1, 42.4, 40.1, 27.4, 24.6, 23.9,  22.2, 21.7, 16.1, 
10; HRMS (ESI-TOF)  m/z: [M + H]
+
 Calcd for C22H40N3O7 458.2866; Found 458.2834. 
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(R)-tert-Butyl 2-(((1R,2S)-1,3-dihydroxy-1-((1R,2S)-2-(morpholine-4-carbonyl)cyclopropyl)- 
propan-2-yl)carbamoyl)pyrrolidine-1-carboxylate
 
(4.2fD). Obtained as a white solid (107 mg, 
63%): 
1
H NMR  (400 MHz, CD3OD; mixture of rotamers)  4.38-4.21 (m, 1H) 4.04-3.96 (m, 
1H), 3.95-3.61 (m, 8H), 3.59-3.41 (m, 3H), 3.40-3.21 (m, 2H), 2.61-2.35 (m, 1H), 2.01-1.71 (m, 
4H), 1.48-1.38 (m, 9H), 1.24-1.18 (m, 2H),  1.01-0.81 (m, 1H);  
13
C NMR (125.8 MHz, CD3OD; 
mixture of rotamers)  174.7, 172.7, 169.4, 169.2, 153.8, 153.5, 78.8, 69.3, 68.8, 67.2, 65.1, 
64.9, 59.9, 59.7, 59.2, 59, 57.9, 55.2, 54.6, 52.3, 44.8, 41, 37.8, 34, 30, 28.9, 26.1, 22.8, 22.6, 
22.5, 22.3, 22, 21, 15, 14.8, 12.2, 12.3, 8.7, 8.6; HRMS (ESI-TOF)  m/z: [M + Na]
+
 Calcd for 
C21H35N3O7Na: 464.2373; Found 464.2317. 
 
tert-Butyl ((S)-1-(((1R,2S)-1,3-dihydroxy-1-((1R,2S)-2-(1,2,3,4-tetrahydroiso-quinoline-2-
carbonyl)cyclopropyl)propan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate (4.2gA). 
1
H NMR (500 MHz, DMSO-d6; mixture of rotamers).  Obtained as a white solid (66 mg,  42%): 
 7.65 (brs, 1H), 7.49 and 7.30  (2s, 9H), 7.04 (brs, 1H), 5.02 (s, 1H),  4.88-4.73 (m, 1H), 4.39 
(brs, 1H), 4.02-3.90 (m, 2H), 3.88-3.64 (m, 3H), 3.39-2.85 (m, 4H), 2.12 (brs, 1H), 1.58-1.29 (m, 
11H), 1.34-1.20 (m, 1H), 0.98-0.82 (m, 1H); 
13
C NMR (125.8 MHz, DMSO-d6; mixture of 
rotamers)  171.2, 169.5, 155.1, 138.3, 135.1, 129.2, 128.3, 127.9, 78, 69.4, 60.4, 55.9, 44, 46.5, 
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42.8, 37.7, 28.2, 28.1, 27.7, 23.9, 16.6, 9.8; HRMS (ESI-TOF)  m/z: Found 538.2914 [M + H] 
+
 
Calcd for C30H40N3O6: 538.2917). 
 
t-Butyl((S)-3-(benzyloxy)-1-(((1R,2S)-1,3-dihydroxy-1-((1R,2S)-2-(1,2,3,4-tetrahydroisoqui-
noline-2-carbonyl)cyclopropyl)propan-2-yl)amino)-1-oxopropan-2-yl)carbamate (4.2gB).  
Obtained as a white solid (80 mg, 46%): 
1
H NMR (400 MHz, DMSO-d6; mixture of rotamers).   
 7.65-7.55 (m, 1H), 7.41-7.25 (m, 5H), 7.23-7.11 (m, 4H), 6.91-6.81 (m, 1H), 4.81-4.78 (m, 
1H), 4.72-4.66 (m, 1H), 4.65-4.41 (m, 4H), 4.35-4.25 (m, 1H), 3.81-3.71 (m, 2H), 3.71-3.41 (m, 
5H), 3.15-3.01 (m, 1H), 2.99-2.80 (m, 1H), 2.78-2.71 (m, 1H), 1.89-1.81 (m, 1H),  1.51-1.21(m, 
10H), 1.05-0.95 (m, 1H), 0.81-0.74 (m, 1H); 
13
C NMR (125.8 MHz,  DMSO-d6; mixture of 
rotamers)  169.4, 169.3, 155.1, 138.2, 135.1, 134.9, 133.6, 133.5, 128.3, 128.1, 127.4, 127.3, 
126.4, 126.2, 126, 78.2, 71.8, 70.1, 69.2, 60.4, 55.9, 54.3, 46.5, 44, 42.8, 28.7, 28.1, 23.9, 16.2, 
9.8; HRMS (ESI-TOF)  m/z: [M + Na]
+
 Calcd for C31H41N3O7Na 590.2842; Found  590.2904.  
 
t-Butyl ((S)-1-(((1R,2S)-1,3-dihydroxy-1-((1R,2S)-2-(1,2,3,4-tetrahydroisoquinoline-2-carbo-
nyl)cyclopropyl)propan-2-yl)amino)-1-oxopropan-2-yl)carbamate (4.2gE). Obtained as a 
white solid (55 mg, 44%): 
1
H NMR (500 MHz, DMSO-d6; mixture of rotamers)  7.47-7.40 (m, 
1H), 7.25-7.13 (brs, 4H), 6.78-6.76 (m, 1H), 4.85 (brs, 1H), 4.70-4.44 (m, 3H), 4.11-3.72 (m, 
3H), 3.68-3.40 (m, 2H), 3.21-3.02 (m, 2H), 2.98-2.72 (m, 2H), 1.98-1.88 (m, 1H), 1.35 (s, 9H), 
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1.25-1.15 (m, 4H), 1.11-1.07 (m, 1H), 0.83-0.76 (m, 1H); 
13
C NMR (125.8 MHz, CDCl3; 
mixture of rotamers)  172.7, 171.0, 156.4, 134.8, 134, 132.8, 132.3, 128.7, 128.3, 127.1, 126.7, 
126.6, 126.5, 126.1, 65.9, 62.3, 54.3, 50.6, 47.6, 44.7, 43.7, 40.5, 29.3, 28.4, 28.3, 18.4, 18.1, 
17.9, 15.3, 11.0, 10.9; HRMS (ESI-TOF)  m/z: [M + Na]
+
 Calcd for C24H35N3O6Na: 484.2423; 
Found 484.2415. 
 
t-butyl((2S)-1-(((1R,2S)-1,3-dihydroxy-1-((1R,2S)-2-(1,2,3,4-tetrahydroisoquin-oline-2-car-
bonyl)cyclopropyl)propan-2-yl)amino)-3-methyl-1-oxopentan-2-yl)carbamate (4.2gf).White 
solid (70 mg, 45%): 
1
H NMR (400 MHz, DMSO-d6; mixture of rotamers)  7.51-7.35 (m, 1H), 
7.29-7.05 (m, 4H), 6.91-6.75 (m, 1H), 4.91-4.75 (m, 1H), 4.71-4.38 (m, 3H), 3.91-3.76 (m, 3H), 
3.71-3.59 (m, 1H), 3.54-3.41 (m, 2H), 3.21-3.01 (m, 1H), 2.99-2.79 (m, 1H), 2.78-2.71 (m, 1H), 
1.99-1.88 (m, 1H), 1.81-1.61 (m, 1H), 1.51-1.31 (m, 10H), 1.15-0.95 (m, 3H), 0.91-0.69 (m, 
7H); 
13
C NMR (125.8 MHz, DMSO-d6; mixture of rotamers)  171, 169.5, 155.3, 135.1, 134.9, 
133.7,  128.3, 126.4, 126.2, 126, 78, 69.5, 69.4, 64.9, 60.5, 59.3, 55.8, 46.5, 44, 42.8, 36.6, 28.7, 
28.1, 24.1, 24, 16.5, 16.2, 15.5, 15.1, 11.1;  HRMS (ESI-TOF)  m/z: [M + H]
+
 Calcd for 
C27H42N3O6: 504.3074; Found 504.2923. 
 
tert-Butyl ((S)-1-(((1R,2S)-1,3-dihydroxy-1-((1R,2S)-2-(((1S,2R)-2-hydroxy-2,3-dihydro-1H-
inden-1-yl)carbamoyl)cyclopropyl)propan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)carba- 
122 
 
mate (4.2hA). Obtained as a white solid (80 mg, 60%): 
1
H NMR (400 MHz, DMSO-d6)  8.25-
8.15 (m, 1H), 7.75-7.65 (m, 1H), 7.41-7.11 (m, 9H), 6.91-6.81 (m, 1H), 5.21-5.05 (m, 1H), 4.91-
4.78 (m, 1H), 4.74-4.65 (m, 1H), 4.61-4.51 (m, 1H), 4.50-4.46 (m, 1H), 4.31-4.11 (m, 1H), 3.91-
3.71 (m, 1H), 3.69-3.41 (m, 3H), 3.05-2.96 (m, 2H), 2.85-2.61 (m, 2H), 1.91-1.75 (m, 1H), 1.41-
1.15 (m, 9H), 1.14-0.99 (m, 2H), 0.89-0.71 (m, 1H); 
13
C NMR
 
(125.8 MHz, DMSO-d6)  171.8, 
171.4, 155.1, 141.6, 141, 138.3, 129.4, 129.2, 127.9, 127.3, 126.2, 126, 124.7, 124.2, 77.9, 72, 
68.5, 64.9, 60.6, 57.5, 55.8, 55.6, 37.7, 28.1, 27.7, 24.1, 17.6, 15.1, 10.2; HRMS (ESI-TOF)  
m/z: [M + H]
+
 Calcd for C30H40N3O7: 554.2866; Found 554.2845. 
 
tert-Butyl ((S)-3-(benzyloxy)-1-(((1R,2S)-1,3-dihydroxy-1-((1R,2S)-2-(((1S,2R)-2-hydroxy-
2,3-dihydro-1H-inden-1-yl)carbamoyl)cyclopropyl)propan-2-yl)amino)-1-oxopropan-2-yl)- 
carbamate (4.2hB). Obtained as a white solid (80 mg, 57%): 
1
H NMR (500 MHz, DMSO-d6)  
8.21-8.11 (m, 1H), 7.71-7.55 (m, 1H), 7.45-7.26 (m, 5H), 7.22-7.11 (m, 4H), 6.88-6.71 (m, 1H), 
5.21-5.11 (m, 1H), 4.89 (s, 1H), 4.70 (s, 1H), 4.59-4.41 (m, 4H), 4.39-4.21 (brs, 1H), 3.85-3.71 
(m, 1H), 3.61-3.41 (m, 5H), 3.09-2.99 (m, 1H), 2.81-2.71 (m, 1H), 1.84-1.75 (m, 1H), 1.42-1.31 
(brs, 9H), 1.27-1.11 (m,1H), 1.03-0.96 (m, 1H), 0.81-0.65 (m, 1H); 
13
C NMR
 
(125.8 MHz, 
DMSO-d6)  171.8, 169.4, 155.1, 141.6, 140.9, 138.2, 128.1, 127.4, 127.3, 124.7, 124.3, 78.2, 
72, 71.8, 70.1, 68.4, 60.5, 57.5, 55.7, 54.3, 28.1, 24.1, 17.5, 10.1; HRMS (ESI-TOF)  m/z: [M + 
H]
+
 Calcd for C31H42N3O8 584.2972; Found 584.2952. 
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t-Butyl ((S)-1-(((1R,2S)-1,3-dihydroxy-1-((1R,2S)-2-(((1S,2R)-2-hydroxy-2,3-dihydro-1H-ind 
den-1-yl)carbamoyl)cyclopropyl)propan-2-yl)amino)-1-oxopropan-2-yl)carbamate (4.2hE). 
Obtained as a white solid (60 mg, 55%): 
1
H NMR (500 MHz, DMSO-d6)  8.21-8.11 (m,1H), 
7.61-7.41 (m, 1H), 7.31-7.11 (m, 4H), 6.87-6.75 (m, 1H), 5.21-5.11 (m, 1H), 4.82 (s, 1H), 4.74-
4.65 (m, 1H), 4.63-4.41 (m, 2H),  4.05-3.91 (m, 1H), 3.81-3.71 (m, 1H), 3.62-3.45 (m, 3H), 3.05-
2.91 (m, 1H), 2.85-2.71 (m, 1H), 1.89-1.71 (m, 1H), 1.44-1.32 (brs, 9H), 1.31-1.11 (m, 4H), 
1.01-0.95 (m, 1H), 0.89-0.75 (m, 1H); 
13
C NMR (125.8 MHz, DMSO-d6)  172.3, 171.8, 154.8, 
141.6, 140.9, 127.3, 126.2, 124.7, 124.2, 78.1, 72, 68.5, 60.6, 57.5, 55.5, 54.8, 49.7, 28.1, 24.2, 
18.6, 17.5, 10.3; HRMS (ESI-TOF)  m/z: [M + H]
+
 Calcd for C24H36N3O7 478.2553; Found 
478.2550.
 
 
tert-Butyl ((2S,3S)-1-(((1R,2S)-1,3-dihydroxy-1-((1R,2S)-2-(((1S,2R)-2-hydroxy-2,3-dihydro-
1H-inden-1-yl)carbamoyl)cyclopropyl)propan-2-yl)amino)-3-methyl-1-oxopentan-2-yl)car- 
bamate (4.2hF). Obtained as a white solid (61 mg, 50%): 
1
H NMR (500 MHz, DMSO-d6)  
8.31-8.11 (m, 1H), 7.61-7.41  (m, 1H), 7.31-7.11  (m, 4H), 6.81-6.61 (m, 1H), 5.21-5.05 (m, 1H),  
4.81-4.75 (m, 1H), 4.74-4.65 (m,  1H), 4.63-4.41 (m,  2H),  3.91-3.77 (m,  2H), 3.76-3.71 (m, 
3H), 3.11-2.95 (m, 1H), 2.89-2.71 (m, 1H), 1.92-1.80 (m, 1H), 1.72-1.68 (m, 1H), 1.59-1.28 (m, 
10H), 1.29-1.18 (m, 1H), 1.11-0.95 (m,2H), 0.91-0.75 (m, 7H); 
13
C NMR (125.8 MHz, DMSO-
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d6)  171.8, 171.2, 155.3, 141.6, 140.9, 127.3, 126.1, 124.7, 124.2, 78.1, 72,  68.5, 60.7, 59.2, 
57.6, 55.6, 36.5, 28.1, 24.2, 17.5, 15.4, 11.1, 10.1; HRMS (ESI-TOF)  m/z: [M + H]
+
 Calcd for 
C27H42N3O7: 520.3023; Found 520.3003.  
 
 (S)-2-Amino-N-((1R,2S)-1,3-dihydroxy-1-((1R,2S)-2-(1,2,3,4-tetrahydroisoquinoline-2-car-
bonyl)cyclopropyl)propan-2-yl)propanamide (as TFA salt) (5.1). Cis-1,2-disubstituted cyclo-
propane dipeptide isostere 4.2gE (40 mg) was dissolved in trifluoroacetic acid (5 mL) and stirred 
at rt for 2 h. The reaction mixture was then subjected to vacuum and triturated with anhydrous 
diethyl ether to obtain the trifluoacetic acid salt of cis-1,2-disubstituted cyclopropane dipeptide 
isostere 5.1 as a hygroscopic solid (26 mg, quant.). 
1
H NMR (500 MHz, D2O)  7.31-7.11 (m, 
4H), 4.95-4.85 (m, 2H), 4.61-4.41 (m, 1H), 4.05-3.85 (m, 2H), 3.84-3.65 (m, 2H), 3.61-3.41 (m, 
1H), 3.19-3.01 (m, 1H), 2.91-2.71 (m, 2H), 2.18-2.01 (m, 1H), 1.81-1.41 (m, 4H), 1.19-1.01 (m, 
2H); 
13
C NMR (125.8 MHz, D2O)  171.9, 163.1, 162.8, 135.2, 135, 132.9, 132.7, 128.3, 126.9, 
126.5, 126.4, 126.2, 117.4, 115.1, 70.2, 60.5, 56.7, 56.6, 49.2, 47.2, 44.8, 43.7, 41.0, 28.4, 27.7, 
22.9, 17.5, 17.2, 16.8, 16.5, 9.9; HRMS (ESI-TOF)  m/z: [M + H]
+
 Calcd for C19H28N3O4: 
362.2080; Found 362.2075. 
 
(1S,2R)-2-((1R,2S)-2-((2S,3S)-2-Amino-3-methylpentanamido)-1,3-dihydroxypropyl)-N-(1S, 
2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl)cyclopropanecarboxamide  (as TFA salt) (5.2). As 
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described above in synthesis of trifluoroacetic acid salt of dipeptidic isostere 5.1, a similar 
protocol was utilized for Boc-deprotection of cis-1,2-disubstituted cyclopropane dipeptide 
isostere 4.2hF  to afford cis-1,2-disubstituted cyclopropane dipeptide isostere 5.2 as a 
hygroscopic solid (30 mg, quant.). 
1
H NMR (500 MHz, D2O)  7.41-7.18 (m, 4H), 5.24 (brs, 
1H), 4.52 (brs, 1H), 4.13 (brs, 1H), 3.91-3.78 (m, 2H), 3.71-3.48 (m, 2H), 3.21-3.02 (m, 1H), 
2.91-2.71 (m, 1H), 2.01-1.81 (m, 2H), 1.61-1.31 (m, 2H), 1.29-1.01 (m, 3H), 1.01-0.79 (m, 6H); 
13
C NMR (125.8 MHz, D2O)  174.4, 169.6 140.3, 139.6, 128.2, 127, 125.3, 123.9, 73.3, 69.2, 
60.5, 58.1, 57.9, 56.7, 38.4, 36.1, 23.7, 23, 18.2, 14.2, 10.6, 10.4; HRMS (ESI-TOF)  m/z: [M + 
H]
+
 Calcd for C22H34N3O5: 420.2498; Found 420.2482.  
5.3.2. Chapter 3. Total Synthesis and Structure
_
Activity Relationship Studies of the Cyto-  
          toxic Anhydrophytosphingosine Jaspine B 
 
 
 
 
 
 
 
Benzyl ((3S,4S,5S)-4-hydroxy-5-(2-hydroxyethyl)tetrahydrofuran-3-yl)carbamate (28.1). 
Step1: To a stirred solution of the bicyclic lactone 6  (1.5 g, 5.4 mmol) in anhydrous 
dichloromethane (25 mL) at -78 °C was added DIBAL-H dropwise (1M in toluene; 6.5 mL, 6.5 
mmol) over 10 min.
28
  After stirring for another 1.5 h at the same temperature, the reaction was 
quenched by adding methanol (1.5 mL) and allowed to attain rt. To the resulting solution, 
ethylacetate (40 mL), and saturated aq. sodium potassium tartarate solution (10 mL) was added 
and stirring continued for another 1 h. The organic layer was separated, and the aq. Layer 
extracted with ethylacetate (3 x 25 mL). The combined extract dried over anhydrous Na2SO4 and 
126 
 
solvent evaporated on a rotary evaporator to obtain 1.55 g of the crude lactol, which was used as 
such for the next reaction. 
Step 2 : The product from step 1 (1.5 g) was dissolved in ethanol (20 mL), the solution cooled to 
0 °C (ice-bath) and powdered NaBH4 (420 mg, 11.11 mmol) added to it in small portions over a 
period of 5 min. After stirring at 0 °C for 15 min, the reaction was quenched by adding crushed 
ice and the resulting mixture extracted thoroughly with ethylacetate (8 x 30 mL). The combined 
extract was dried (anhydrous. Na2SO4), concentrated, and the residue purified by column 
chromatography (hexanes : EtOAc = 1:1 to 1:2) to afford the pure diol 28.1 as a white solid (1.2 
g, 77% over two steps); mp = 105-107 °C; [α]D 14.4 (c 0.4, CH3OH); 
1
H NMR (500 MHz, 
CDCl3)  7.45-7.30 (m, 5H), 5.53 (brs, 1H, exchangeable with D2O), 5.12 (s, 2H), 4.50-4.35 (m, 
1H), 4.21 (s, 1H), 4.12-3.96 (m, 2H), 3.95-3.85 (brs, 1H), 3.75-3.67 (m, 1H), 3.66 (t, 1H, J = 10 
Hz), 3.37 (brs, 1H, exchangeable with D2O), 2.25 (brs, 1H, exchangeable with D2O) 2.10-1.71 
(m, 2H); 
13
C NMR (125.8 MHz, CDCl3)  158, 136.3, 128.6, 128.2, 128.1, 81.9, 71.4, 69.9, 
66.9, 59.5, 53.9, 31.2; HRMS (ESI-TOF)  m/z: [M + H]
+
 Calcd for C14H20NO5 282.1341; Found 
282.1334. 
 
 
(3aS,6S,6aS)-Benzyl 2,2-diethyl-6-(2-hydroxyethyl)tetrahydrofuro[3,4-d]oxazole-3(2H)-car-
boxylate (28.2). An ice-cooled solution of the diol 28.1  (2 g, 7.1 mmol), 3-pentanone (12 mL) 
and freshly prepared 3,3-dimethoxypentane
268
 (20 mL) was treated with a catalytic amount of 
BF3•OEt2 (0.1 mL). After stirring the resulting solution at the same temperature for 3 h, the 
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reaction was quenched with triethylamine (0.5 mL) and concentrated under vacuum. The crude 
residue was purified by flash chromatography (hexanes : EtOAc = 4:1 to 1:1), affording the 
corresponding oxazolidine derivative 28.2 as a viscous liquid (2g, 81%): [α]D  71 (c 1.8, CH2Cl2); 
1
H NMR (500 MHz, CDCl3, mixture of rotamers )  7.45-7.25 (m, 5H), 5.21-5.05 (m, 2H), 4.71-
4.41 (m, 2H), 4.18 and 4.01 (2m, 1H), 3.91-3.74 (m, 2H), 3.73-3.55 (m, 2H), 2.21-1.66 (m, 7H), 
0.92-0.71 (m, 6H); 
13
C NMR (125.8 MHz, CDCl3 mixture of rotamers)  152.9, 151.6, 136.5, 
136.1, 128.6, 128.2, 128.1, 128.0, 127.7, 102.4, 101.6, 82.0, 81.9, 81.5, 80.9, 73.8, 73.3, 67.4, 
66.7, 64.0, 62.8, 60.8, 60.7, 31, 30.9, 30.8, 30.3, 29.6, 29.3, 8.1, 7.4; HRMS (ESI-TOF)  m/z: [M 
+ Na]
+
 Calcd for C19H27NO5Na 372.1787; Found 372.1826. 
 
(3aS,6S,6aS)-Benzyl 2,2-diethyl-6-(2-(tosyloxy)ethyl)tetrahydrofuro[3,4-d]oxazole-3(2H)-
carboxylate (28.3). To an ice-cooled solution of the oxazolidine alcohol 28.2  (2 g, 5.73 mmol) 
in anhydrous dichloromethane (30 mL) were added p- toluenesulfonyl chloride (9.85 g, 9 mmol), 
pyridine (0.9 mL, 11.1 mmol), and a catalytic amount of 4-DMAP (30 mg). After stirring the 
resulting solution at rt for 48 h, the reaction was quenched with 10% aq. HCl solution (50 mL). 
The organic layer was separated, and the aqueous layer extracted once with dichloromethane (50 
mL). The combined organic layer was washed with brine (1x50 mL), dried over anhydrous 
Na2SO4, and concentrated under vacuum. Purification of the crude residue by flash 
chromatography (hexanes : EtOAc = 4:1 to 2:1) afforded the pure tosylate 28.3 as a viscous 
liquid (2.6 g, 90%); [α]D  48.8 (c 0.6, CH2Cl2); 
1
H NMR (400 MHz, CDCl3, mixture of rotamers ) 
 7.81 (d, J = 8.24 Hz, 2H), 7.43-7.31 (m, 7H), 5.21-5.05 (m, 2H), 4.60 – 4.46 (m, 2H), 4.29-
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4.14 (m,  2H), 4.21 and 3.94 (2d,  J = 10.0 Hz and 8.2 Hz, 1H), 3.60-3.41 (m, 2H), 2.47 (s, 3H), 
2.11-1.61 (m, 6H), 0.90-0.73 (m, 6H); 
13
C NMR (125.8 MHz, CDCl3)  152.9, 151.6, 144.8, 
136.5, 136.1, 132.9, 130, 128.6, 128.6, 128.4, 128.2, 128.1, 128.0, 127.9, 127.7, 102.3, 101.5, 
80.7, 73.7, 73.1, 68.0, 67.4, 66.7, 64.1, 63.0, 30.9, 30.1, 29.6, 29.1, 28.0, 21.6, 21.6, 8.0, 7.4; 
HRMS (ESI-TOF)  m/z: [M + H]
+
 Calcd for C26H34NO7S 504.2056; Found 504.2093. 
 
 (3aS,6S,6aS)-Benzyl 2,2-diethyl-6-tetradecyltetrahydrofuro[3,4-d]oxazole-3(2H)-carboxy- 
late (28.4). To a cooled mixture (-78 °C) of the tosylate 28.3 (250 mg, 0.5 mmol) and finely 
powdered CuI (190 mg, 1 mmol) in dry THF (8 mL) was added dodecyl magnesium bromide 
(1M soln. in ether, 3.4 mL, 3.4 mmol) dropwise over a period of 10 min. After stirring at -78°C 
for 30 min, the reaction mixture was warmed to 0°C (ice-bath) and stirring continued for another 
1.5 h. The reaction was quenched with 5 mL of satd. NH4Cl solution, and extracted with ethyl 
acetate (5x25 mL). The combined extract washed sequentially with water and brine, dried over 
anhydrous Na2SO4 and solvent removed under vacuum. Purification of the crude residue by flash 
chromatography (hexanes : EtOAc = 9 : 1) afforded the fully protected Jaspine B derivative 28.4 
as a viscous liquid (180 mg, 72%): [α]D  65.7 (c 0.6, CH2Cl2); 
1
H NMR (500 MHz, CDCl3, 
mixture of rotamers )  7.46-7.30 (m, 5H), 5.22-5.06 (m, 2H), 4.56-4.50 (2s, 2H), 4.09 and 4.01 
(2d, J = 10.75 Hz and 10.5 Hz, 1H), 3.70-3.54 (m, 1H), 3.44-3.34 (m, 1H), 2.19-1.98 (m, 1H), 
1.97-1.71 (m, 5H), 1.48-1.15 (m, 24H), 0.95-0.81 (m, 9H); 
13
C NMR (125.8 MHz, CDCl3; 
mixture of rotamers)  153.0, 151.7, 136.6, 136.2, 128.6, 128.5, 128.2, 128.1, 128.0, 127.7, 
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102.1, 101.3, 83.5, 83.4, 81.1, 80.5, 73.6, 73, 67.4, 66.6, 64.1, 63.0, 31.9, 29.7, 29.6, 29.5, 29.4, 
28.1, 26.3, 22.7, 14.1, 8.1, 7.4; HRMS (ESI-TOF)  m/z: [M+H]
+
 Calcd for C26H52NO4 502.3846; 
Found 502.3846. 
 
Jaspine B hydrochloride. A solution of the N,O-protected Jaspine B derivative 28.4 (85 mg, 
0.169 mmol) in 50% aq. HCl (10 mL) was refluxed for 16 h. The reaction mixture was cooled to 
rt and extracted once with ether (10 mL) to remove any organic soluble impurities. The aqueous 
layer was then concentrated in a rotary evaporator and the residual oily liquid kept under high 
vacuum overnight to afford the desired jaspine B hydrochloride salt as a white solid (44 mg, 
77%): [α]D  2.5 (c 0.46, CH3OH); 
1
H NMR (400 MHz, CD3OD )  4.25 (br s, 1H), 3.95-3.84 (m, 
2H), 3.83-3.75 (m, 1H), 3.73-3.66 (m, 1H), 1.72-1.57 (m, 2H), 1.51-1.20 (m, 24H), 0.88 (t, J = 
5.6 Hz, 3H); 
13
C NMR (125.8 MHz, CD3OD)  84.4, 71.0, 69.0, 54.1, 33.1, 30.9, 30.8, 30.7, 
30.5, 29.7, 23.8, 14.4; HRMS (ESI-TOF)  m/z: [M + H]
+
 Calcd for C18H38NO2 300.2903; Found 
300.2879. 
 
General procedure for the synthesis of C2 alkyl analogs 29.1-29.3  
To a cooled mixture (-78°C) of the tosylate 28.3 (1 equiv.) and finely powdered CuI (2 
equiv.) in dry THF (8 mL) was added the respective Grignard reagents (7 equiv.) dropwise over 
a period of 10 min. After stirring at -78°C for 30 min, the reaction mixture was warmed to 0°C 
(ice-bath) and stirring continued for additional 12 h – 16 h (monitoring by TLC). Subsequently, 
the reaction was quenched with 5 mL of satd. NH4Cl solution and extracted with ethyl acetate 
(5x25 mL). The combined extract washed sequentially with water and brine, dried over 
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anhydrous Na2SO4 and solvent removed under vacuum. Purification of the crude residue by flash 
chromatography (hexanes : EtOAc = 9 : 1) afforded the corresponding C2 alkyl analogs 29.1-
29.3. 
 
(3aS,6S,6aS)-Benzyl 2,2-diethyl-6-propyltetrahydrofuro[3,4-d]oxazole-3(2H)-carboxylate  
(29.1). Obtained as a viscous liquid (72 mg, 82%):  [α]D  90 (c 1.1, CH2Cl2); 
1
H NMR (500 
MHz, CDCl3, mixture of rotamers )   7.41-7.21 (m, 5H), 5.21-5.11 (m, 2H), 4.61-4.53 (m, 
1.4H), 4.51-4.45 (m, 0.6H), 4.15-4.06 (m, 0.4H), 4.05-3.98 (m, 0.6H), 3.69-3.59 (m, 1H), 3.45-
3.38 (m, 1H), 2.07-1.71 (m, 6H), 1.54-1.41 (m, 2H), 1.01-0.95 (m, 3H), 0.91-0.81 (m, 6H); 
13
C 
NMR (125.8 MHz, CDCl3; mixture of rotamers)  152.9, 151.6, 136.6, 136.1, 128.6, 128.5, 
128.1, 128.0 127.6, 102.0, 101.3, 83.2, 83.1, 80.5, 73.5, 73.0, 67.3, 66.6, 64.1, 62.9, 30.9, 30.3, 
30.2, 30.1, 29.5, 29.3, 19.6, 14.3, 8.08, 8.07, 7.4; HRMS (ESI-TOF)  m/z: [M+H]
+
 Calcd for 
C20H30NO4 348.2175; Found 348.2165. 
 
(3aS,6S,6aS)-Benzyl 2,2-diethyl-6-hexyltetrahydrofuro[3,4-d]oxazole-3(2H)-carboxylate  
(29.2). Obtained as a viscous liquid  (63 mg, 66%):  [α]D 82 (c 0.85, CH2Cl2); 
1
H NMR (400 
MHz, CDCl3; mixture of rotamers)  7.41-7.29 (m, 5H), 5.21-5.11 (m, 2H), 4.61-4.53 (m, 1.4H), 
4.51-4.49 (m, 0.6H), 4.18-4.11 (m, 0.4H) 4.01-3.91 (m, 0.6H) 3.71-3.51 (m, 1H), 3.42-3.31 (m, 
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1H), 2.40-1.70 (m, 6H), 1.49-1.23 (m, 8H), 0.95-0.71 (m, 9H); 
13
C NMR (125.8 MHz, CDCl3; 
mixture of rotamers)  152.9, 151.6, 136.6, 136.2, 128.5, 128.4, 128.1, 128.06, 128.0, 127.6, 
102.0, 101.3, 83.4, 81.1, 80.5, 73.5, 73.0, 67.3, 66.6, 64.1, 62.9, 31.7, 30.9, 30.3, 29.7, 29.5, 29.4, 
29.3, 28.08, 26.3, 22.5, 14.09, 8.07, 7.4; HRMS (ESI-TOF)  m/z: M+H Calcd for C23H36NO4 
390.2644; Found 390.2661. 
 
(3aS,6S,6aS)-Benzyl 2,2-diethyl-6-(3-phenylpropyl)tetrahydrofuro[3,4-d]oxazole-3(2H)-car-
boxylate (29.3). The crude product 29.3 was purified by column chromatography (ethyl 
acetate/hexane) to obtain the product as a viscous liquid (63 mg, 67%): [α]D 88.4 (c 0.5, CH2Cl2); 
1
H NMR (400 MHz, CDCl3; mixture of rotamers)  7.31-7.12 (m, 10H) 5.22-5.11 (m, 2H), 4.62-
4.51 (m, 1.4H), 4.51-4.45 (m, 0.6H), 4.18-4.11 (m, 0.4H), 4.05-3.96 (m, 0.6H), 3.71-3.55 (m, 
1H), 3.48-3.35 (m, 1H), 2.78-2.61 (m, 2H), 2.15-1.93 (m, 1H), 1.91-1.71 (m, 7H), 0.91-0.75 (m, 
6H); 
13
C NMR (125.8 MHz, CDCl3; mixture of rotamers)  152.9, 151.6, 142.2, 136.6, 136.1, 
130.5, 129.5, 129.3, 128.7, 128.6, 128.6, 128.5, 128.4, 128.3, 128.2, 128.1, 128.0, 127.9, 127.8, 
127.5, 127.2, 126.9, 126.1, 125.9, 125.7, 102.1, 101.3, 83.2, 83.2, 81.1, 80.5, 73.6, 73.0, 67.3, 
66.6, 65.2, 64.1, 62.9, 35.9, 35.8, 30.8, 30.3, 29.7, 29.5, 29.4, 29.0, 28.7, 28.1, 27.9, 27.8, 27.7, 
27.7, 8.11, 8.09, 7.94, 7.47; HRMS (ESI-TOF)  m/z: [M + Na]
+
 Calcd for C26H33NO4Na 
424.2603; Found 424.2542. 
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General procedure for global deprotection of the acetonide protected C2 alkyl analogs 
29.1-29.3. 
The N,O- protected C2 alkylated analogs (29.1-29.3)  were refluxed in a solution of 50% aq. HCl 
for 12–16 h (monitored by TLC). The reaction mixture was cooled to rt. and extracted once with 
dichloromethane (10 mL) to remove any organic soluble impurities. The aqueous layer was then 
concentrated in a rotary evaporator and the residual oily liquid kept under high vacuum overnight 
to afford the desired Jaspine B C2 alkyl analogs 29.4-29.6 as their hydrochloride salts. 
 
(2S,3S,4S)-4-Amino-2-propyltetrahydrofuran-3-ol (HCl salt) (29.4). Obtained as a 
hygroscopic solid (31 mg, 82%); [α]D 7.7 (c 0.6, CH3OH); 
1
H NMR (500 MHz, CD3OD)  4.29 
(brs, 1H), 3.98-3.89 (m, 2H), 3.88-3.81 (m, 1H), 3.79-3.72 (m, 1H), 1.72-1.61 (m, 2H), 1.59-1.41 
(m, 2H), 1.05-0.95 (m, 3H); 
13
C NMR (125.8 MHz, CD3OD)  81.8, 68.6, 66.7, 52.1, 28.6, 18.2, 
12.3; HRMS (ESI-TOF)  m/z: [M+H]
+
 Calcd for C7H16NO2 146.1181; Found 146.1153.  
 
(2S,3S,4S)-4-Amino-2-hexyltetrahydrofuran-3-ol (HCl salt) (29.5). Obtained as a hygroscopic 
solid (35 mg, 83%); [α]D 5.48 (c 1.35, CH3OH); 
1
H NMR (500 MHz, CD3OD)  4.21-4.15 (m, 
1H), 3.91-3.78 (m, 2H), 3.77-3.68 (m, 1H), 3.67-3.59 (m, 1H), 1.64-1.51 (m, 2H), 1.41-1.19 (m, 
8H), 0.89-0.76 (m, 3H); 
13
C NMR (125.8 MHz, CD3OD)  83.2, 69.7, 67.8, 53.2, 31.8, 29.4,  
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28.6, 26.0, 22.5, 13.3; HRMS (ESI-TOF)  m/z: [M + H]
+
 Calcd for C10H22NO2 188.1651; Found 
188.1635. 
 
(2S,3S,4S)-4-Amino-2-(3-phenylpropyl)tetrahydrofuran-3-ol (HCl salt)  (29.6). Obtained as a 
hygroscopic solid (60 mg, 90%); [α]D 10.4 (c 0.86, CH3OH); 
1
H NMR (500 MHz, CD3OD)  
7.39-7.09 (m, 5H), 4.41-4.21 (m, 1H), 4.11-3.75 (m, 4H), 2.81-2.61 (m, 2H), 1.94-1.61 (m, 4H); 
13
C NMR (125.8 MHz, CD3OD)  143.5, 129.7, 129.4, 129.3, 126.7, 84.2, 70.8, 69, 54.3, 36.9, 
29.3, 29.1; HRMS (ESI-TOF)  m/z: [M + H]
+
 Calcd for C13H20NO2 222.1494; Found 222.1475. 
 
General procedure for Jaspine B C2 Ether analogs 30.1-30.3. 
To an ice-cooled solution of the oxazolidine alcohol 28.2 (1 equiv.) in THF (10% 
solution w/v) was added potassium tert-butoxide (3 equiv, 1 M solution in THF) and stirred for 
30 min. The respective alkyl halides (1.2 equiv.) were then added to the ice-cooled solution with 
stirring. The reaction mixture was allowed to attain rt, and stirring continued for another 6-16 h 
(monitored by tlc). The reaction was then quenched with saturated aqueous NH4Cl solution and 
extracted with EtOAc (3x). The combined organic layers washed with brine and dried over 
anhydrous Na2SO4. Removal of solvent under vacuum and purification of the residue by flash 
chromatography (EtOAc:hexanes = 1:9) afforded the C2 alkyloxy analogs 30.1-30.3.  
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(3aS,6S,6aS)-Benzyl 6-(2-ethoxyethyl)-2,2-diethyltetrahydrofuro[3,4-d]oxazole-3(2H)-car-
boxylate (30.1). Obtained as a syrupy liquid (75 mg, 70%); [α]D 79.3 (c 0.38, CHCl3); 
1
H NMR 
(500 MHz, CDCl3; mixture of rotamers):  7.41-7.29 (m, 5H),  5.21-5.09 (m, 2H), 4.63-4.45 (m, 
2H), 4.18-4.09 (m, 0.4H) 4.03-3.95 (m, 0.6H), 3.68-3.55 (m, 4H), 3.51-3.45 (m, 2H), 2.15-2.01 
(m, 3H), 1.99-1.69 (m, 3H), 1.21-1.15 (m, 3H), 0.98-0.75 (m, 6H); 
13
C NMR
 
(125.8 MHz, 
CDCl3; mixture of rotamers) 152.9, 151.6, 136.6, 136.1, 128.5, 128.0, 127.6, 102.1, 101.3, 81.2, 
80.6, 80.2, 73.6, 73.0, 67.5, 67.4, 67.3, 66.6, 66.1, 64.1, 63, 30.9, 30.2, 29.7, 29.6,  29.2, 28.5, 
15.2, 8.1, 7.4, 7.3; HRMS (ESI-TOF)  m/z: [M+H]
+
 Calcd for : C21H32NO5: 378.2280; Found 
378.2278. 
 
(3aS,6S,6aS)-Benzyl 6-(2-(dodecyloxy)ethyl)-2,2-diethyltetrahydrofuro[3,4-d]oxazole-3(2H) 
carboxylate (30.2). Obtained as a viscous liquid (70 mg, 79%): 
 
[α]D  59.25 (c 0.675, CHCl3); 
1
H 
NMR (500 MHz, CDCl3; mixture of rotamers)  7.41-7.29 (m, 5H),  5.21-5.09 (m, 2H), 4.63-
4.55 (m, 1.4H), 4.53-4.49 (m, 0.6H), 4.15-4.11 (m, 0.4H), 4.05-3.95 (m, 0.6H), 3.71-3.51 (m, 
4H), 3.51-3.35 (m, 2H), 2.19-1.95 (m, 3H), 2.01-1.71 (m, 3H), 1.41-1.21 (m, 20 H), 0.95-0.81 
(m, 9H); 
13
C NMR (125.8 MHz, CDCl3; mixture of rotamers) 152.96, 151.65, 136.61, 136.17, 
128.57, 128.56, 128.08, 128.04, 127.66, 102.12, 101.35, 81.22, 80.63, 80.34, 73.59, 73.03, 71.07, 
71.05, 67.73, 67.66, 67.38, 66.67, 64.18, 63.02, 32.83, 31.93, 30.99, 30.28, 29.73, 29.68, 29.64, 
29.56, 29.51, 29.46, 29.37, 29.26, 28.53, 26.19, 25.76, 22.70, 14.14, 8.10, 7.41; HRMS (ESI-
TOF)  m/z: [M+H] + Calcd for : C31H52NO5: 518.3845; Found 518.3857. 
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(3aS,6S,6aS)-Benzyl 6-(2-(benzyloxy)ethyl)-2,2-diethyltetrahydrofuro[3,4-d]oxazole-3(2H)-
carboxylate (30.3). Obtained as a viscous liquid (120 mg, 70%); [α]D 40.36 (c 0.55, CH2Cl2); 
1
H 
NMR (500 MHz, CDCl3; mixture or rotamers):  7.39-7.29 (m, 10H),  5.21-5.11 (m, 2H), 4.59-
4.56 (m, 1H), 4.55-4.45 (m,  3H), 4.16-4.13 (m, 0.4H), 4.12-3.98 (m,  0.6H), 3.69-3.58 (m, 3H), 
2.18-2.14 (m, 3H), 2.11-1.71 (m, 4H), 0.91-0.86 (m, 3H), 0.83-0.78 (m, 3H); 
13
C NMR (125.8 
MHz, CDCl3 ; mixture or rotamers) 152.9, 151.6, 138.4, 136.6, 136.1, 128.6, 128.5, 128.3, 128.1, 
127.6, 127.6, 127.5, 102.1, 101.3, 81.1, 80.6, 80.3, 73, 61, 73.0, 72.9,  67.9, 67.4, 67.3, 66.6, 
64.2,  63.0, 31,  30.3,  29.6, 29.3, 28.5, 25.6, 8.1, 7.4; HRMS (ESI-TOF)  m/z: [M + H]
+
 Calcd 
for C26H34NO5 440.2437; Found 440.2433. 
General procedure for the synthesis of acetonide deprotected C2 alkyloxy N-Cbz-Jaspine B 
analogs 30.4-30.6. 
An ice-cooled solution of TFA:H2O (excess) was added to the N,O-oxazolidine  C2 
alkyloxy analogs 30.1-30.3 and stirred at room temperature for 3-4 h. After completion of 
reaction (monitored by TLC), the reaction mixture was neutralized by cautiously pouring into a 
saturated solution of NaHCO3. The resulting solution was extracted thoroughly with chloroform 
(5x). The combined organic layers were washed with brine and dried over anhydrous Na2SO4. 
Removal of solvent under vacuum and purification of the residue by flash chromatography 
afforded the acetonide deprotected C2 ether analogs 30.4-30.6.  
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Benzyl ((3S,4S,5S)-5-(2-ethoxyethyl)-4-hydroxytetrahydrofuran-3-yl)carbamate  (30.4). 
Obtained as a white solid (48 mg, 79%): [α]D 13.45 (c 0.55, CDCl3); 
1
H NMR (500 MHz, 
CDCl3):  7.48-7.29 (s, 5H), 5.65-5.51 (m, 1H), 5.21-5.01 (m, 2H), 4.48-4.31 (m, 1H) 4.14 (s, 
1H), 4.09-4.01 (m, 1H), 4.0-3.91 (m, 1H), 3.84 (s, 1H) 3.71-3.61 (m, 2H), 3.58-3.41 (m, 2H), 
3.40-3.31 (m, 1H), 2.21-2.01 (m,1H), 1.99-1.81 (m, 1H), 1.31-1.11 (m, 3H); 
13
C NMR (125.8 
MHz, CDCl3)  156.2, 136.4, 128.5, 128.1, 82.1, 71.1, 69.9, 66.8, 66.8, 66.7, 53.8, 29.9, 15; 
HRMS (ESI-TOF)  m/z: [M + H]
+
 Calcd for C16H24NO5 310.1654; Found 310.1645. 
 
Benzyl ((3S,4S,5S)-5-(2-(dodecyloxy)ethyl)-4-hydroxytetrahydrofuran-3-yl)carbamate 
(30.5). Obtained as a fluffy solid  (50 mg, 76%); [α]D 7.7 (c 0.45, CHCl3): 
1
H NMR (400 MHz, 
CDCl3)  7.45-7.25 (m, 5H), 5.61-5.51 (m, 1H), 5.14 (s, 2H), 4.48-4.31 (m, 1H) 4.18-4.11 (m, 
1H) 4.09-4.02 (m, 1H), 4.01-3.91 (m, 1H), 3.87 (s, 1H) 3.68-3.55 (m, 2H), 3.51-3.33 (m, 3H) 
2.21-2.05 (m, 1H), 1.95-1.81 (m, 1H), 1.41-1.21 (m, 20H), 0.95-0.85 (m, 3H); 
13
C NMR (125.8 
MHz, CDCl3)  156.23, 136.46, 128.53, 128.13, 82.15, 71.75, 71.12, 70.33, 70.0, 67.04, 66.82, 
53.88, 31.92, 29.91, 29.65, 29.61, 29.54, 29.51, 29.38, 29.36, 26.09, 22.71, 14.14; HRMS (ESI-
TOF)  m/z: [M+H]
+
 Calcd for C26H44NO5 450.3219; Found 450.3225. 
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Benzyl ((3S,4S,5S)-5-(2-(benzyloxy)ethyl)-4-hydroxytetrahydrofuran-3-yl)carbamate (30.6) 
Obtained as a white solid (55 mg, 85%): [α]D 5.6 (c 0.52, CHCl3); 
1
H NMR (400 MHz, CDCl3) 
 7.41-7.21 (m, 10H), 5.61-5.51 (m, 1H), 5.13 (brs, 2H), 4.61-4.51 (m, 2H) 4.45-4.31 (m, 1H), 
4.21-4.11 (m, 1H) 4.09-3.91 (m, 2H), 3.77-3.47 (m, 4H), 2.21-2.05 (m, 1H), 2.02-1.89 (m, 1H); 
13
C NMR (125.8 MHz, CDCl3)  156.2, 137.1, 136.4, 128.6, 128.5, 128.4, 128.1, 127.8, 127.6, 
81.9, 73.74, 71.1, 69.9, 66.8, 66.7, 60.4, 54.2, 50.8, 21.0, 14.2, 14.1; HRMS (ESI-TOF)  m/z:, 
[M + H]
+
 Calcd for C21H26NO5: 372.1811; Found 372.1805.  
 
General procedure for hydrogenolysis of the N-Cbz-protected C2 ether analogs 30.4-30.6 
The N-Cbz-protected analogs 30.4-30.6 were dissolved in methanol (1% solution w/v) 
and 10% Pd-C (10% wt) added to it. Flushed the reaction mixture with hydrogen (twice) and 
stirred under a hydrogen atmosphere for 3-10 h (monitored by TLC). The reaction mixture was 
filtered through a celite pad and the residue washed with methanol (3x). Removal of solvent 
under vacuum, and subjecting the residue to high vacuum overnight provided the respective pure 
products 30.7-30.9. 
 
(2S,3S,4S)-4-Amino-2-(2-ethoxyethyl)tetrahydrofuran-3-ol (30.7).  Obtained as a viscous 
liquid (20 mg, 89%): [α]D 8.2 (c  1.15, CH3OH); 
1
H NMR (400 MHz, CD3OD)  3.99-3.88 (m, 
1H), 3.87-3.79 (m, 2H), 3.61-3.31 (m, 6H), 1.91-1.73 (m, 2H), 1.21-1.05 (m, 3H); 
13
C NMR 
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(125.8 MHz, CD3OD)  81.4, 73.5, 72.1, 68.5, 67.3,  66.0, 56.0, 31.08, 15.4;  HRMS (ESI-TOF)  
m/z: [M + H]
+
 Calcd for C8H18NO3: 176.1287; Found 176.1281. 
 
 
(2S,3S,4S)-4-Amino-2-(2-(dodecyloxy)ethyl)tetrahydrofuran-3-ol (30.8). Obtained as a 
viscous liquid (25 mg, 89%): [α]D 8.8 (c 0.54, CH3OH); 
1
H NMR (400 MHz, CD3OD)  4.31-
4.21 (m, 1H), 3.95-3.75 (m, 4H), 3.61-3.51 (m, 2H),  3.45-3.35 (m,2H), 1.98-1.81 (m,  2H), 1.61-
1.51 (m, 2H), 1.41-1.21 (m, 18H), 0.92-0.81 (m, 3H); 
13
C NMR (125.8 MHz, CD3OD)  79.0, 
69.5, 68.4, 66.4, 66, 51.70, 30.4, 28.0, 27.9, 27.8, 27.6, 24.6, 21.0, 11.7; HRMS (ESI-TOF)  m/z: 
[M + H]
+
 Calcd for C18H38NO3  316.2852; Found 316.2843.  
 
(2S,3S,4S)-4-Amino-2-(2-(benzyloxy)ethyl)tetrahydrofuran-3-ol (30.9). Obtained as a viscous 
liquid (21 mg, 82%): [α]D  9.6 (c 1.2, CH3OH); 
1
H NMR (500 MHz, CD3OD)  7.38-7.31 ( m, 
4H), 7.30-7.21 (m, 1H), 4.55-4.45 (m, 2H), 4.05-3.95 (m, 1H), 3.93-3.81 (m, 2H), 3.78-3.58 (m, 
2H), 3.55-3.48 (m, 1H), 3.46-3.38 (m, 1H), 2.11-1.81 (m, 2H); 
13
C NMR (125.8 MHz, CD3OD) 
 137.0, 126.7, 126.2, 126.0, 78.7, 71.7, 71.3, 70.8, 69.5, 65.7, 53.3, 27.0; HRMS (ESI-TOF)  
m/z:, [M+H]
+
 Calcd for C13H20NO3 238.1443;  Found 238.1441. 
General procedure for synthesis of N-Cbz protected Jaspine B C2-alkylamine analogs 31.1-
31.3 
To a stirred, ice-cooled solution of the bicyclic lactol 26.1 (1 equiv.) in dry THF (10% 
solution w/v) was added NaBH(OAc)3 (1.2 equiv.) followed by the respective alkyl amines (1 
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equiv.). The reaction mixture was allowed to attain room temperature and stirring continued for 
another 2-3 hours. After completion of the reaction (monitored by TLC), the reaction mixture 
was quenched with saturated aqueous NaHCO3 solution and extracted with ethyl acetate. The 
aqueous layer was saturated with solid NaCl and re-extracted with EtOAc (2x). The combined 
extract washed sequentially with water and brine, and dried over anhydrous Na2SO4. Solvent was 
removed under vacuum, and the crude product purified by flash chromatography (MeOH: DCM 
+ 0.1% NH4OH = 5:95) affording the C2-alkylamino tetrahydrofuran derivatives 31.1-31.3.  
 
 
Benzyl((3S,4S,5S)-5-(2-(butylamino)ethyl)-4-hydroxytetrahydrofuran-3-yl)carbamate 
(31.1). Obtained as a light brown solid (50%): [α]D 18 (c 0.5, CHCl3); 
1
H NMR (500 MHz, 
CDCl3):  7.49-7.29 (m, 5H), 5.71-5.61 (m, 1H), 5.11 (brs, 2H), 4.45-4.31 (m, 1H), 4.13-4.03 
(m, 2H), 4.02-3.99 (m, 1H), 3.71-3.61 (m, 1H), 2.95-2.85 (m, 1H), 2.75-2.51 (m, 3H), 2.04-1.81 
(m, 3H), 1.52-1.41 (m, 2H), 1.41-1.31 (m, 2H), 0.94-0.85 (m, 3H);
 13
C NMR (125.8 MHz, 
CDCl3)  156.3, 136.5, 128.5, 128.0, 82.1, 70.4, 70.1, 66.7, 54.2, 43.2, 31.7, 20.3, 13.9; HRMS 
(ESI-TOF)  m/z: [M + H]
+
 Calcd for : C18H29N2O4: 337.2127; Found 337.2111. 
 
Benzyl((3S,4S,5S)-5-(2-(benzylamino)ethyl)-4-hydroxytetrahydrofuran-3-yl)carbamate 
(31.2). Obtained as a light brown solid (140 mg, 39%): [α]D 18 (c 0.5, CHCl3); 
1
H NMR (400 
MHz, CDCl3):  7.49-7.25 (m, 10H), 5.75-5.61 (m, 1H), 5.12 (brs, 2H), 4.41-4.21 (m,1H), 4.15-
3.91 (m, 4H), 3.85-3.68 (m, 2H), 3.67-3.59 (m, 1H), 2.91-2.81 (m, 1H), 2.61-2.48 (m, 1H), 2.01-
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1.81 (m, 2H);
 13
C NMR (125.8 MHz, CDCl3)  154.2, 136.3, 134.5, 126.8, 126.7, 126.5, 126.5, 
126.5, 126.3, 126.2, 126.1, 126.1, 125.6, 80.1, 68.4, 68.1, 64.7, 52.2, 51.7, 40.9, 27.6; HRMS 
(ESI-TOF)  m/z: [M + H]
+
 Calcd for : C21H27N2O4: 371.1971; Found 371.1942. 
 
Benzyl((3S,4S,5S)-5-(2-(dodecylamino)ethyl)-4-hydroxytetrahydrofuran-3-yl)carbamate 
(31.3). Obtained as a light brown solid (95 mg, 50%): [α]D 10.4 (c 0.5, CH2Cl2); 
1
H NMR (500 
MHz, CDCl3):  7.49-7.31 (m, 5H), 5.71-5.61(m, 1H), 5.14 (brs, 2H), 4.41-4.31 (m, 1H), 4.11-
4.02 (m, 2H), 4.01-3.91 (m, 1H), 3.71-3.61 (m, 1H), 2.95-2.81 (m, 1H), 2.71-2.51 (m, 3H), 1.99-
1.85 (m, 2H), 1.51-1.42 (m, 2H), 1.41-1.21 (m, 15H), 0.95-0.81 (m, 3H);
 13
C NMR (125.8 MHz, 
CDCl3)  156.3, 136.5, 128.4, 128.0, 82.1, 70.4, 70.1, 66.7, 54.2, 49.5, 43.3, 31.8, 29.6, 29.5, 
29.4, 29.3, 27.1, 22.6, 14.1; HRMS (ESI-TOF)  m/z: [M+H]
+
 Calcd for C24H41N2O4 421.3066; 
Found 421.3027. 
General procedure for the synthesis of C2-alkyl amine anlogs 31.4-31.6 
A solution of the N-Cbz protected alkyl amine (31.1-31.3) was refluxed in 6 M HCl 
solution (excess) for 12-16 hours. After completion of reaction (monitored by TLC), the reaction 
mixture was extracted with dichloromethane (once) to remove any organic impurities and the 
aqueous layer concentrated under vacuum. The resulting product was subjected to high vacuum 
overnight to afford the pure Jaspine B C2 alkyl amine analogs 31.4-31.6 as the corresponding 
HCl salts.  
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(2S,3S,4S)-4-Amino-2-(2-(butylamino)ethyl)tetrahydrofuran-3-ol hydrochloride (HCl salt) 
(31.4). Obtained as a light brown hygroscopic solid (32 mg, 80%): [α]D 13.6 (c 0.44, CH3OH); 
1
H NMR (500 MHz, CD3OD)  4.45-4.35 (m, 1H), 4.01-3.81 (m, 4H), 3.25-3.15 (m, 2H), 3.01-
2.91 (m, 2H), 2.21-2.11 (m, 1H), 2.05-1.95 (m, 1H), 1.81-1.65 (m, 2H), 1.51-1.35 (m, 2H), 1.05-
0.95 (m, 3H); 
13
C NMR (125.8 MHz, CD3OD)  81.8, 71.1, 69.5, 54.2, 47.0, 30.3, 29.3, 26.9, 
26.1, 25.5, 20.91, 14.0; HRMS (ESI-TOF)  m/z: [M + H]
+
 Calcd for C10H23N2O2: 203.1760;  
Found 203.1745.  
 
 
(2S,3S,4S)-4-Amino-2-(2-(benzylamino)ethyl)tetrahydrofuran-3-ol (HCl salt) (31.5). 
Obtained as a light brown solid (40mg, 57%): [α]D - 22.7 (c 0.43, CH3OH); 
1
H NMR (400 MHz, 
CD3OD)  7.61-7.41 (m, 5H), 4.34 (brs, 1H), 4.28-4.12 (m, 2H), 4.01-3.75 (m, 4H), 3.21-3.11 
(m, 2H), 2.21-2.09 (m, 1H), 2.05-1.91 (m, 1H); 
13
C NMR (125.8 MHz, CD3OD)  132.5, 131.1, 
130.7, 130.5, 130.3, 81.8, 71.1, 69.5, 54.2, 52.4, 46.6, 26.7; HRMS (ESI-TOF)  m/z: [M + H]
+
 
Calcd for : C13H21N2O2 : 237.1603; Found 237.1604. 
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(2S,3S,4S)-4-Amino-2-(2-(decylamino)ethyl)tetrahydrofuran-3-ol (HCl salt) (31.6). Obtained 
as a light brown hygroscopic solid (43 mg, 78%): [α]D 2.76 (c 1.12, CH3OH);
 1
H NMR (500 
MHz, CD3OD)  4.36 (brs, 1H), 3.97-3.88 (m, 4H), 3.18 (brs, 2H), 3.0 (brs, 2H), 2.18-2.07 (m, 
1H), 2.05-1.95 (m, 1H), 1.69 (brs, 2H), 1.30 (brs, 14H), 0.89 (brs, 3H); 
13
C NMR (125.8 MHz, 
CD3OD)  79.1, 68.4, 66.8, 51.5, 44.2, 30.4, 28.0, 27.9, 27.8, 27.6, 25.0, 24.6, 24.2, 21.1, 11.8; 
HRMS (ESI-TOF)  m/z: Found 287.2687 [M+H]
+
 Calcd for C16H35N2O2: 287.2699). 
 
Synthesis of C4-N,N’-di-Boc-guanidine analog of Jaspine B (32.2)  
 
 
To a stirred solution of Jaspine B (25 mg, 83.19 mmol) in 1,4-dioxane (2 mL) at room 
temperature was added N,N'-Di-Boc-N''-triflylguanidine (32.1)
269
 (93.5 mg, 249.6 mmol), 
followed by triethylamine  (24 mg, 249.6 mmol).
8
 After stirring for 6 h, the reaction mixture was 
concentrated and the residue partitioned between chloroform and water. The organic layer was 
separated, and the aqueous layer extracted with CHCl3 (3x10 mL). The combined organic layers 
dried over anhydrous Na2SO4 and concentrated under vacuum. The residue is purified by flash 
chromatography (EtOAc : hexanes = 12 : 88) to afford the product 32.1 as a white solid (24 mg, 
58 %): [α]D 6.3 (c 0.19, CH2Cl2); 
1
H NMR (500 MHz, CDCl3):  11.48  (brs, 1H), 8.91 (brs, 
1H), 4.89-4.71 (m, 1H), 4.28-4.11 (m, 2H), 3.88-3.75 (m, 1H), 3.71-3.58 (m, 1H), 1.95  (brs, 
1H), 1.71-1.61 (m, 2H), 1.59-1.56 (m, 2H), 1.54-1.48 (m, 15H), 1.39-1.21 (m, 25H), 0.93-0.71 
(m, 3H);
 13
C NMR (125.8 MHz, CDCl3)  163.46, 156.20, 152.98, 83.31, 82.06, 79.45, 72.07, 
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70.21, 54.03, 31.93, 29.71, 29.69, 29.68, 29.66, 29.57, 29.52, 29.37, 28.93, 28.29, 28.06, 22.70, 
14.14; HRMS (ESI-TOF)  m/z: [M+H]
+
 Calcd for C29H56N3O6: 542.4169; Found 542.4123. 
 
1-((4S,5S)-4-Hydroxy-5-tetradecyltetrahydrofuran-3-yl)guanidine (32.3). The N,N’-di-boc-
guanidine Jaspine B was dissolved in a premixed solution of DCM and TFA (2 mL, 1:1) and 
stirred at rt for 4h. The reaction mixture is then concentrated and the residue flushed with 
dichloromethane  (2x3 mL) under high vacuum. The resulting residue was triturated with hot 
dichloromethane:hexane (15 mL, 2:1). Drying of the product under high vacuum afforded the 
C4-guanidino Jaspine B analog (32.3) as a white solid (19 mg, 90%); [α]D 2.2 (c 0.008, CH3OH); 
1
H NMR (500 MHz, CD3OD)  4.25-4.15 (m, 2H), 4.08-3.99 (m, 1H), 3.85-3.75 (m, 1H), 3.71-
3.55 (m, 1H), 1.71-1.58 (m, 2H), 1.51-1.18 (m, 24H), 0.95-0.85 (m, 3H); 
13
C NMR (125.8 MHz, 
CDCl3)  157.2, 82.6, 78, 70.3, 68.7, 54.3, 31.6, 31.3, 29.4, 29.3, 29.2, 29, 28.7, 25.7, 22.3, 22.2, 
13; HRMS (ESI-TOF)  m/z: [M+H]
+
 Calcd for : C19H40N3O2: 342.3121; Found 342.3106. 
 
(2S,3S,4S)-4-azido-2-tetradecyltetrahydrofuran-3-ol (33.1)  Step 1: To an ice-cooled solution 
of NaN3 (157 mg, 2.42 mmol) in water (1 mL) was added dichloromethane (1 mL), followed by 
trifluoromethanesulfonic anhydride
270
 (339 mg, 1.2 mmol) under vigorous stirring. After stirring 
for 2 h at 0 °C, the organic phase was separated and the aqueous layer extracted with 
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dichloromethane (3x2 mL). The combined organic layers are washed with saturated aqueous 
NaHCO3 solution, water, brine, and dried over anhydrous Na2SO4. 
Step 2: To a solution of Jaspine B hydrochloride salt (45 mg, 0.134 mmol) in dichloromethane 
(1 mL) was added triethylamine (40.5 mg, 0.401 mmol) at rt. Cooled the solution to 0 °C (ice-
bath) and treated dropwise with the triflyl azide (as synthesized above in Step 1). The reaction 
mixture was allowed to attain room temperature and stirred for 2h. The reaction was quenched 
by saturated aqueous NaHCO3 solution (3 mL) and the organic layer separated. The aqueous 
layer was extracted with dichloromethane (3x3 mL), the combined extract washed with brine, 
and dried over anhydrous Na2SO4.  Removal of solvent under vacuum and purification of the 
residue by flash chromatography (EtOAc : hexanes = 1 : 9) afforded the C4-Azido-Jaspine B 
(33.1) (34 mg, 71%) as a white shiny solid. [α]D 11.8 (c 0.5, CHCl3); IR (Neat) 3330, 2916, 2848, 
2102 cm
-1
;
 1
H NMR (400 MHz, CDCl3) δ 4.26-4.09 (m, 2H), 4.04-3.95 (m, 1H), 3.92-3.73 (m, 
2H), 2.17-1.95 (m, 1H), 1.71-1.57 (m, 2H), 1.46-1.16 (m, 24H), 0.92-0.85 (m, 3H).
13
C NMR 
(125.8 MHz, CDCl3) δ 133.9, 125.0, 82.1, 72.5, 68.4, 63.7, 31.9, 31.6, 29.7, 29.6, 29.5, 29.4, 
28.9, 26.1, 22.7, 22.6, 14.1. 
                                                  
(2S,3S,4S)-4-(4-propyl-1H-1,2,3-triazol-1-yl)-2-tetradecyltetrahydrofuran-3-ol
 
(34.1).  To the 
C-4-azido Jaspine B (33.1) (40 mg, 0.123 mmol) was added a solution of t-BuOH and H2O (2 
mL, 1:1), followed by addition of 1-pentyne (18.4 mg, 0.27 mmol), CuSO4 (15.4 mg, 0.0984 
mmol), and L-Sodium Ascorbate (10 mg, 0.0490 mmol). The resulting mixture was stirred at  
room temperature for 20 h. After completion of the reaction, the reaction mixture was 
145 
 
concentrated under vacuum, and residue purified by flash chromatography (EtOAc : Hexanes = 
15 : 85)  to afford the 4-(1,4-disubstituted-triazolo) Jaspine B (34.1) as a white powder (26 mg, 
67%). [α]D 14.8 (c 0.28, CH2Cl2); 
1
H NMR (400 MHz, CDCl3) δ 7.43 (s, 1H), 5.31-5.18 (m, 
1H), 4.61-4.41 (m, 1H), 4.31-4.11 (m, 2H), 4.03-3.89 (m, 1H), 3.61 (brs, 1H), 2.69-2.54 (m, 2H), 
1.81-1.62 (m, 5H), 1.41-1.19 (m, 22H), 0.97-0.93 (m, 6H); 
13
C NMR (125.8  MHz, CDCl3) δ 
147.7, 121.1, 83, 71.8, 68.5, 63.5, 31.9, 29.7, 29.6, 29.5, 29.3, 28.9, 27.6, 26.1, 22.7, 22.4, 14.1, 
13.7. HRMS (ESI-TOF)  m/z:  [M+H]
+
 Calcd for C23H43N3O2  394.3355; Found 394.3423. 
                                                      
 
 
 
 
(2S,3S,4S)-4-(5-propyl-1H-1,2,3-triazol-1-yl)-2-tetradecyltetrahydrofuran-3-ol
 
(34.2).
 
To a 
stirred solution of C-4-azido Jaspine B (33.1) (15 mg, 0.046 mmol) in anhydrous THF (2 mL) 
was added RuCp*Cl(PPh3)2 (3 mg, 0.004 mmol),
217
 followed by addition of 1-pentyne (33 mg, 
0.46 mmol). After refluxing the mixture for 24 h, solvent was removed under vacuum, and the 
residue purified by flash chromatography (EtOAc : hexanes = 1 : 4)  to afford the 4-(1,4-disub-
stituted-triazolo) Jaspine B 34.2 as a light brown solid (11 mg, 61%). [α]D 14.25 (c 0.4, CH2Cl2); 
1
H NMR (400 MHz, CDCl3)  δ 7.41 (brs, 1H), 4.99-4.79 (m, 1H), 4.51-4.38 (m, 2H), 4.32-4.01 
(m, 1H), 3.99-3.81 (m, 1H), 3.80-3.58 (m, 1H), 2.79-2.68 (m, 2H), 1.91-1.51 (m,  4H), 1.61-1.18 
(m, 20H), 1.17-1.03 (m, 4H), 1.0-0.80 (m, 6H); 
13
C NMR (125.8 MHz, CDCl3) δ 147.7, 121.4, 
83.5, 72.2, 68.6, 60.4, 31.9, 29.7, 29.6, 29.4,28.8, 26, 25.2, 22.7, 25.2, 22.7, 21.5, 14.1, 13.8. 
HRMS (ESI-TOF)  m/z: [M+H]
+
 Calcd for C23H44N3O2 394.3434; Found 394.3382. 
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N-((3S,4S,5S)-4-hydroxy-5-tetradecyltetrahydrofuran-3-yl)tridecanamide
 
(35.1). To a room 
temperature mixture of Jaspine B hydrochloride salt  (30 mg, 0.1 mmol) in a biphasic solution of 
saturated aqueous NaHCO3 and EtOAc (4 mL, 1:1) was  added palmitoyl chloride (137 mg, 0.5 
mmol) and stirred for 1 h. The organic layer was separated and the aqueous layer extracted with 
EtOAc (3x5 mL). The combined extract washed with brine and dried over anhydrous Na2SO4.  
Removal of solvent under vacuum and purification of the residue by flash chromatography 
(EtOAc : hexanes = 1 : 4) afforded the Jaspine B carboxamide analog 35.1 as a white greasy 
solid (24 mg, 47%):  
1
H NMR (400 MHz, CD3OD)  δ 4.24 (brs, 1H), 3.96-3.86 (m, 2H), 3.43-
3.35 (m, 1H), 3.22-3.17 (m, 1H), 2.35-2.22 (m, 2H), 1.70-1.57 (m, 4H), 1.35 (brs, 42H), 0.93-
0.84 (m, 6H);
 13
C NMR (125.8 MHz, CD3OD) δ 176.3, 83, 69.5,67.6, 53, 29.2, 29, 28.8, 28.3, 
25.8, 22.3, 13.0. HRMS (ESI-TOF) m/z: [M+Na]
+
 Calcd for C31H61NO3Na 518.4549; Found 
518.4549. 
 
(3aS,6S,6aS)-6-allyltetrahydrofuro[3,4-d]oxazol-2(3H)-one (36.1). To a stirred solution of  
methyltriphenylphosphonium bromide (2 g, 5.62 mmol) in anhydrous THF (40 mL) at – 78 °C 
was added potassium tertiary butoxide (1M soln. in THF, 5 mL, 5 mmol) dropwise and the 
resulting solution stirred for 2 h (solution turned yellow-orange)
28
. A solution of the lactol 26.1 
(0.35 g, 1.25 mmol in 40 mL anhydrous THF) was then added dropwise to the above Wittig ylide 
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solution. After stirring for 1 h at – 78 °C, the reaction mixture was allowed to attain room 
temperature and stirring continued for an additional 16 h. The reaction was quenched by addition 
of a saturated ammonium chloride solution (5 mL), organic layer was separated and the aqueous 
layer extracted with EtOAc (2x10 mL). The combined extracts dried over anhydrous Na2SO4 and  
concentrated under vacuum. The residue was purified by flash chromatography  (EtOAc) to 
afford the C3-allyl-substituted bicyclic oxazolidine 36.1 as a white crystalline solid (77mg, 43 
%): [α]D  67.45 (c 0.55; CH2 Cl2); 
1
H NMR (400 MHz, CDCl3)  δ 6.01-5.91 (M, 1H), 5.85-5.71 
(m, 1H),  5.31-5.01 (m, 2H), 4.91-4.71 (m, 1H), 4.51-4.31 (m, 1H), 4.21-4.11 (m, 1H), 4.01-3.81 
(m, 1H), 3.80-3.73 (M, 1H), 2.51-2.21 (m, 2H); 
 13
C NMR (125.8 MHz, CDCl3) δ159.0, 132.6, 
118.4, 83.5, 83.2, 73, 56.4, 35.2;  HRMS (ESI-TOF)  m/z: [M+Na]
+
 Calcd for C8H11NO3Na: 
192.0637; Found 192.0735. 
                                                            
(3aS,6S,6aS)-6-((E)-tetradec-2-en-1-yl)tetrahydrofuro[3,4-d]oxazol-2(3H)-one (36.2). To a 
solution of the C2-allyl-substituted bicyclic oxazolidine 36.1 (50 mg, 0.35 mmol) in anhydrous 
dichloromethane (10 mL) was added 1-tridecene (0.318 g, 1.75 mmol) followed by Grubbs’ 
second-generation catalyst (5 mg, 0.005 mmol). After refluxing for 3 h, the reaction mixture was 
concentrated under vacuum, and the residue purified by flash chromatography to afford the 
cross-metathesis product 36.2 as a white solid (43 mg, 67%):  [α]D 30 (c 0.75, CH2Cl2); 
 1
H 
NMR (400 MHz, CDCl3) δ 6.18-5.91 (m, 1H), 5.71-5.62 (m, 1H), 5.50-5.40 (m, 1H), 4.99-4.91 
(m, 1H),  4.51-4.31 (m, 1H), 4.01-3.92 (m, 1H), 3.61-3.42 (m, 1H),  2.71-2.51 (m, 2H), 2.21-1.98 
(m, 2H). 1.41-1.11 (m, 19H), 0.96-0.85 (m, 3H); 
13
C NMR (125.8 MHz, CDCl3) δ 159.6, 134.5, 
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124.2, 83.1, 80.8, 73.5, 57.1,  32.6, 31.9, 31.4, 29.7, 29.6, 29.5, 29.4, 29.3,  29.3, 29.1, 22.7, 14.1. 
HRMS (ESI-TOF)  m/z:  [M+Na]
+
 Calcd for C19H33NO3Na 346.2358; Found 346.2336. 
 
(2S,3S,4S)-4-amino-2-((E)-tetradec-2-en-1-yl)tetrahydrofuran-3-ol (36.3). The bicyclic oxa-
zolidine derivative 36.2 (53 mg, 0.16 mmol) was dissolved in a premixed solution of aqueous 1 
M KOH:Ethanol (12 mL, 1:1) and the solution refluxed for 3 h. After removal of solvent under 
vacuum the residue was purified by flash chromatography to afford the C-2 alkenyl Jaspine B 
analog 36.3 as a white solid (37 mg, 76%): [α]D 5.58 (c 1.2, CH3OH); 
1
H NMR (400 MHz, 
CD3OD) δ 5.65-5.41 (m, 2H), 4.21-4.10 (m, 1H), 4.01-3.88 (m, 1H), 3.83-3.61  (m, 3H), 2.51-
2.21 (m, 2H), 2.20-1.97 (m, 2H), 1.61-1.19 (m, 18H), 0.99-0.81 (m, 3H);
 13
C NMR (125.8 MHz, 
CDCl3) δ132.7, 125.6, 83.0, 70.2, 68.8, 53.5, 32.3, 32.0, 31.7, 29.4, 29.3, 29.2, 29.1, 29.0, 28.8, 
22.3, 13.0. HRMS (ESI-TOF)  m/z: [M+H]
+
 Calcd for C18H36NO2: 298.2746; Found 298.2696. 
 
N-((3S,4S,5S)-4-hydroxy-5-((E)-tetradec-2-en-1-yl)tetrahydrofuran-3-yl)palmitamide 
(36.4). To a room temperature solution of the C-2 alkenyl Jaspine B analog 36.3 in a biphasic 
mixture of saturated aqueous NaHCO3 and  EtOAc (4 mL, 1:1) was added palmitoyl chloride (82 
mg, 0.3 mmol) with stirring. After stirring for 30 min, the organic layer was separated and the 
aqueous layer extracted with EtOAc (3x5 mL). The combined extracts washed with brine, dried 
over anhydrous Na2SO4, and concentrated under vacuum. The residue was subjected to flash 
chromatography to afford Jaspine B-Ceramide hybrid 36.4 as a white greasy solid (14 mg, 40%): 
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[α]D - 49.3(c 0.3, CH2Cl2); 
 1
H NMR (400 MHz, CDCl3) δ 6.18-6.01 (m, 1H), 5.71-5.55 (m, 1H), 
5.51-5.40 (m, 1H), 4.66-4.56 (m, 1H), 4.21-4.01 (m, 2H), 3.93-3.81 (m, 1H), 3.67-3.57 (m, 1H), 
2.49-2.30 (m, 2H), 2.26-2.19 (m, 2H), 2.09-1.95 (m, 2H), 1.73-1.49 (m, 5H), 1.47-1.01 (m, 40H), 
0.91-0.71 (m, 6H); 
 13
C NMR (125.8 MHz, CDCl3) δ173.4, 134.1, 124.9, 81.6, 71.9, 70.7,  52.5, 
36.7, 32.6, 32.5, 31.9, 30.9, 29.7 ,29.6, 29.5, 29.4, 29.3, 29.2, 25.7, 22.7, 14.2, 14.1.  HRMS 
(ESI-TOF)  m/z: [M+Na]
+
 Calcd for C34H65NO3Na 558.4862; Found 558.4815. 
5.3.3. Chapter 4: A Rapid Approach Towards Diastereoselective Synthesis of Azacarbo- 
         hydrate Scaffolds of Biological Significance 
 
 
 (5R,6R)-5-Hydroxy-6-(hydroxymethyl)piperidin-2-one (49.2). Step 1: To an ice-cooled 
solution of aminobutenolide 1 (400 mg, 1.26 mmol) in CH2Cl2 was added HCOOH [(99 %): 8 
mL)] and stirred at the same temperature for 2 h. A second lot of HCOOH (3 mL) was added to 
the reaction mixture and stirring continued at 0° C for another 60 min. The reaction mixture was 
diluted with ethanol (5 mL) and excess solvent and HCOOH was removed under high vacuum at 
rt to afford the acetonide deprotected unsaturated lactone 49.1 as a viscous liquid, which was 
used as such for the next reaction.  
Step 2: The amino alcohol 49.1 as obtained above (Step 1) was dissolved in methanol (10 mL) 
and catalytic Pd(OH)2 (30 mg, 0.21 mmol) added to it. After flushing twice with hydrogen, the 
reaction mixture was stirred under hydrogen atmosphere for 18 h. After completion of reaction 
(monitored by IR), the reaction mixture was filtered over a Celite pad and the residue washed 
with hot methanol (4 x10 mL). The combined filtrate was concentrated under vacuum to afford 
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the free amine as a viscous liquid, which was directly used for the next reaction without any 
further purification.  
Step 3: The amino alcohol from the above reaction (Step 2) was dissolved in ethanol (10 mL) 
and a catalytic amount of NaOMe (2 drops) added to it. After stirring the resulting mixture at 
room temperature for 1 hour, solvent was removed under vacuum, and the residue subjected to 
flash chromatography (MeOH : CH2Cl2 = 1 : 4 + 1 mL of NH4OH) to afford the pieperidinone 
diol 49.2 as a greasy white solid (140 mg, 76%, 3 steps):  [α]D  - 0.316 (c 0.655, CH3OH); IR 
(Neat) 3307, 1639, 1409, 1066 cm
-1
; 
1
H NMR (400 MHz, DMSO-d6):  7.05 (brs, 1H), 5.76 
(brs, 1H), 5.09-4.89 (m, 1H), 4.84-4.72 (m, 1H), 3.85-3.61 (m, 1H), 3.18-3.08 (m,  2H), 2.32-
2.18 (m, 1H), 2.17-2.03 (m, 1H), 1.89-1.74 (m, 1H), 1.70-1.59 (m, 1H);   
13
C NMR (125.8 MHz, 
CD3OD)  173.3, 63.9, 62.5, 60.2, 27.3, 26.5; HRMS (ESI-TOF)  m/z: [M+Na]
+
 Calcd for 
C6H11NO3Na 168.0637; Found 168.0613.  
 
 (5R,6R)-5-((tert-butyldimethylsilyl)oxy)-6-(((tert-butyldimethylsilyl)oxy)methyl) Piperidine 
2-one (49.3). To an ice-cooled solution of the piperidinone diol 49.2 (150 mg, 1.03 mmol) in 
anhydrous DMF (6 mL) was added with stirring, TBDMSCl (1.086 g, 7.21 mmol) and imidazole 
(0.595 mg, 8.75 mmol).  The reaction mixture was allowed to attain room temperature, and 
stirring continued for 4h. The reaction was quenched by adding ice-cold water (5 mL) and 
diluted with Et2O (10 mL). The two layers were separated, and the aqueous layer extracted with 
Et2O (3x5 mL). The combined extract dried over anhydrous Na2SO4, solvent removed under 
vacuum, and the residue purified by flash chromatography (EtOAc : hexanes = 3 : 7) to afford 
the Di-TBS protected piperidinone derivative  49.3 as a white fluffy solid (300 mg, 81%);  
1
H 
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NMR (400 MHz, CDCl3):  5.94 (s, 1H), 3.88-3.79 (m, 1H), 3.75-3.65 (m, 1H), 3.45-3.38 (m, 
1H), 3.35-3.28 (m, 1H), 2.61-2.46 (m, 1H), 2.39-2.23 (m, 1H), 1.91-1.75 (m, 2H), 0.98-0.78 (m, 
18H), 0.11-0.03 (m, 12H); 
13
C NMR (125.8 MHz, CDCl3)  171.3, 66.3, 66.1, 64.7, 64.6, 64.4, 
60.7, 60.3, 29, 28.2, 28.1, 27.3, 26.3, 26.1, 25.3, 25.1, 24.1, 18.2, 17.8, -3.9, -4.5, -4.9, -5.0, -5.5, 
-6; HRMS (ESI-TOF)  m/z: [M + Na]
+
 Calcd for C18H39NO3Si2Na 396.2366; Found 396.2263. 
 
(2R,3R)-2-(hydroxymethyl) piperidin-3-ol hydrochloride (49.5). Step 1: To a solution of the 
Di-TBS protected piperidinone derivative 49.3 (55mg, 0.147 mmol) in anhydrous THF (4 mL) 
was added BH3.Me2S (112 mg/140 mL, 1.47 mmol) and the solution refluxed for 3 h. After 
quenching the excess BH3.SMe2 with methanol (3 mL), the reaction mixture was concentrated 
under vacuum to afford the corresponding piperidine derivative 49.4 as a syrupy liquid (35 mg). 
The residue was directly continued for the next step without any further purification.  
Step 2: The O-Di-TBS piperidine as obtained from the above reaction (Step 1) was dissolved in 
methanol (4 mL) and conc. HCl (5 drops) added to it. After refluxing for 3 h, solvent was 
removed under vacuum, and the residue triturated with ether to afford the 2,3,4-
trideoxyazacarbohydrate analog 49.5 as its HCl salt (12 mg, 55%, 2 steps): [α]D – 66.8 (c 0.6, 
CH3OH); 
1
H NMR (400 MHz, CD3OD)  3.92-3.85 (m, 1H), 3.82-3.75 (m, 1H), 3.69-3.59 (m, 
1H), 3.26-3.19 (m, 1H), 2.98-2.82 (m, 2H), 2.12-2.02 (m, 1H), 2.01-1.89 (m, 1H), 1.81-1.61 (m, 
1H), 1.61-1.41 (m, 1H);   
13
C NMR (125.8 MHz, CDCl3)  64.5, 62.4, 57.9, 43.3, 31.0, 20.5; 
HRMS (ESI-TOF)  m/z: [M+H]
+
 Calcd for C16H14NO2: 132.1025; Found 132.0944.  
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(S)-Benzyl 2,2-dimethyl-4-((1S,2S,5S)-4-oxo-3,6-dioxabicyclo[3.1.0]hexan-2-yl)oxazolidine-
3-carboxylate (50.1). Step 1: To an ice-cooled solution of the aminobutenolide 1  (500 mg, 1.57 
mmol) in pyridine (10 mL) was added with stirring NaOCl [(5.3 w/v %) 0.47 g/8.8 mL)].
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 The 
resulting solution was stirred at 0 °C for 1 h and allowed to reach rt over an additional 2h. The 
mixture was then poured onto CH2Cl2  - water (4:1) and aqueous 1 M NaHCO3 solution (24 mL) 
added to it. The bicarbonate layer was separated, washed with ethyl acetate (once), acidified to 
pH 1-2, and extracted thoroughly with ethyl acetate (3x20 mL). The combined extract dried over 
anhydrous Na2SO4 and concentrated under vacuum to afford the crude product (600 mg, 
quantitative) as a viscous liquid. The epoxy carboxylic acid thus obtained was used as such for 
the next reaction. 
Step 2: The epoxy acid (600 mg, 1.812 mmol) from the above reaction (Step1) was dissolved in 
anhydrous CH2Cl2 and cooled to 0 °C in an ice-bath. To this solution was added EDCI (520 mg, 
2.718 mmol) followed by DMAP (cat.) and stirred at the same temperature for 2h. The reaction 
was quenched with cold water and the organic layer was separated. The aqueous layer was 
saturated with solid NaCl and extracted (2x10 mL) with CH2Cl2. The combined extract was dried 
over anhydrous Na2SO4 and concentrated under vacuum. The residue on purification by flash 
chromatography (EtOAc : hexanes = 2 : 3) afforded the bicyclic epoxy lactone 50.1 as a syrupy 
liquid (410 mg, 76 %):  [α]D
  
- 48.6 (c 0.485, CH3OH);  IR (Neat) 2985, 2939, 1794, 1696 cm
-1
; 
1
H NMR (400 MHz, CDCl3; mixture of rotamers):  7.29-7.48 (m, 5H), 4.99-5.39 (m, 2H), 4.31-
4.51 (m, 1.5H), 3.91-4.21 (m, 3.5 H), 3.30 (2 brs, 1H), 1.51-1.81 (m, 6H); 
13
C NMR (125.8 
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MHz, CDCl3 ; mixture of rotamers)   169.8, 154.2, 135.5, 128.8, 95.4, 95, 79.2, 68.1, 67.7, 65.4, 
64.7, 58, 57.5, 56.9, 56.4, 49.7, 49.3, 27.9, 27, 24.2, 22.7, HRMS (ESI-TOF)  m/z: Found  
356.1018 [M + Na]
+
 Calcd for C17H19NO6Na : 356.1110). 
 
 (S)-Benzyl 4-((2S,3R)-3-hydroxy-5-oxotetrahydrofuran-2-yl)-2,2-dimethyloxazolidine-3-car 
-boxylate (50.2). To a mixture of diphenyl diselenide (750 mg, 2.4 mmol) in EtOH (3 mL), 
NaBH4 (186 mg, 4.92 mmol) was added in batches at 0 °C. After stirring at room temperature for 
15 min, the solution was treated with acetic acid (0.36 mL, 6 mmol).
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 After 10 min, a solution 
of the epoxy lactone 50.1 (200 mg, 0.6 mmol) in THF:EtOH (4 mL, 1:1 ) was added to the 
PhSeH reagent prepared above and allowed to warm to room temperature. After stirring for 30 
min, the reaction mixture was diluted with EtOAc, purged with air for 5 min and then 
concentrated under vacuum. The residue was purified by flash chromatography (EtOAc : 
hexanes = 1 : 1) to give the β-hydroxy lactone 50.2 as a syrupy liquid (170 mg, 80%):  [α]D  
18.37 (c 0.8, CH2Cl2);
 1
HNMR (400 MHz, CDCl3 ; mixture of rotamers):  7.29-7.41 (m, 5H), 
4.95-5.38 (m, 2H), 4.42 and 4.68 (2 brs, 1H), 4.09-4.28 (m, 2H), 3.89-4.09 (m. 3H), 2.79-3.01 
(m, 1H), 2.51-2.68 (m, 1H), 1.55-1.71 (m, 6H)  
13
C NMR (125.8 MHz, CDCl3; mixture of 
rotamers)  174.9, 154.4, 135.5, 128.7, 128.5, 128.3, 128.1, 94.8, 86.4, 69.6, 68, 65, 58.7, 37.2, 
36.8, 27.7, 27.5, 27, 24.3, 24.1; HRMS (ESI-TOF)  m/z: Found 358.1287 [M + Na]
+
 Calcd for 
C17H21NO6Na: 358.1267). 
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Benzyl((S)-2-((t-butyldimethylsilyl)oxy)-1-((2S,3R)-3-((tert-butyldimethylsilyl)oxy)-5-oxo-
tetrahydrofuran-2-yl)ethyl)carbamate (50.3). Step 1:  β-hydroxy lactone 50.2 (280 mg, 0.835 
mmol) was dissolved in CH2Cl2 (5 mL) and cooled to 0 °C. To this ice-cold solution added (99 
%) HCOOH (10 mL) and continued stirring at 0 °C for 14 h. Diluted reaction mixture with 
ethanol (3 mL) and concentrated under high vacuum at rt. The residue was adsorbed to silica and 
subjected to flash chromatography to afford the corresponding acetonide deprotected dihydroxy 
lactone as a viscous liquid (174 mg, 70%): [α]D 18.4 (c 0.8; CH2Cl2); 
1
H NMR (400 MHz, CD-
Cl3):  7.41-7.29 (m, 5H), 5.71 (brs, 1H), 5.10 (s, 2H), 4.59-4.41 (m, 1H), 4.38-4.29 (m, 1H), 
3.95-3.65 (m, 3H), 2.92-2.79 (m, 1H), 2.61-2.41 (m, 1H), 1.99-1.71 (m, 2H);  
13
C NMR (125.8 
MHz, CDCl3)  176.9, 157.1, 136, 128.6, 128, 86.5, 68.5, 67.2, 60.9, 52.9, 36.9; HRMS (ESI-
TOF)  m/z: [M+Na]
+
 Calcd for C14H17NO6Na 318.0954; Found 318.0921. 
Step 2: To a room temperature solution of the above dihydroxy lactone 
 
 (40 mg, 0.136 mmol) in 
anhydrous DMF (1 mL) was added imidazole (55.5 mg, 0.816 mmol), and TBDMSCl (102.5 mg, 
0.68 mmol) and stirred for 14 h. After quenching the reaction with ice water (4 mL), the solution 
was extracted with EtOAc (3x10 mL), the combined extract washed with brine, dried over 
anhydrous Na2SO4 and concentrated under vacuum. The residue on purification by flash column 
chromatography (EtOAc : hexanes = 1 : 4) afforded the O-Di -TBS protected lactone 50.4 (60 
mg, 75 %, 2 steps) as a shiny white solid; [α]D 23.3 (c 0.88; CH2Cl2); 
1
H NMR (400 MHz, CD-
Cl3):  7.49-7.31 (m, 5H), 5.39-5.29 (m, 1H), 5.18-5.02 (m, 2H), 4.59-4.47 (m, 1H, ), 4.38-4.29 
(m, 1H), 3.83-3.75 (m, 1H), 3.71-3.61 (m, 1H), 3.61-3.48 (m, 1H), 2.99-2.85 (m, 1H), 2.49-2.38 
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(m, 1H), 0.99-0.79 (m, 30H);  
13
C NMR (125.8 MHz, CDCl3)  175.5, 156.4, 136, 128.6, 128.4, 
86.2, 69.5, 67.3, 61.3, 52.7, 37.6, 25.8, 25.6, 18.2, 17.8, -4.8, -5, -5.5; HRMS (ESI-TOF)  m/z: 
[M + Na]
+
 Calcd for C26H45NO6Si2Na: 546.2683; Found  546.2631. 
 
 (4R,5S,6R)-4-((tert-butyldimethylsilyl)oxy)-6-(((tert-butyldimethylsilyl)oxy)methyl)-5-hyd- 
roxypiperidin-2-one (50.4) Step 1: The O-di-TBS protected lactone 50.3 (250 mg, 0.47 mmol) 
was dissolved in ethanol (10 mL) and Pd(OH)2 (10 mg, 10 mol %) added to it. Degassing of the 
reaction mixture with hydrogen was followed by stirring of the reaction mixture under hydrogen 
atmosphere for 16 h. After completion of reaction, the mixture was filtered through celite, and 
the residue washed with warm ethanol (5x5 mL). The combined filtrate is concentrated under 
vacuum to afford the free amine which was used for the next reaction without any further 
purification. 
Step 2: The amino lactone obtained from the previous reaction (Step 1) was dissolved in 
methanol (15 mL) and a catalytic amount of sodium methoxide added to it. After stirring the 
reaction mixture at room temperature for 8 h,  solvent was removed under vacuum. Purification 
of the residue by flash chromatography (hexanes : EtOAc = 3 : 2) afforded the lactam 50.4 as a 
white solid (120 mg, 60%): IR (Neat) 2957, 1652 cm
-1
; [α]D  - 94.9 (c 0.28; CH2Cl2); 
1
H NMR 
(400 MHz, CD3OD)  5.9 (s, 1H), 4.21-4.14 (m, 1H), 3.91-3.79 (m, 1H), 3.71-3.45 (m, 3H), 2.55 
(brs, 2H), 2.14 (brs, 1H, exchangeable with D2O),  0.99-0.81 (m, 18H), 0.21-0.05 (m, 12H); 
13
C 
NMR (125.8 MHz, CDCl3)   169.5, 69, 68.3, 65, 55.4, 37.7, 25.8, 18.2, -4.5, -4.8, -5.4, -5.5; 
HRMS (ESI-TOF)  m/z: [M + Na]
+
 Calcd for C18H39NO4Si2Na : 412.2315; Found 412.2323.   
156 
 
 
(4R,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)piperidin-2-one (50.5). A solution of the di-TBS 
lactam 50.4 (30 mg, 0.079 mmol) in methanol (4 mL) was treated with a few drops of conc. HCl 
(5 drops) and the reaction mixture stirred at room temperature for 3h. Removal of solvent under 
vacuum afforded the trihydroxy lactam 50.5 as a greasy solid (10 mg, 95%); [α]D - 29.27 (c 0.75; 
CH3OH); 
1
H NMR (400 MHz, D2O):  4.21-4.17 (m, 1H), 3.98-3.89 (m, 1H), 3.80-3.66 (m, 
2H), 3.55-3.49 (m, 1H), 2.71-2.61 (m, 1H), 2.51-2.41 (m, 1H); 
13
C NMR (125.8 MHz, D2O)   
173.5, 66.1, 61.3, 55.4, 35.9; HRMS (ESI-TOF)  m/z: Found 162.0774 [M+H] + Calcd for 
C6H12NO4: 162.0766). 
 
 (2R,3S,4R)-4-((tert-Butyldimethylsilyl)oxy)-2-(((t-butyldimethylsilyl)oxy)methyl) piperidin-
3-ol (50. 6). Di-OTBS piperidinone 50.4 (60 mg, 0.154 mmol) was dissolved in anhydrous THF 
(6 mL) and BH3.SMe2 (117 mg/0.146 mL, 1.54 mmol) added to it. After refluxing for 2 h, excess 
BH3.SMe2 was quenched with methanol (3 mL), and solvents removed under vacuum. 
Subjecting the residue to flash chromatography (EtOAc : hexanes = 5 : 95) afforded the O-Di-
TBS piperidine 50.6 as a greasy solid (32 mg, 55%): [α]D  - 52.3 (c 0.6, CH2Cl2); IR (Neat) 3508, 
3245, 2950, 2896, 1461 cm
-1 
; 
1
H NMR (400 MHz, CDCl3):  4.58-4.48 (m, 1H), 4.18-4.09 (m, 
1H), 3.96-3.88 (m, 1H), 3.71-3.51 (m, 2H), 3.21-2.91 (m, 2H), 2.70-2.62 (m, 1H), 1.94-1.83 (m, 
2H), 1.64-1.75 (m, 1H), 0.75-0.99 (m, 18H), 0.02-0.21 (m, 12H); 
13
C NMR (125.8 MHz, 
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CD3OD)  67.7, 67.1, 62.9, 57.6, 46.7, 31.1, 25.9, 25.7, 18.4, 18, -4.4, -5, -5.3, -5.6; HRMS 
(ESI-TOF)  m/z: [M+H]
+
 Calcd for C18H42NO3Si2: 376.2703; Found  376.2668. 
 
(2R,3S,4R)-2-(hydroxymethyl)piperidine-3,4-diol (50.7). A solution of di-TBS piperidine 50.6 
(15 mg, 0.038 mmol) in methanol (5 mL) and conc. HCl (5 drops) was refluxed for 3 h. Removal 
of solvent and drying of the product under high vacuum afforded 4-epi-fagomine (50.7) as its 
hydrochloride salt (5.5 mg, 79%): [α]D  - 7.3 (c 0.3, CH3OH); 
1
H NMR (400 MHz, CD3OD):  
4.11-3.91 (m, 1H), 3.89-3.75 (m, 2H), 3.71-3.61 (m, 1H), 3.41-3.15 (m, 2H), 3.11-2.95 (m, 1H), 
2.11-1.71 (m, 2H); 
13
C NMR (125.8 MHz, CD3OD)  66.6, 65.5, 58, 56.2, 38.1, 27.8; HRMS 
(ESI-TOF)  m/z: [M + H]
+
 Calcd for C6H14NO3 : 148.0974;  Found  148.0968. 
 
Benzyl((S)-1-((2S,3S,4S)-3,4-bis((tert-butyldimethylsilyl)oxy)-5-oxotetrahydrofuran-2-yl)-2-
((tert-butyldimethylsilyl)oxy)ethyl)carbamate (51.2). Step 1: To an ice-cooled solution of 
acetonide diol 51.1 (90 mg, 0.256 mmol)
26
 in CH2Cl2 (4 mL) was added HCOOH (99%, 4 mL) 
and the solution stirred at the same temperature for 5h. After removal of solvent under vacuum, 
the residue was purified by flash chromatography (MeOH: CH2Cl2 = 4:96) to afford the 
acetonide deprotected triol as a white solid (75 mg, 95%): 
1
H NMR (400 MHz, CD3OD)  7.41-
7.18 (m, 5H), 5.21-5.01 (m, 2H), 4.65-3.99 (m, 2H), 4.38-4.18 (m, 2H), 3.75-3.71 (brs, 1H), 
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3.65-3.61 (m, 2H); 
13
C NMR (125.8 MHz, CD3OD)   176.4, 157.4, 136.7, 128.3, 127.8, 127.6, 
83.6, 69, 68.4, 66.6, 60.6, 52.9; HRMS (ESI-TOF)  m/z: [M + H]
+
 Calcd for C14H18NO7 
312.1083; Found 312.1085. 
Step 2: To a room temperature solution of the triol 51.1 (0.24 g, 0.77 mmol) in anhydrous DMF 
(5 mL) was added imidazole (0.42 g, 6.16 mmol) and TBDMSCl (0.812 g, 5.39 mmol) 
sequentially. After stirring for 2 h, the reaction was quenched by ice water (10 mL) and extracted 
with EtOAc (3x20 mL). The combined extract washed with brine, dried over anhydrous Na2SO4 
and concentrated under vacuum. The residue was purified by flash chromatography (hexanes: 
EtOAc = 95 : 5) to afford the tri-O-TBS protected lactone 51.2 as a white solid (320 mg, 77%, 2 
steps): 
1
H NMR (400 MHz, CDCl3):  7.38-7.27  (m, 5H), 5.38 (d, J = 8.8 Hz, 1H), 5.24  and 
5.05 (2d, J = 12 Hz, 2H), 4.62 (d, J = 4.4 Hz, 1H), 4.29-4.19 (m, 2H), 3.91-3.81 (m, 1H), 3.69-
3.61  (m, 1H), 3.58-3.51 (m, 1H), 0.99-0.77 (m, 27 H), 0.22-0.01(m, 18H); 
13
C NMR (125.8 
MHz, CDCl3):  174.6, 156.4, 136.1, 128.7, 128.5, 82.8, 71.1, 69.8, 67.3, 61.2,  52.2, 25.8, 25.6, 
18.4, 18.2, 18.1, -4.6, -4.8, -5.2, -5.5; HRMS (ESI-TOF)  m/z: [M + Na]
+
 Calcd for 
C32H59NO5Si3Na  644.3599; Found 644.3571. 
 
 (3S,4S,5S)-5-((S)-1-Amino-2-((tert-butyldimethylsilyl)oxy)ethyl)-3,4-bis((tert-butyldimethyl 
-silyl)oxy)dihydrofuran-2(3H)-one (51.3). The trisilylated lactone 51.2 (220 mg, 0.52 mmol) 
was dissolved in anhydrous ethanol (5 mL) and Pd(OH)2 (10 mg, 13 mol%) added to it. After 
degassing the mixture with hydrogen, the reaction mixture was stirred under hydrogen 
atmosphere at room temperature for 19 h. The reaction mixture was filtered over celite bed and 
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the residue was washed thoroughly with EtOAc (3x10 mL). The combined filtrate was 
concentrated under vacuum and the residue purified by flash chromatography  (hexanes : EtOAc 
= 3 : 2) to afford the free amino lactone 51.3 as a white solid (160 mg, 63%): [α]D
 
-6.6 [c 0.45, 
CH2Cl2]; 
1
H NMR (400 MHz, CDCl3):  4.50 (s, 2H), 4.16 (d, J = 8.4 Hz, 1H), 3.69-3.58 (m, 
2H), 2.91-2.75 (m, 1H), 1.56 (brs, 2H, exchangeable with D2O), 0.99-0.81 (m, 27H), 0.21-0.05 
(m, 18H); 
13
C NMR (125.8 MHz, CDCl3)   174.7, 86, 71.2, 70.3, 64.4, 53.3, 25.9, 25.8, 26.7, 
18.4, 18.2, 18.1, -4.5, -4.6, -4.8, -4.9, -5.5; HRMS (ESI-TOF)  m/z: [M+H]
+
 Calcd for 
C24H54NO5Si3 : 520.3310; Found  520.3169. 
 
(3S,4S,5S,6R)-3,4-bis((tert-butyldimethylsilyl)oxy)-6-(((tert-butyldimethylsilyl)oxy) methyl)-
5-hydroxypiperidin-2-one (51.4). A solution of the amino lactone 51.3 (35 mg, 0.067 mmol) in 
anhydrous methanol (2 mL) and a catalytic amount of NaOMe (1 drop) was stirred at room 
temperature for 2 h. The reaction was quenched with saturated aqueous NH4Cl (2 mL) and 
subjected to rotatory evaporation under vacuum to remove methanol. The residue thus obtained 
was taken up in CH2Cl2 (25 mL) and washed with water and brine. After drying over anhydrous 
Na2SO4 and removal of solvent under vacuum, the residue was purified by flash chromatography 
(hexanes : EtOAc  =  9 : 1) to afford the piperidinone 51.4 as a white solid (24 mg, 69%): IR 
(Neat) 2952, 2929, 2910, 2858, 1674 cm
-1
;
 
[α]D
  
- 78.7 (c 0.24, H2O);
 1
H NMR (400 MHz, 
CDCl3):  5.92 (s, 1H, exchangeable  with D2O), 4.20 (s, 1H), 3.98 (s, 1H), 3.89-3.81 (m, 1H), 
3.79-3.61 (m, 2H), 3.52-3.41 (m, 1H), 3.37 (s, 1H, exchangeable with D2O), 0.99-0.77 (m, 27H), 
0.18-0.05 (m, 18H); 
13
C NMR (125.8 MHz, CDCl3)   172.4, 73.4, 69.3, 69.2, 64, 57.1, 27.4, 
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26.4, 25.4, 25.3, 24.3, 18.4, 18.3, 18, -3.6, -4.2, -4.3, -4.5, -4.9, -5.4; HRMS (ESI-TOF)  m/z: [M 
+ Na]
+
  Calcd for C24H53NO5Si3Na 542.3129; Found 542.3065. 
 
(3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)piperidin-2-one (51.5). A solution of the 
O-Tri-TBS piperidinone 51.4 (350 mg, 0.67 mmol) in methanol (10 mL) and conc. HCl (5 drops) 
was refluxed for 6h. After removal of solvent under vacuum, the polyhydroxy lactam 51.5 was 
obtained as a light brown solid (108 mg, 86%):  [α]D
  
- 78.8 (c 0.9, CH2Cl2); IR (Neat) 3274, 
3220, 1650 cm
-1
;
 1
H NMR (400 MHz, D2O):  4.28-4.21 (m, 2H), 4.01-3.98 (m, 1H), 3.81-3.69 
(m, 2H), 3.52-3.43 (m, 1H); 
13
C NMR (125.8 MHz, D2O)   173.9, 71.6, 68.1, 65.1, 60.3, 55.6; 
HRMS (ESI-TOF)  m/z: [M + Na]
+
  Calcd for C6H11NO5Na 200.0535; Found  200.0535.  
 
(2R,3S,4S,5R)-4,5-bis((tert-butyldimethylsilyl)oxy)-2-(((tert-butyldimethylsilyl)oxy)methyl) 
piperidin-3-ol (51.6). A solution of the tri-OTBS lactam 51.4 (60 mg, 0.115 mmol) in anhydrous 
THF (4 mL) and  BH3•DMS (52 mg/0.065 mL, 0.69 mmol) was refluxed vigorously for 2h. After 
cooling to room temperature, the reaction mixture was quenched with methanol (3 mL) and 
solvent removed under vacuum. The residue was purified by flash chromatography (hexanes: 
EtOAc = 85:15) to afford the piperidine 51.6. (34 mg, 59%) as a viscous liquid: [α]D
  
- 24.9 (c 
0.9, CH2Cl2);  
1
H NMR (400 MHz, CDCl3):  4.41-4.31 (m, 1H), 4.10 (s, J=10.4 Hz, 1H), 3.83 
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(d, J=10.4 Hz, 1H), 3.78-3.55 (m, 3H), 3.28-3.02 (m, 2H), 2.98-2.81 (m, 1H), 1.89-1.51 (m, 1H), 
0.99-0.71 (m, 27H), 0.31-0.25 (m, 18H); 
13
C NMR (125.8 MHz, CDCl3)   73.9, 69, 67.8, 60.4, 
56.8, 51.9, 29.7, 26.1, 26, 18.5, 18.2, 18.1, -2.6, -3.9, -4.3, -4.7, -5, -5.4; HRMS (ESI-TOF)  m/z: 
[M + H]
+
 Calcd for C24H56NO4Si3 506.3517; Found 506.3499. 
 
 (2R,3S,4R,5R)-2-(Hydroxymethyl) piperidine-3,4,5-triol (51.7). To a solution of the tri-O-
TBS piperidine 51.6 (30 mg, 0.0593 mmol) in methanol (4 mL) was added conc. HCl (5 drops) 
and the solution refluxed for 6 h. Removal of solvent and drying of the product under high 
vacuum afforded talo-deoxynojirimycin (51.7) as its HCl salt (12 mg, 100%): [α]D  - 13.6 (c 0.7, 
CH3OH); 
1
H NMR (400 MHz, MeOD):  4.02-3.96 (m, 1H), 3.81-3.70 (m, 3H), 3.71-3.61 (m, 
1H), 3.28-3.18 (m, 1H), 3.11-2.92 (m, 2H); 
13
C NMR (125.8 MHz, CDCl3)   71.9, 67.2, 66.4, 
59.1, 56.6, 43.4; HRMS (ESI-TOF)  m/z: (ES-) (M-H) Calcd for C6H12NO4 162.0766; Found  
162.0783.  
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